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ABSTRACT 
Breast cancer is one of the most common forms of cancer in not only South African women, 
but women all over the world. The molecular chaperone heat shock protein 90 (HSP90) is 
upregulated in cancer and is almost exclusively associated with proteins involved in 
intracellular signal transduction, thus it plays an important role in signalling pathways within 
the cell. In cancer, there is an aberrant activation of the Wnt signaling pathway, which results 
in stabilized β-catenin being able to translocate to the nucleus where it can trigger the 
transcription of oncogenes found to be involved in the self-renewal of cells. The level of β-
catenin is usually kept in check by a destruction complex comprising glycogen synthase 
kinase 3-beta (GSK-3β), axin1, adenomatous polyposis coli (APC) which phosphorylate β-
catenin, resulting in its ubiquitination and degradation. HSP90 has been found to be 
associated with GSK-3β, but whether this association is only transient is debatable. Very little 
is known about the association of HSP90 with other members of the Wnt pathway in breast 
cancer. In this study, we have attempted to further identify the direct associations between 
HSP90 and GSK-3β, β-catenin, p-β-catenin and axin1. Immunofluorescence and confocal 
microscopy co-localization studies suggested a potential association between HSP90 and 
these proteins. Treatment with HSP90 inhibitors, 17-AAG and novobiocin resulted in a shift 
of axin1 to what appeared to be the plasma membrane. The associations of HSP90 with GSK-
3β, β-catenin, p-β-catenin and axin1 were confirmed biochemically by co-
immunoprecipitation and inhibition using 17-AAG, geldanamycin and novobiocin. We 
showed, for the first time that HSP90 is associated in a possible complex with β-catenin, p-β-
catenin and axin1 therefore is potentially involved in the modulation of p-β-catenin in the 
Wnt pathway through the stabilization of the destruction complex. 
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1.1 Definition of Cancer 
Cancer refers to a tumour formed by cells that multiply outside the limitations of tightly 
controlled pathways.  These cells become malignant when they start to invade another part of 
the body that is normally occupied by other cells (Alberts et al., 2002). Tumour 
transformation, invasion and metastasis relies on an intricate interconnected network of 
signals from the extracellular matrix as well as intracellular signal transduction pathways 
(Kumar and Weaver, 2009).  
1.2 Epidemiology of Cancer 
Cancer has been reported as second only to heart disease as the leading cause of death 
(Miniño et al., 2007). The number of deaths attributed to cancer exceeds that of heart disease 
for persons under the age of 85 years (Jemal et al., 2008). The Cancer Association of South 
Africa (CANSA, 2010, website 1) reported that there are approximately 80 000 cancer-
related deaths each year in South Africa, of which breast cancer makes up 3 200 deaths 
(CANSA, 2010, website 1) and has been reported by the International Agency for Research 
on Cancer (IARC, 2010, website 2) as most pertinent type of cancer diagnosed in women. 
Colorectal cancer is the third most frequently diagnosed cancer, with 72 % of the cases being 
located in the colon, whilst the remaining is in the rectum (Jemal et al., 2008). However, the 
statistics for sub-Saharan Africa are incomplete therefore these statistics could increase 
drastically.  
Although there has been a gradual decline in the death rate from breast cancer since 1990, 
there are still more than 10 million known cases of cancer diagnosed each year (Eaton, 2003; 
Kakarala and Wicha, 2008). This decrease in deaths could be attributed to early detection 
instead of the effects of new treatments (Calvocoressi et al., 2008). This holds true for 
colorectal cancer too, with a decrease in death rate since 1998 (Jemal et al., 2008) not 
necessarily meaning a decrease in the cancer, but could be due to the removal of 
precancerous polyps (Cress et al., 2006).  Furthermore, it must be noted that there has been 
no significant change in the overall survival of women diagnosed with metastatic breast 
cancer (Miniño et al., 2007) and recurrence of the disease still arises in an extensive 
proportion of women even after adjuvant therapy (Kakarala and Wicha, 2008).  
1.3 Etiology of Cancer 
There are three broad groups of risk factors that contribute to breast cancer, which include 
hereditary, hormonal & reproductive factors and environmental factors (Debruin and 
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Josephy, 2002). It was interesting to note that over 70 % of breast cancers are associated with 
environmental factors (Lichtenstein et al., 2000) and over 78 % of breast cancers are 
diagnosed in post-menopausal women, possibly due to long latency periods of chemical 
carcinogenesis (Debruin and Josephy, 2002).  
Estrogens and progesterone are required for normal mammary development, but it is thought 
that their activation is linked to procarcinogenesis (Debruin and Josephy, 2002). Numerous 
identified risk factors for breast cancer can be attributed to their effects on lifetime exposure 
to estrogen and other hormones (Henderson and Feigelson, 2000). In addition to this, 
estrogens have been found to be metabolically converted to cytotoxic and genotoxic products, 
such as the oxidation of catechol estrogens to catechol quinones (Cavalieri et al., 1997).  
Many breast cancers overexpress the nuclear hormone receptor estrogen receptor-α (ER-α). 
(Mastroianni et al. 2010). Mastroianni et al. (2010) proposed that ectopic Wnt signaling can 
substitute for estrogen to stimulate division of ERα-positive cells, resulting in estrogen-
independent tumours. 
Breast cancer is linked to oncogene activation and tumour suppressor gene inactivation 
(Russo and Russo, 2001). Overexpression of the proteins, human epidermal growth factor 2 
(HER-2) (Hung and Lau, 1999) and Bcl-2 are involved in maintaining the oncogenic 
phenotype. Overexpression of the proto-oncogene product, Bcl-2 is linked to better prognosis 
whilst downregulation of Bax is associated with poor clinical outcome (Daidone et al., 1999; 
Schorr et al., 1999). Another gene that is mutated in 40 % of breast cancers is p53, which is 
involved in cell cycle regulation, DNA repair and apoptosis (Coles et al., 1992). Cancers that 
have mutated p53 have been found to be more aggressive and resistant to chemotherapy 
(Howard et al., 2004).  
Hereditary factors are linked mainly with early-onset premenopausal breast cancer. Women 
who have mutations in the breast cancer gene (BRCA) BRCA1 or BRCA2 have an increased 
risk of developing breast cancer (Bennet et al., 1999). These genes are involved in 
transcriptional regulation, cell cycle control; apoptosis and DNA repair (Wang et al., 2001). 
Epigenetics describes the study of alterations that occur during gene expression which are 
independent of the alterations in the primary DNA sequence (Sharma et al., 2010). 
Differentiation may be a consequence of these alterations which remain stable throughout 
numerous cell cycle divisions, allowing for the cells to have distinct identities (phenotypes) 
4 
 
whilst they contain the same genetic information (genotypes) (Sharma et al., 2010). 
Epigenetic alterations that occur include methylation of cytosine bases in DNA; and post-
translational changes of histone proteins, in addition to changes in the nucleosome location 
along the DNA. This regulates what part of the gene can be used and therefore results in 
cellular diversity (Sharma et al., 2010). If these epigenetic changes are not kept in check, 
signaling pathways can become dysregulated, which ultimately leads to cancer (Jones and 
Baylin, 2002). It has also been proposed that epigenetic mutations that occur within normal 
stem and progenitor cells can lead to cancer (Feinberg et al., 2006). Reversal of epigenetic 
mutations forms the basis of novel cancer therapies (Yoo and Jones, 2006).  
1.3.1 Etiology of Breast cancer 
The mammary gland, unlike other organs in the body, undergoes morphological change 
during distinct developmental periods in an adult‟s life (Howard, 2000). These stages include 
fetal development, puberty, pregnancy and finally lactation. After lactation, expansive tissue 
remodeling occurs in the breast, whereby apoptosis allows for the glands to return to the same 
structure as that prior to pregnancy (Strange et al., 2001). It can therefore be said that within 
the breast, there exists a compartment of cells that has the ability to differentiate and self-
renew, so called adult stem cells, and these cells are required for multiple pregnancies to 
occur (Dontu et al., 2004; Lawson et al., 2009). These cells are described as being stem cell-
like, and are thought to be the origin of breast cancer, whereby mutations in these adult stem 
cells transform the cells into cancer stem cells (Dontu et al., 2004). Since the adult breast 
stem cells are slow dividing and long lived cells, with a high potential to proliferate, 
mutations due to genotoxic agents can build up over an extensive period, thus leading to 
carcinogenesis (Dontu et al., 2004; Lawson et al., 2009).  
1.3.2 Etiology of Colorectal Cancer 
Colorectal cancer starts off as noncancerous polyps with the majority of colorectal cancers 
being described as adenocarcinomas which form from glandular tissue (Stewart et al., 2006).  
It has been estimated that more than 50 percent of a given population will develop one or 
more adenomas in a life time (Schatzkin et al., 1994); however, a small percentage (5-10 %) 
of colorectal cancer patients have an inherited genetic mutation that causes the cancer 
(Lagerstedt Robinson et al., 2007). An example of such a syndrome is familial adenomatous 
polyposis (FAP) which is passed on as an autosomal dominant trait due to a mutation in the 
gene encoding for adenomatous polyposis coli (APC), whereby patients develop benign 
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polyps in the colorectal epithelium during early adulthood. Some of these polyps will develop 
into cancerous tumours that metastasize (Kotiligam et al., 2008). Another example is 
hereditary nonpolyposis colorectal cancer (HNPCC) (Lynch syndrome), whereby there is a 
mutation in one of the mismatch repair genes (MMR) (Vasen et al., 2007). 
1.4 Cancer stem cells 
Classic models of carcinogenesis describe cancerous tumours as “stochastic” or “random”, in 
which any cell can be transformed by mutations (Martinez-Climent et al., 2006). In contrast 
to this, there is growing evidence that malignant tumours are heterogeneous and comprise a 
subpopulation of cells with stem cell characteristics, and are thus termed cancer stem cells 
(CSCs) or tumour initiating cells (Korkaya and Wicha, 2007). Furthermore, within the cancer 
cell hierarchy (Figure 1.1) some tumours are similar to that of the tissue from which the 
tumour arose (Cariati and Purushotham, 2008). In addition, tumours formed from cancer stem 
cells, have been found to have the same heterogenic complexity as the original tumour (Al-
Hajj et al., 2003).  
Normal stem cells and cancer stem cells share many important characteristics, including the 
ability to self-renew; the capacity to differentiate; active expression of telomerase; activation 
of anti-apoptotic pathways; increase in membrane transporter activity; and capacity to 
metastasize (reviewed in Wicha et al., 2006).  Furthermore, cancer stem cells are resistant to 
changes in temperature, pH as well as exposure to toxicants (Miyagi et al., 2001; Woodward 
et al., 2005). A possible explanation for this is that they possess high stress tolerances and are 
assisted by highly complexed heat shock proteins that are upregulated in cancer thus allowing 
for cancer cells to withstand environments that occur due to deregulated signaling pathways 
(Takayama et al., 2003; Whitesell and Lindquist, 2005). 
There are two separate, but interlinked theories describing how cancer stem cells are formed. 
The first theory suggests that carcinogenic tumours are caused by rare cells that have stem 
cell properties, which are described as cancer stem cells/ tumour initiating cells. On the other 
hand, the second theory describes how cancer stem cells arise from deregulated self-renewal 
pathways in the normal stem/ progenitor cells (Graziano et al., 2008; Campbell Marotta and 
Polyak, 2009).  
Many cancerous tumours contain a rare population of cells, termed the side population (SP) 
cells that comprise a vast proportion of cancer stem-like cells (Kondo et al., 2004; 
Hirschmann-Jax et al., 2004; Patrawala et al., 2005). Ex vivo cancer cell lines like the human 
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epithelial breast cancer line, MCF7 and the colorectal cell lines HT29 contain a 
subpopulation of cells (side population) that have stem cell-like characteristics. This SP have 
been shown to have a higher colony formation capacity in comparison to non-SP cells (Zhou 
et al., 2007; Haraguchi et al., 2008), thus could be used as models for cancer stem-like cell 
research. 
 
Figure 1.1. A schematic model of the hierarchical organization of the cancer tumour. The tumour initiating 
cells can sustain the tumour by self-renewal. In addition to this, it can differentiate into the different cancer cells 
comprising the bulk of the tumour, as well as form a metastatic population which can form new tumours. 1: 
asymmetric division. 2. symmetric division (adapted from Reya et al., 2001).  
Several important signaling pathways identified in both cancer stem cells and normal stem 
cells include human epidermal growth factor receptor 2 (HER-2), phosphatase and tensin 
homolog (PTEN), Notch, Hedgehog and Wingless (Wnt). Pathways involved in cell survival 
and proliferation of the MCF7 SP cells include phosphatidylinositol3-kinase (PI3-K)/ 
mammalian target of rapamycin (mTOR), PTEN, signal transducer and activator of 
transcription 3 (STAT3). Genes of the Wnt/β-catenin pathway were also upregulated in SP 
cells in comparison to non-SP cells (Zhou et al., 2007). mTOR signaling positively regulates 
the STAT3 pathway, whilst the PTEN acts as a negative inhibitor of both the mTOR and 
STAT3 pathways (Zhou et al., 2007). This evidence suggests the importance of studying the 
SP and its signaling pathways in order to elucidate the pathways important for cancer stem-
like cell maintenance. 
1.4.1 Cancer stem cells and chemotherapy  
Conventional chemotherapies are aimed at targeting the bulk and cycling populations of 
tumours (Korkaya and Wicha, 2007). However, it has been found that cancer stem cells are 
resistant to current chemotherapeutic agents (Wicha et al., 2006). There are several reasons 
for this resistance, which include the cell cycle kinetics of cancer stem cells, whereby cancer 
stem cells remain in the G0 phase, and thus have increased resistance to cell cycle 
chemotherapeutic agents (Venezia et al., 2004). Another explanation is that certain protective 
mechanisms are stimulated which prevent the cancer stem cell from senescence and 
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apoptosis. These mechanisms comprise: the stimulation of self-renewal pathways such as the 
Wnt/β-catenin pathway; expression of anti-apoptotic proteins such as B-cell lymphoma 2 
(BCL-2); overexpression of drug-effluxing pumps which permits the cell to expel toxic drugs 
(Moserle et al., 2010). A further explanation could be that cancer stem cells have increased 
resistance to DNA-damaging chemotherapeutic agents due to their asynchronous DNA 
synthesis as well as good DNA repair (Cairns, 2002).  
Cancer stem cells are radio-resistant, and have been linked to repopulating the tumour during 
a relapse after radiation (Woodward et al., 2007; Eyler and Rich, 2008). One of the 
mechanisms that is thought to be adapted to radiotherapy is the Wnt/β-catenin pathway, 
whereby DNA damage results in the stimulation of the Wnt/β-catenin pathway thus 
promoting genomic instability by converting non-tumourigenic stem cells into CSC or SP and 
enabling tumour cells to survive irradiation (Chen et al., 2007; Shiras et al., 2007).  
It has been suggested that therapies aimed at targeting cancer stem cells should be 
incorporated into drug development (Wicha et al., 2006; Moserle et al., 2010). Cariati and 
Purushotham (2008) noted that targeting cancer stem cells instead of differentiated or transit 
amplifying cells would provide a long term cure for malignant tumours. Two approaches 
include: targeting molecular pathways which are over-activated in malignant stem cells and 
sensitizing cancer stem cells to standard therapies (Moserle et al., 2010).  It must be noted, 
however, that this could prove to be a challenge since many pathways are shared by both 
cancer stem cells and normal stem cells, especially those involved in self-renewal  (Wicha et 
al., 2006). An approach to drug design is “differentiation therapy” which induces 
differentiation in cancer tumours and has had some positive results (Spira and Carducci, 
2003; Sell, 2004). It is thought that this differentiation therapy induces differentiation in 
cancer stem cells thus inhibiting the cancer stem cell‟s ability to self-renew (Korkaya and 
Wicha, 2007). However, as with targeted destruction of cancer stem cells, differentiation 
therapy may result in initiation of terminal differentiation of adult stem cell populations. 
1.5 Signaling pathways in cancer 
Signaling pathways involved in the differentiation and self-renewal of cancer cells are the 
Wnt, PTEN, Notch and Hedgehog pathways. Whilst in some instances, the pathways may act 
independently of one another for tissue self-renewal, proliferation and inhibition of 
differentiation, in other instances the different pathways may be interlinked in a hierarchical 
manner such that they influence one another (Figure 1.2) (Reya and Clevers, 2005).  
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Some studies (Liu et al., 2005) have suggested that Hedgehog signaling acts downstream of 
Notch signaling, other studies have shown that Sonic hedgehog (Shh) acts upstream of Notch 
(Figure 1.2, step 1) (Morrow et al., 2009). Notch signaling prevents the differentiation of 
stem cells (Figure 1.2, step 2) (Dontu et al., 2004), whilst Hedgehog signaling stimulates the 
self-renewal of cells (Figure 1.2, step 5) (Liu et al., 2006). These two pathways form a 
feedback loop that controls normal development, and deregulation of this loop could be 
associated with carcinogenesis (Liu et al., 2005). The Wnt pathway acts downstream of 
Notch (Figure 1.2, step 3) and Hedgehog pathways (Figure 1.2, step 4) (Liu et al., 2005) and 
has been found to be activated by transformation of the Notch pathway (Figure 1.2, step 3) 
(Kopper and Hadju, 2004). When the Wnt pathway is not stimulated, glycogen synthase 
kinase (GSK-3β) phosphorylates β-catenin (Figure 1.2, step 7) and prevents it from becoming 
stabilized and moving into the nucleus (Figure 1.2, step 8) (Kimelman and Xu, 2006). At the 
same time, GSK-3β   inhibits mTOR kinase (Figure 1.2, step 9) (Inoki et al., 2006). In the 
presence of Wnt signal, GSK-3β  is inhibited from phosphorylating β-catenin thus resulting 
in stabilized β-catenin moving into the nucleus to target genes involved in self-renewal 
(Figure 1.2, step 8) (Amit et al., 2002). PTEN prevents Akt from being activated (Figure 1.2, 
step 10). A reduction in PTEN results in Akt being activated by PI3-K (Figure 1.2, step 11) 
(Cross et al., 1995). Akt in turn inhibits GSK-3β (Figure 1.2, step 12) from phosphorylating 
β-catenin, resulting in an increase of stabilized β-catenin (Covey et al., 2010). In addition to 
this mTOR is stimulated (Figure 1.2, step 13) which can stimulate the signal transducer and 
activator of transcription (STAT3) pathway (Figure 1.2, step 14) resulting in the self-renewal 
of cells (Figure 1.2, step 15) (Zhou et al., 2007). 
Elucidation of these pathways that regulate differentiation of stem cells and cancer has 
increased the understanding of how dysregulation of these tightly controlled processes could 
play a role in carcinogenesis. Additionally it would be important to understand the 
coordinated activity of these pathways such that they could offer a target for cancer 
prevention and therapy (Reya and Clevers, 2005; Kakarala and Wicha, 2008).  
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Figure 1.2. Schematic representation of the pathways involved in stem cell renewal and differentiation. 
See text for details. Arrow represents stimulated pathway, whilst blunted line represents inhibited pathway. 
Solid lines represent known interactions whilst dotted lines represent possible interactions GSK-3β: glycogen 
synthase kinase-3β. PI3-K: phosphatidylinositol 3-kinase. PTEN: phosphatase and tensin homolog mTOR: 
mammalian target of rapamycin. STAT3: signal transducers and activators of transcription 3. Ptch 1: Patched 1. 
Intricacies of the Akt pathway are discussed later in 1.6 (adapted from Liu et al., 2005; Prinsloo et al., 2010).  
1.5.1 Wnt Signaling 
Wnt proteins comprise a family of 19 highly conserved glycoproteins that are associated with 
signaling pathways (reviewed in Angers and Moon, 2009). Cell surface Wnt receptors 
comprise a seven transmembrane protein of the Frizzled (Fz) family, and low density 
lipoprotein receptor proteins 5/6 (LRP5/6) (Polakis, 2000; Mao et al., 2001). When the Wnt 
proteins bind to the receptors on the cell surface membrane, different pathways are 
stimulated. The non-canonical pathways, which are β-catenin independent, are stimulated 
when Wnt proteins bind to the Frizzled receptors in the absence of LRP5 or LRP6 (Angers 
and Moon, 2009). Other Wnt receptors include Ryk and ROR2 which can antagonize Wnt/β-
catenin signaling (van Amerongen et al., 2008).  
1.5.1.1 Wnt/β-catenin pathway 
In normal cells, endogenous β-catenin is complexed with E-cadherin and α-catenin in cell 
junctions, and therefore plays a role in cell adhesion. Excess, newly synthesized β-catenin is 
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degraded by the destruction complex, comprising axin, APC, glycogen synthase kinase-3β 
(GSK-3β), protein phosphatase 2A (PP2A) and casein kinase 1 (CK1) (Price, 2006). 
The canonical Wnt/β-catenin pathway is stimulated when the Wnt protein binds to the Fz/ 
LRP complex (Figure 1.3 and Figure 1.4A) (Hocevar et al., 2003). It does this by bringing 
Frizzled and LRP together (Cong et al., 2004B). This in turn activates the cytoplasmic 
protein, Disheveled (Dsh) (Figure 1.3, step 1), which acts as a mediator by receiving signals 
from receptors and passing them on to the relevant effector molecules (Hocevar et al., 2003).  
How this activation occurs is still not fully understood. It is, however, thought that 
phosphorylation by CK1 and CK2 at serine 45 of β-catenin may play a role in this process 
(Amit et al., 2002). 
There is much debate about whether β-catenin is stabilized by the direct inhibition of GSK-3β   
or whether it is due to axin degradation. One theory suggests that the activated Dsh complex 
inhibits β-catenin from being phosphorylated and degraded by another multiprotein complex 
comprising APC, axin, glycogen synthase kinase-3β (GSK-3β) and β-catenin (Figure 1.3, 
step 2) (Polakis, 2000; Wharton, 2003). It does this by associating with CK1, and preventing 
CK1 from priming β-catenin. This in turn prevents β-catenin from being phosphorylated by 
GSK-3β at serine 41, 37 and 33 (Amit et al., 2002). In addition to this, Dsh recruits GSK-3 
binding protein (GBP) (Figure 1.3, step 3) which is thought to separate GSK-3β from axin, 
therefore leading to the inhibition of phosphorylation of β-catenin (Li et al., 1999). 
Another theory suggests that when Wnt binds to LRP5/6, GSK-3β and CK1γ phosphorylate 
LRP5/6 (Davidson et al., 2005; Zeng et al., 2005), which is a key event in receptor activation 
(Tamai et al., 2004). Both LRP5 and LRP6 have the motifs PPSPxS (P, proline, S, serine or 
threonine, x a variable residue) which, when phosphorylated, become docking sites for the 
axin complex (Figure 1.4A) (Tamai et al., 2004; Davidson et al., 2005). Although one study 
argued that upon Wnt stimulation, phosphorylation only occurs by CK1 (Davidson et al., 
2005), there is growing evidence that GSK-3β primes the xS motif for phosphorylation by 
CK1 (Zeng et al., 2005; Khan et al., 2007). This results in axin being sequestered to the 
membrane where it associates with LRP5/6 since hyperphosphorylated LRP5/6 has a high 
affinity for axin. Sequentially, the inactive axin is dephosphorylated and degraded by an 
unknown mechanism (Mao et al., 2001). Axin, which is present in limiting levels within the 
cell (Lee et al., 2003), is the key scaffolding protein in the destruction complex, therefore 
without it, the destruction complex is rendered incapable of phosphorylating β-catenin 
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(Willert et al., 1999). In contrast, a recent study (Cselenyi et al., 2008) has shown that in the 
absence of axin degradation, LRP6 promotes the stabilization of β-catenin by directly 
inhibiting GSK-3β from phosphorylating β-catenin. 
Interestingly, studies have shown that the Fz-Dsh interaction is important for the 
phosphorylation and activation of LRP6 (Bilić et al., 2007; Zeng et al., 2008). Since axin is 
recruited to the membrane via Dsh, it is proposed that when Fz recruits Dsh, the GSK-3β-
axin complex is also recruited, subsequently allowing for GSK-3β to phosphorylate and 
activate LRP6 (Zeng et al., 2008). It can therefore be said that GSK-3β and axin play 2 
antagonistic roles in the Wnt pathway; positive regulation via LRP phosphorylation and 
negative regulation via β-catenin phosphorylation (reviewed in Huang and He, 2008). 
Although the Dsh-Fz and Dsh-axin associations are weak (Wong et al., 2003; Schwarz-
Romond et al., 2007B), both Dsh and axin have a DIX domain that allows for polymerization 
(Schwarz-Romond et al., 2007A). Subsequently, Dsh and axin can form large aggregates that 
form weak but dynamic protein associations. Furthermore, Wnt-stimulated receptor 
clustering needs the DIX domain (Schwarz-Romond et al., 2007A). 
Stabilized β-catenin (Figure 1.3, step 4) can translocate to the nucleus to form a complex with 
the DNA binding proteins, T-cell-specific factor/ lymphoid enhancer binding factor 1 (TCF/ 
LEF-1) (Figure 1.3, step 5). The amino terminus of β-catenin modulates the stability of the 
protein (Barth et al., 1997), whilst the carboxy terminus acts as the transcriptional activator 
domain (Tutter et al., 2001). This in turn activates the transcription of genes involved in 
oncogenesis (Figure 1.3, step 6) (He et al., 1998; Shtutman et al., 1999). These genes include 
those involved in cell proliferation, such as c-myc (He et al., 1998) and c-jun (Mann et al., 
1999); inhibition of apoptosis, such as survivin (Zhang et al., 2001); and tumour metastasis 
such as (matrix metalloprotease 7) MMP7 (Crawford et al., 1999). β-catenin is involved in 
modulating the expression of a vast number of genes involved in cell proliferation, migration, 
invasion and morphogenesis, including those encoding for cyclin D1, the cell adhesion 
molecule L1-CAM, MMP and the metastasis gene S100A4, as well as Fascin, which has been 
found to be important for filopodia formation and cancer cell invasion (Vignjevic et al., 
2007). Numerous co-activators of β-catenin have been identified, such as cyclic adenosine 
monophosphate (cAMP) response element-binding protein (CREB)-Binding Protein 
(CBP)/p300 (Ma et al., 2005), Pygopus (Städeli and Basler, 2005) and BCL-9 (Hoffmans and 
Basler, 2005). They interact with the C-terminus of β-catenin, thus regulating the association 
of β-catenin with the TCF/LEF complex and the chromatin (Parker et al., 2008).  
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In the absence of the Wnt ligand (Figure 1.3, dotted arrows; Figure 1.4B), CK1 is recruited 
by axin, the scaffolding protein (Clevers, 2006), which results in the priming of β-catenin in 
preparation for phosphorylation by GSK-3β. GSK-3β is also recruited by axin to the 
multiprotein complex (Behrens et al., 1998). The subsequent phosphorylation of axin and 
APC by GSK-3β and CK1 increases the association of axin and APC with β-catenin (Figure 
1.3, step 8) (Peifer and Polakis, 2000; Huang and He, 2008). The phosphorylation of β-
catenin results (Figure 1.3, step 8) in its ubiquitination (Figure 1.3, step 9) by the ubiquitin-
proteome pathway involving SKP1–cullin 1– F-box (SCFβ-TrCP the 26S proteosome 17) E3 
ligase and to its degradation by the 26S proteosome (Figure 1.3, step 10) (Kimelman and Xu, 
2006), thus reducing the level of cytosolic β-catenin (Kitagawa et al., 1999).   
In the resting state, low levels of β-catenin are present and the Wnt target genes are inhibited 
by the Groucho family of transcriptional repressors, which are bound to the lymphoid 
enhancer factor (LEF) and T cell factor (TCF) proteins (Angers and Moon, 2009). In normal 
and unstimulated cells, β-catenin is mainly localized to cell-cell junctions where it forms a 
complex with α-catenin and E-cadherin (Huber and Weis, 2001). This means that there are 
low levels of β-catenin in the cytoplasmic or nuclear regions due to its rapid turnover by the 
Dsh complex (Luu et al., 2004). Upon Wnt activation, β-catenin translocates to the nucleus 
where it displaces Groucho and activates target genes (Daniels and Weis, 2005). It is thought 
that APC can also have a chaperoning effect, by exporting nuclear β-catenin into the 
cytoplasm for degradation (Henderson, 2000; Neufeld et al., 2000). However, Eleftheriou et 
al. (2001) did not find that the chaperoning function was important and that β-catenin can 
move between the nucleus and cytoplasm without the aid of APC.  
Extracellular antagonists and inhibitors also regulate the Wnt pathway (Figure 1.3, step 7). 
These include secreted Fz related proteins (sFRPs), Wnt inhibitory protein (WIF) (Bovolenta 
et al., 2008), Dickkopf (Dkk) (Aguilera et al., 2006; Semënov et al., 2001) and the 
Wise/SOST family (Li et al., 2005) which bind to Wnt ligands and are antagonistic to Wnt. 
These proteins have been found to have decreased expression in cancer (Suzuki et al., 2008). 
Interestingly, various self-regulatory loops have been found in the Wnt pathway, which are 
cell-specific. Examples include the proteins Fz, LRP6, axin2, TCF/LEF, Dkk1 being either 
negatively or positively regulated by TCF/β-catenin (Logan and Nusse, 2004; Chamorro et 
al., 2005; Khan et al., 2007) 
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Axin acts as a scaffolding protein in the destruction complex of β-catenin and is thus a 
negative regulator of the Wnt pathway. The two human homologs, axin1 (Axin homolog) and 
axin2 (Conductin homolog) share 45 % amino acid identity (Zeng et al., 1997; Mai et al., 
1999). Whilst axin1 is constitutively expressed and thus maintains the basal level of Wnt 
pathway activity, axin2 is stimulated by an increase in β-catenin levels and thus regulates the 
intensity and extent of the Wnt/β-catenin signal (Lustig et al., 2002). Axin2 is also a 
downstream target of the Wnt pathway, and is possibly linked to controlling Wnt signaling 
via negative feedback (Lustig et al., 2002). Axin2 also contains TCF binding sites (Leung et 
al., 2002).  
GSK-3β is constitutively active with phosphorylation of GSK-3β   resulting in loss of its 
activity (Cole and Sutherland, 2008). Two isoforms of GSK-3 are identified, GSK-3β and 
GSK-3α which share 95 % similarity in their protein kinase catalytic domain (Woodgett, 
1990). It has been found that GSK-3β can be substituted by GSK-3α in many of its kinase 
activities in the Wnt pathway (Manoukian and Woodgett, 2002). A recent study has identified 
another role of GSK-3β in the Wnt pathway which does not involve the phosphorylation of β-
catenin. It is suggested that GSK-3β translocates to the nucleus, where it binds to axin and β-
catenin, decreasing the levels of β-catenin/TCF transcription (Caspi et al., 2008). Sadot et al. 
(2002) proposed that β-catenin gets dephosphorylated rather than degraded when colon 
cancer cells are treated with LiCl, an inhibitor of GSK-3β.  
Both protein phosphatase 1 (PP1) and PP2A are positive regulators of the Wnt pathway. PP1 
associates with axin and dephosphorylates the CK1 primed sites on axin. This results in a 
conformational change of axin leading to the decrease in the association of GSK-3β with 
axin. β-catenin is therefore not phosphorylated (Luo et al., 2007). PP2A, on the other hand, 
dephosphorylates β-catenin (Zhang et al., 2009A). Another negative regulator of the Wnt 
pathway is the Wilms Tumor gene on the X chromosome (WTX) (Major et al., 2007). WTX 
associates with the destruction complex, causing the ubiquitination and degradation of β-
catenin (Major et al., 2007). 
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Figure 1.3. Simplified diagram of the canonical Wnt/β-catenin signaling pathway. Wnt proteins bind to receptors, Frizzled (Fz) and low density lipoprotein receptor-
related proteins (LRP). This stimulates Disheveled (Dsh) (step 1) which leads to inactivation of a multiprotein complex (step 2) which normally renders β-catenin unstable. 
GBP is also recruited by Dsh (step 3) which can dislodge glycogen synthase kinase-3β (GSK-3β) from axin.  Stabilized β-catenin (Step 4) can therefore move into the nucleus 
(step 5) to activate target genes (step 6). When the Wnt signals are inhibited (step 7) by Dickkopf (Dkk) or secreted Fz related proteins (sFRPs), phosphorylation within the 
multiprotein complex comprising axin, adenomatous polyposis coli (APC), and GSK-3β   occurs (step 8). Subsequently, β-catenin gets phosphorylated (step 8) and is targeted 
for ubiquitination (Ub) by the E3 ligase and TrCP (E3/TrCP) leading to its degradation by proteosome (step 10). CK1: casein kinase 1, GBP, GSK-3 binding protein, TCF: T 
cell factor protein, LEF: lymphoid enhancer factor Arrows represent pathways stimulated. Blunted lines represent pathways inhibited. Solid arrow and blunted line represent  
signaling in the presence of Wnt, whilst dotted arrows and dotted blunted lines represent signaling when Wnt is not present (adapted from Brown, 2001; website 3). 
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1.5.1.2 Wnt Signaling in normal cells 
Wnt signaling is involved in many cellular processes including cell fate, cell proliferation 
versus differentiation, cell survival vs apoptosis, cell behavior and migration (Logan and 
Nusse, 2004), as well as the self-renewal and differentiation of stem cells (Kakarala and 
Wicha, 2008). Not only is it involved in regulating the stem cell population of the crypts of 
the small and large intestine (Hoppler and Kavanagh, 2007), but is also important for 
mammary gland development. A loss of Wnt signaling results in mammary developmental 
defects, possibly due to the mammary gland stem cell population being compromised 
(Lindvall et al., 2007). 
1.5.1.3 Wnt signaling in cancer 
Aberrant activation of the Wnt/β-catenin pathway is associated with cancer (Figure 1.4C). 
This can be caused by mutations in the Wnt pathway (Table 1.1) or overexpression of the 
Wnt ligands (Table 1.1) (Brown, 2001; Polakis, 2007). Mutations have been found in genes 
encoding for β-catenin (Morin et al., 1997), APC (Schlosshauer et al., 2000) and axin (Jin et 
al., 2003),  resulting in the stabilization of β-catenin which becomes Wnt independent and 
thus can translocate to the nucleus to activate target oncogenes (Figure 1.4C) (Hoppler and 
Kavanagh, 2007). Interestingly, nuclear localization of β-catenin is linked to epithelial-
mesenchymal transitions (EMTs) which are identified by the loss of E-cadherin (Brabletz et 
al., 2001) and increase in mesenchymal markers such as fibronectin (Kirchner and Brabletz, 
2000). EMT is the key event in metastasis, whereby the cell transforms from epithelial 
phenotype to a mesenchymal phenotype which is capable of migrating to another site of 
metastasis formation (Thiery, 2002). Loss of intercellular adhesion is linked to increased 
motility of the cancer cell and hence increased metastatic ability (Hiscox et al., 2006). 
Table 1. 1 Mutations in the Wnt pathway that result in cancer. 
Mutated gene Function Effect of mutation Reference 
Axin1 tumour suppressor loss of function Oates et al., 2006; 
Satoh et al., 2000) 
Axin2 tumour suppressor loss of function Lammi et al., 2004 ; 
Liu et al., 2000) 
APC tumour suppressor loss of function Schlosshauer et al., 
2000 
β-catenin oncogene gain of function Morin et al., 1997 
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Phosphorylation sites on the N-terminus of β-catenin have been found to be mutated, thus 
resulting in an increase in the nuclear mutated protein (Morin et al., 1997; Rubinfeld et al., 
1997; Wong et al., 2001). The mutations are thought to be located around the binding site of 
the ubiquitin proteosome, thus inhibiting the ubiquitination and degradation of β-catenin 
(Wong et al., 2001). Of the serine/ threonine mutations that occur, the residues, serine 32 and 
45, were the most commonly mutated (Wong et al., 2001). Amit et al. (2002) suggested that 
serine 45 is phosphorylated by CK1 and axin, which primes β-catenin for phosphorylation by 
GSK-3β. Therefore, a change in the serine or threonine residues inhibits the phosphorylation 
and degradation of β-catenin, thus increasing its stability (Morin et al., 1997). 
In cancer, there is a defined decrease in the expression or inactivation of the Wnt antagonists, 
Dkk, Wnt-inhibiting factor-1 (WIF-1) and sFRP due to hypermethylation of their promoters 
(Suzuki et al., 2004; Gehrke et al., 2009). Not only has a decrease in sFRP1 been reported in 
breast cancer (Wong et al., 2002), but also WIF-1, whereby its RNA expression was 
decreased up to 60 % (Wissmann et al., 2003). Gehrke et al. (2009) suggested a possible 
therapeutic strategy could be employed that would use demethylating agents (an epigenetic 
therapy) to reinduce the gene expression. This would allow for the expression of Dkk, WIF-1 
and sFRP which would negatively regulate Wnt/β-catenin signaling and inhibiting 
tumourigenic target gene expression. 
Figure 1.4. Comparison of the Wnt/β-catenin pathway in the presence of Wnt (A), absence of Wnt (B) and 
in cancer (C). Wnt proteins bind to receptors, Frizzled (Fz) and low density lipoprotein receptor-related 
proteins (LRP). The destruction complex comprises axin, adenomatous polyposis coli (APC) and glycogen 
synthase kinase-3β (GSK-3). In the presence of Wnt (A), signaling via Disheveled (Dsh) and/or axin leads to the 
inactivation of the destruction complex resulting in β-catenin stabilization and accumulation in the cytosol 
where it translocates to the nucleus and binds to the proteins T-cell factor (TCF)/ lymphoid enhancer factor-1 
(LEF1) family, initiating the transcriptions of target genes. In the absence of Wnt (B), the destruction complex 
phosphorylates β-catenin leading to its degradation. In cancer (C), the Wnt pathway is aberrantly activated due 
to a number of factors including mutations within the destruction complex. Wnt, wingless-type integration site 
family member (adapted from Brown, 2001; website 3). 
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1.5.1.4 Wnt signaling in colon cancer 
In more than 80 % of colon cancer diseases, the APC gene is mutated, generally in the centre 
of the APC gene (reviewed in Henderson and Fagotto, 2002) resulting in a truncated protein. 
Since APC is involved in the negative regulation of the Wnt pathway, the functional loss of 
APC results in the accumulation of β-catenin in the nucleus, which constitutively associates 
with TCF4 (Korinek et al., 1997). This can result in cancer (Yang et al., 2006). Not only is 
the ability of the truncated protein to bind to other regulatory proteins compromised, but its 
association with microtubules is also disrupted, resulting in a decrease in the microtubule 
stability (Polakis, 2000; Henderson and Fagotto, 2002; Kroboth et al., 2007). Although the 
truncated protein can bind weakly to β-catenin, it does not induce degradation of β-catenin. 
This is because the other members of the destruction complex are not bound. It must be 
noted, however, that APC is only necessary when axin levels are limiting, and that when axin 
expression is increased in cancer cells that lack APC, the activity of the destruction complex 
is returned to normal (reviewed in Clevers, 2006). 
When one of the tumour suppressor APC alleles is mutated, the inherited disorder familial 
adenomatous polyposis (FAP) results, which is characterized by numerous formations of β-
catenin-enriched adenomas in the intestine in early adulthood (Miyoshi et al., 1992; Clevers, 
2006). If there are mutations in both alleles, sporadic colorectal cancer arises (Kohler et al., 
2009). Individuals with mutations in the gene encoding for axin2 are predisposed to 
colorectal cancer (Lammi et al., 2004). 
LEF-1 is not typically expressed in the adult human colon, yet, in colon cancer, full length 
LEF-1 isoforms are expressed (Hovanes et al., 2001). Due to more active TCF/LEF present 
in cancer, more Wnt target gene expression can occur (Hoppler and Kavanagh, 2007). 
The phosphorylation of β-catenin and its degradation ensures that the cytoplasmic levels of β-
catenin are kept in check. Colonospheres are a group of colon cancer cells that have cancer 
stem cell-like characteristics. In these cells, the expression levels of axin1 and p-β-catenin are 
found be lower than that of normal colon cancer cells (Kanwar et al., 2010). In contrast the 
expression levels of β-catenin (immunohistochemical staining) and phosphorylated GSK-3β 
are higher in the colonospheres in comparison to the normal colon cancer cells indicating that 
the Wnt pathway plays a key function in growth and maintenance of colonospheres (Kanwar 
et al., 2010). 
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1.5.1.5 Wnt signaling in breast cancer 
Nuclear/ cytoplasmic accumulation of β-catenin has been found in more than 60 % of breast 
cancers (Lin et al., 2000; Nakopoulou et al., 2006) suggesting that the Wnt pathway is 
aberrantly activated. On the other hand, there are studies that have found little or no 
nuclear/cytoplasmic β-catenin (Gillett et al., 2001; Wong et al., 2002; Dolled-Filhart et al., 
2006). Further evidence supporting the theory that the Wnt pathway is activated in breast 
cancer comes from the activation of the Wnt pathway by truncation of the APC gene in mice, 
which leads to tumours forming in the mouse mammary tissues (Moser et al., 2001). In 
murine breast cancer, the gene encoding for Wnt-1 was identified as an oncogene that was 
activated by the mouse mammary tumour virus (Nusse and Varmus, 1992). More recently, 
Schlange et al. (2007) confirmed that the Wnt pathway is constitutively active in breast 
cancer cells by identifying that there were consistent expression levels of phosphorylated 
Dsh, a downstream constituent of the activated pathway.  
In addition to mutations in the Wnt pathway, alterations to the Wnt pathway can occur by 
other means, such as at the Wnt-ligand interface (Collu et al., 2009). Examples include the 
overexpression of Wnts (Milovanovic et al., 2004), decrease in sFRP1 expression (Veeck et 
al., 2006 and 2008), and the overexpression of Dsh1, whose gene product is required in the 
canonical pathway (Nagahata et al., 2003; Milovanovic et al., 2004). Furthermore, treatment 
of breast cancer cells with purified sFRP resulted in cell proliferation being inhibited by as 
much as 30 % and a decrease in active β-catenin in some cell lines, whilst other cell lines, 
such as MCF7 cells were not affected (Schlange et al., 2007). Another study linked Wnt 
signaling to cell motility in the breast cancer cell line, MDA-MB-231, such that treatment of 
the cells with sFRP1 decreased the motility (Matsuda et al., 2009). 
Downregulation of Dsh resulted in a decrease in β-catenin as well as the Wnt target, c-Myc in 
some of the breast cancer lines (Schlange et al., 2007). As expected, the transcriptional 
activity due to the β-catenin-TCF association increases in some breast cancer cell lines (Lin et 
al., 2000). An example is Cyclin D1, which is overexpressed in half of the breast cancer 
patients. Since the gene encoding for cyclin D1 has a T cell factor (TCF4) binding site, it is 
thought there is some link between its expression and the β-catenin/TCF4 pathway (Kelleher 
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et al., 2006). Indeed, an association was found between the activation of β-catenin and cyclin 
D1, which resulted in poorer clinical outcome (Lin et al., 2000). 
The differences in the Wnt pathway mutations, if any, could be attributed to different tissues 
and organs requiring redundant proteins for different uses (Brown, 2001). An example of this 
is axin and APC, which are necessary members of the destruction complex in the liver and 
colon, whilst their homologs, Conductin and APC2 might be essential in breast tissue 
(Brown, 2001). However, studies on these mutations are not well documented. Another 
explanation could be that in breast cancer, there are mutations upstream of the axin complex, 
such as in the Wnt receptors which could account for the nuclear β-catenin staining (Brown, 
2001). An example is the Wnt10b gene, which is expressed at low levels under normal 
circumstances and when overexpressed causes murine mammary breast cancer. A similar link 
has been found between the overexpression of the human WNT10B gene and breast cancer 
(Bui et al., 1997). The Wnt pathway in breast cancer may also be stimulated by other 
regulators of the pathway (Brown, 2001).  
Although there are many theoretical approaches to inhibiting the Wnt/β-catenin pathway, it is 
rare that they have been put to use in the human system due to the risk of side effects (Gehrke 
et al., 2009). These could arise if the signaling pathway is interrupted too far upstream. It has 
however been shown that inhibiting the components further downstream has been linked to 
anti-neoplastic effects with a reduction in side effects (Gehrke et al., 2009. It is thus 
interesting to see if selective disruption of the Wnt signaling will have an effect on cancer 
treatment (Gehrke et al., 2009).  
1.6 Other Signaling pathways 
1.6.1 PTEN  
Akt is involved in cell proliferation and survival and is overexpressed in many cancers such 
as breast, prostate, lung, pancreatic, ovarian, and colorectal cancers (Vivanco and Sawyers, 
2002). It is stimulated by upstream kinases, PI3-K and pyruvate dehydrogenase kinase (PDK) 
1 (Zhang and Burrows, 2004) and is counteracted by PTEN through a dephosphorylation 
process. Decrease in PTEN stimulates Akt, mTOR, inhibiting PI3-K and resulting in the 
deactivation of GSK-3β by phosphorylation and increase in stabilized β-catenin (Figure 1.2) 
(Cross et al., 1995). Akt has also been found to be a client protein of HSP90; depending on 
HSP90 for its stability and activity (Basso et al., 2002A and B). 
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In a similar manner, GSK-3β affects mTOR independently of β-catenin (Inoki et al., 2006) 
(Figure 1.2). When Wnt is not present, GSK-3β phosphorylates tuberin which activates the 
GTPase-activating protein (GAP) activity of tuberin, leading to the inhibition of mTOR 
kinase. Therefore, when Wnt is present, GSK-3β is inhibited resulting in an upregulation of 
mTOR activity (Wullschleger et al., 2006).   
1.6.2 Notch Signaling 
Notch signaling plays a key role in cell fate determination, apoptosis and proliferation during 
mammary development by inhibiting the differentiation of stem/progenitor cells (Dontu et 
al., 2004). It has been suggested that aberrant activation of Notch signaling is associated with 
carcinogenesis (Stylianou et al., 2006). Furthermore, inhibition of Notch signaling can 
change the transformed phenotype of human breast cancer cell lines (Stylianou et al., 2006), 
giving an implication of the benefits of inhibiting this signaling for therapeutic designs 
(Stylianou et al., 2006). The Notch and Wnt pathway are linked in breast cancer, whereby 
ectopic Wnt-1 expression resulted in the transformation of human mammary epithelial cells 
by a mechanism that involved the upregulation of Notch signaling (Ayyanan et al., 2006). 
Furthermore, Notch1 has been found to bind directly to β-catenin (Hayward et al., 2006) and 
both the Wnt pathway and Notch pathway share common cofactors (Alves-Guerra et al., 
2007), GSK-3β phosphorylates Notch which regulates its activity (Espinosa et al., 2003), and 
β-catenin activation of the Notch ligand by transcription (Rodilla et al., 2009). 
When the ligands, Delta and Jagged bind to Notch receptors, three proteolytic cleavages are 
initiated (Figure 1.5). These include two cleavages in the extracellular domain followed by 
one in the plasma membrane by the complex γ-secretase complex. This results in the release 
of the intracellular domain of the receptor into the cytoplasm where it translocates to the 
nucleus to act on target genes (Frisén and Lendahl, 2001). Certain therapies have been 
developed that target the inhibition of the γ-secretase complex, which has been shown to 
inhibit Notch signaling and decrease the stem cell population or slow the γ-secretase growth 
of some tumours (Fan et al., 2006). 
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Figure 1.5. Schematic representation of Notch signalling. Notch is activated by the binding of its ligands 
Delta and Jagged to the ligand receptors. This results in the cleavage of the Notch extracellular domain by 
TACE, following which γ-secretase cleaves the intracellular domain from the membrane. The Notch 
intracellular domain then moves to the nucleus where it interacts with the CSL to activate transcription of target 
genes. TACE, tumour necrosis factor alpha converting enzyme, CSL, transcription factor (adapted from 
Hambardzumyan et al., 2008). 
 
1.6.3 Hedgehog Signaling 
Hedgehog signaling comprises three ligands Sonic, Desert and Indian. Hedgehog signaling is 
involved in the self-renewal of both normal and malignant mammary stem cells and 
deregulation of the pathway is linked to cancer (Liu et al., 2006). Furthermore, an inhibitor of 
the Hedgehog pathway, cyclopamine has been shown to reduce the rate of mammary tumour 
cells in vitro (Kubo et al., 2004). However, MCF7 cells were found to be more resistant to 
cyclopamine (Kubo et al., 2004).  
The pathway is highly organized and kept inhibited by the transmembrane protein Patched1 
(Ptch 1). Activation of the pathway occurs when Shh binds to the receptor (Figure 1.6), Ptch 
1 which in turn activates the transmembrane protein Smoothened (Smo). This sequesters the 
release of Gli which translocates to the nucleus and activates the target genes (Ingham and 
McMahon, 2001). 
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Figure 1.6. Schematic representation of Sonic hedgehog (Shh) signaling pathway. When Shh binds to the 
receptor, Ptch1, Smo is activated to activate Gli, which translocates to the nucleus and activates the target genes 
(adapted from Hambardzumyan et al., 2008). Ptch 1, Patched 1; Smo, Smoothened; Gli, transcriptional 
activator. 
1.7 Molecular chaperones and HSP90 
Heat shock proteins (HSPs) are chaperones that have an increased expression in tissues that 
are exposed to proteotoxic stressors such as elevated temperatures, heavy metals, hypoxia and 
acidosis (Whitesell and Lindquist, 2005). In addition to this, Westerheide and Morimoto 
(2005) reviewed that there is an increased expression of HSPs when cells undergo mutations 
or are exposed to environmental stress, such as inflammation, tissue repair, cancer, and 
neurodegenerative diseases. In spite of the name “heat shock protein”, most chaperones are 
constitutively expressed under normal conditions and their adaptive response ensures cell 
survival (Whitesell and Lindquist, 2005). 
Heat shock protein 90 (HSP90) is a 90 kDa protein which is one of the most abundant 
chaperones and is highly conserved in prokaryotes and eukaryotes (Borkovich et al., 1989; 
Ferrarini et al., 1992) and, under normal physiological conditions, is required for important 
cellular processes, which include hormone signaling, self-renewal and differentiation 
(Helmbrecht et al., 2000). In addition to this, it assists with protein folding and translocation 
(Young et al., 2001; Picard, 2002; Wandinger et al., 2008). 
Five isoforms of HSP90 have been identified, which include HSP90α, HSP90β, HSP90N, 
Grp94 and Trap1 (reviewed in Li et al., 2009). HSP90β is constitutively expressed whilst 
HSP90α is induced by stress and both are cytosolic (Sreedhar et al., 2004). The membrane 
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associated HSP90N completely lacks the N-terminus which is involved in ATPase activity 
(Grammatikakis et al., 2002). Grp94, associated within the endoplasmic-reticulum and Trap1, 
associated with the mitochondria, have only been described in higher eukaryotes (Felts et al., 
2000; Ni and Lee, 2007).   
Studies of the crystal structures of yeast HSP90 (Ali et al., 2006) and Grp94 (Dollins et al., 
2007) provide evidence that HSP90 exists primarily as a homodimer, although 
heterodimerization of HSP90α and HSP90β can occur (Neckers et al., 1999). Each monomer 
comprises three highly conserved domains: the amino terminal domain (N-terminal), middle 
domain and the carboxy terminal domain (C-terminal) (Figure 1.7) (Pearl and Prodromou, 
2006). The N-terminal domain has an ATP-binding pocket with ATPase activity (Dutta and 
Inouye, 2000). The middle domain is also involved in client protein binding (Hawle et al., 
2006), whilst the C-terminal dimerization domain reinforces the association between the two 
N-terminal domains of the monomers (Terasawa et al., 2005). The C-terminal domain of 
eukaryotic, cytosolic HSP90 has a pentapeptide (-MEEVD) which binds to the 
tetratricopeptide repeat (TPR) domain of HSP90 co-chaperones, such as HSP70/90 
organizing protein (Hop) (Terasawa et al., 2005; Pearl et al., 2008). 
The HSP90 dimer undergoes a conformational change that allows it to associate with its 
client protein (Figure 1.7). In the “open” conformation, the N-terminal domains are separate 
allowing for the binding of a client protein (Richter et al., 2008) (Figure 1.7A). When ATP 
binds to the N-terminal domains, a conformational change results in the N-terminal domains 
coming together and “clamping” the client protein (Richter et al., 2008) (Figure 1.7B). The 
ATPase activity of HSP90 drives the chaperone cycle (Kamal et al., 2004).  
The chaperone cycle starts with the nascent protein binding to the Hsp70/Hsp40 complex, 
which is associated with the “open” HSP90 conformation via Hop, which binds to both 
HSP90 and Hsp70 (Pearl et al., 2008). Hop not only binds to the –MEEVD region of HSP90, 
but also to the N-terminal, preventing HSP90 from “closing” so that the client protein can be 
transferred to HSP90 from Hsp70 (Terasawa et al., 2005). Upon ATP binding to HSP90, Hop 
is displaced by p23 and immunophilins, and the intermediate chaperone complex is 
transformed to the mature complex (Neckers, 2003). Activator of HSP90 ATPase (Aha1), 
binds to the middle domain of HSP90, assisting with the HSP90 conformational change so 
that ATP can bind (Meyer et al., 2004). ATP hydrolysis stimulates the release of the client 
protein from HSP90 (Terasawa et al., 2005). 
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Figure 1.7. Schematic diagram of the binding of HSP90 to its client protein via its ATP-molecular clamp. 
HSP90 exists as a dimer, with each monomer comprising C-terminal domain (C), middle domain (M) and N-
terminal domain (N). (A) When ATP is not bound, an antiparallal dimer is formed by the C-terminal domain, 
with the N-terminal domains open for capture of the client protein. (B) When ATP binds to the N-terminal 
domain, a conformational change causes the N-terminal domains to clamp over the client protein (adapted from 
Brown et al., 2007). 
1.8 HSP90 and cancer 
There is an increased expression of HSP90 in tumours and cancers in comparison to normal 
tissues, such that it comprises as much as 4-6 % of the total protein in cancer cells in 
comparison to 1-2% in normal cells (Chiosis and Neckers, 2006). It has been found that 
HSP90 is in a highly complexed state with high ATPase activity in tumours in comparison to 
normal cells where it is relatively uncomplexed and in a latent state (Kamal et al., 2003; 
Chiosis and Neckers, 2006). This suggests its potential roles in assisting the tumour cells with 
maintaining homeostasis, as well as regulating growth and survival in a hostile environment 
(Solit and Chiosis, 2008). HSP90 stabilizes and protects oncogenic client proteins from 
proteosomal degradation and assists in oncogenesis and malignant transformation (Grbovic et 
al., 2006). 
HSP90 plays an important role in the oncoproteins involved in cell proliferation and survival 
of cancer cells (Table 1.2). These client proteins include serine/ threonine kinases (Akt) and 
protein expressed from v-raf-1 murine leukemia viral oncogene homolog 1 (RAF-1); human 
epidermal growth factor receptor 2 (HER-2) and hypoxia inducible factor 1/ signal transducer 
and activator of transcription 3 (HIF-1α/STAT3) in addition to p53, casein kinase 2 (CK2), 
cell division kinase 4 (Cdk4) and mutated p53 (Kim et al., 2008). For a more extensive list of 
HSP90 interactors see Appendix A9. The inhibition of HSP90 has been linked to cancer cell 
differentiation (Goetz et al., 2003). 
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It is well known that chaperones and client proteins are involved in senescence programs in 
cancer (Restall and Lorimer, 2010). An example of a protein that is associated with the 
HSP90 complex is cell division cycle 37 (Cdc37), which has been found to be up-regulated in 
cancer (Stepanova et al., 2000). Cdc37 is involved in cell division and maintenance of 
signaling pathways associated with kinases such as Src, RAF-1 and Cdk4 (Stepanova et al., 
1996). The immunophilins, FK506-binding protein (FKBP) 52 FKBP52 and FKBP51 are 
also upregulated in cancer cells (Periyasamy et al., 2007) and mouse embryonic stem cells. 
Another particularly interesting protein is mortalin, which inhibits p53 (Wadhawa et al., 
1998) and thus is involved in tumour formation. Furthermore, p53 inhibits the 
phosphorylation of STAT3, whilst STAT3 down regulates the expression of p53 in cancers 
(Lin et al., 2002; Niu et al., 2005).  
STAT3 is linked to the activation of the Wnt pathway. Leukemia inhibitory factor (LIF) and 
the interleukin 6 family bind to their receptors, gp130 on the cell surface membrane, 
triggering a signal cascade, in which the STAT3 becomes phosphorylated, resulting in the 
transcription of genes involved in stem cell proliferation, such as WNT5A (Darnell et al., 
1994; Katoh and Katoh, 2007). The WNT5A in turn activates the canonical Wnt signaling 
pathway (reviewed in Katoh and Katoh, 2007), and an upregulation of WNT5A has been 
found in breast cancer (Iozzo et al., 1995). WNT5A is upregulated in the initial stages of 
primary tumours due to tumour-stromal interaction. Studies have shown that inhibition of 
HSP90 disrupted the STAT3 pathway, such that there was a decrease in phosphorylation of 
STAT3 which was associated with a decrease in tumour growth (Lang et al., 2007). A 
possible explanation for this could be that the inhibition of the phosphorylation of STAT3 by 
HSP90 resulted in the inhibition of the transcription of WNT5A, a key gene in cancer cell 
proliferation (Katoh and Katoh, 2007). 
Although HSP90 is required for both cancer and normal cells, cancer cells appear to have a 
higher sensitivity to inhibition of the HSP90 chaperone function (Park et al., 2003). Inhibitors 
of HSP90 could thus be used in addition to or as an alternative to chemotherapy (Pick et al., 
2007). On the other hand, it must be noted that to compromise the HSP90 function could 
result in exposing the underlying genotypic diversity, such as the cancer stem-like cells, 
resulting in an acceleration of malignancy in advanced cancers (Whitesell and Lindquist, 
2005). It can therefore be said that timing of cancer therapies is a key factor. There is 
suggestion for the potential role of HSP90 as a prognostic marker since high HSP90 
expression is associated with decreased survival in primary breast cancer (Pick et al., 2007).  
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Table 1.2 HSP90 client proteins involved in proliferation and survival of cancer cells  
Client 
protein 
Function of client protein and association with HSP90 Reference 
mutated p53 Tumour suppressor protein. Abrogated p53 interacts with 
HSP90/p23 to form stable complex 
Zhau et al., 
2000; Vousden 
and Lu, 2002 
p60v-src HSP90 associates with p60v-src and assists with the 
translocation of its inactive form to the plasma membrane 
Brugge, 1983 
CK2 Involved in cell proliferation. HSP90 binds to CK 2 and is 
involved in kinase activity, preventing self aggregation  
Miyata and 
Yahara, 1992 
Cdk4/ Cdk6 Involved in cell progression through G1 phase. HSP90 
folds and maintains Cdk4 in an primed, inactive state 
Stepanova et al., 
1996 
STAT3 Inhibits apoptosis and increases cell transformation. 
HSP90 stabilizes STAT-transporter interactions  
Kim et al., 2008 
 p60v-src, tyrosine kinase of Rous sarcoma virus, CK, casein kinase, Cdk4, cyclin dependent kinase 4, STAT3, signal 
transducer and activator of transcription 3 
 
1.9 HSP90 inhibitors 
A number of HSP90 inhibitors have been investigated, which are separated into four classes 
according to their method of inhibition (Table 1.3). Benzoquinone ansamycins, such as 
geldanamycin, bind to the N-terminus of HSP90, competing with ATP. HSP90 is thus kept in 
its ADP-bound conformation and therefore prevented from clamping around a client protein, 
resulting in the degradation of the client protein (Blagg and Kerr, 2006; Neckers, 2006). In a 
similar manner, novobiocin binds to the C-terminus of HSP90 and therefore results in the 
degradation of client proteins (Marcu et al., 2000).  
HSP90 receives client proteins from HSP70/HSP40 with the aid of Hop and client protein 
association is increased in the presence of other co-chaperones such as p23 and Cdc37 
(Richter and Buchner, 2001).  In comparison to targeting the ATP binding, HSP90 inhibitors 
that target the co-chaperone association with HSP90 or HSP90 and client protein association, 
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provide a better target of inhibition since the progression of the chaperone cycle is inhibited 
(Pearl et al., 2008).  
Table 1.3. Examples of HSP90 inhibitors and their mode of action (adapted from Prinsloo et al., 2010) 
HSP90 Inhibitor Inhibitor mode of action 
Geldanamycin
1
, 17-AAG
2
, IPI-504
3
, 
Radicocol
1
, 17-DMAG
3
 
Competitive inhibition of ATP at N-terminus 
 
 
Novobiocin
4
, chlorobiocin
4
, coumermycin 
A1
5
 
Competitive inhibition of ATP at C-terminus 
Celastrol
6
 Targeting of HSP90/ co-chaperone 
association 
Shepherdin
7
 Targeting of HSP90/ client protein 
association 
Tubocapsenolide A
8
 Interference with post-translational 
modification of HSP90 
1 
Roe et al., 1999. 2 Goetz et al., 2003. 3 Hollingshead et al., 2005. 4 Marcu et al., 2000. 5Burlison and Blagg, 2006. 6 Zhang et al., 2009B. 7 
Plescia et al., 2005. 8 Chen et al., 2008 
There are currently 13 HP90 inhibitors in clinical trial (Kim et al., 2009), such as 17-AAG, 
which has been used in Phase 1 trials since 1999 (Pacey et al., 2006) and is now being tested 
in Phase 2 clinical trials (Ronnen et al., 2006). Together with trastuzumab, 17-AAG has 
shown promising anti-tumour activity (Modi et al., 2007). However, it must be noted that 17-
AAG has a few disadvantages, such as low water-solubility, instability in solution and 
decreased oral bioavailability (Messaoudi et al., 2008).  
Different client proteins respond differently to HSP90 inhibitors, with some exhibiting more 
sensitivity than others. For example, HER-2 is more sensitive than Akt in response to HSP90 
inhibition by ansamycin antibiotics (Basso et al., 2002A). Client proteins that are rapidly 
degraded are more likely to require HSP90 for stability (Liu and Carpenter, 1993; Xu et al., 
2001). A factor that may influence the sensitivity and kinetics of a client protein for HSP90 is 
the affinity of the protein for the HSP90 complex as well as the intracellular concentration of 
the protein in the cell (Zhang and Burrows, 2004). Therapies targeted at the inhibition of 
HSP90 alone could be counter-intuitive since other co-chaperones could be upregulated as a 
result. Instead, therapies should be aimed at targeting the co-chaperone interaction (reviewed 
in Prinsloo et al., 2010). 
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1.10 Cytosolic HSP90 and the Wnt pathway  
Very little is known about the role of HSP90 in the Wnt signaling pathway in breast cancer. 
One study suggested that HSP90 assisted in the correct folding of GSK-3β, preventing the 
kinase from degradation (Banz et al., 2009). It was also shown to be involved in the 
autophosphorylation of GSK-3β in rabbit reticulocyte lysate; a process which occurs as GSK-
3β matures. HSP90-induced inhibition by geldanamycin had an effect on the transitional 
intermediate of GSK-3β, but did not affect the mature, phosphorylated GSK-3β (Lochhead et 
al., 2006). More recently, HSP90 has been found to be associated with GSK-3β in human 
hepatocellular carcinoma Hep3B cells, thus indicating the importance of HSP90 for the 
serine/threonine activity of the mature GSK-3β   (Banz et al., 2009).  
IĸB kinase (IKK) has been found to be associated with HSP90 and Cdc37 (Chen et al., 2002). 
IKK regulates β-catenin by phosphorylation resulting in degradation (Lamberti et al., 2001) 
therefore providing a link between HSP90 and the Wnt pathway. Zhang and Burrows (2004) 
reviewed that because β-catenin is involved in cell-cell adhesions and plays a role in the 
association of E-cadherin with intracellular actins, inhibition of HSP90 could influence these 
events of cell adhesion.  
More recently, Kurashina et al. (2009) showed that upon 17-AAG and D-MAG treatment, 
there was a decreased expression of the downstream target gene encoding for TCF7L2 in 
adult T cell leukemia/lymphoma (ATL) cells. They hypothesized that treatment with HSP90 
inhibitors cause the dephosphorylation of Akt, thus activating GSK-3β, which in turn 
phosphorylates β-catenin for ubiquitination.  
Other potential HSP90 clients involved in the Wnt pathway include casein kinase 2 (CK2), 
which is linked to the phosphorylation of Cdc37 in the HSP90-Cdc37 complex (Miyata, 
2009). Since Cdc37 mediates the recruitment of HSP90 to kinases (Hinz et al., 2007), 
Prinsloo et al. (2010) proposed that the CK2-HSP90-Cdc37 complex is associated with the 
Wnt destruction complex by GSK-3β. 
It would be important to characterize the possible association between HSP90 and the 
components of the Wnt signaling pathway in breast cancer in order to provide a mechanistic 
understanding of the fundamental regulation of the Wnt pathway. In would thus allow for an 
understanding of where to target therapeutic HSP90 inhibitors to disrupt the Wnt pathway.  
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1.11 Problem statement and knowledge gap 
The multichaperone complex requires clarification in the Wnt pathway in breast cancer. 
HSP90 has been found to be associated with GSK-3β but little is known about the 
involvement of HSP90 with other members of the Wnt pathway in breast cancer. In addition 
to this, the interactions between HSP90 and the Wnt pathway proteins, particularly β-catenin 
and p-β-catenin require clarification in breast cancer. 
1.12 Hypothesis 
HSP90 plays a significant role in the Wnt pathway through the modulation of the disheveled 
complex and p-β-catenin in breast cancer. 
1.13 Objectives 
The broad objective is to characterize the interaction between HSP90 and the Wnt pathway 
components in the breast cancer line MCF7, with a comparative analysis of expression levels 
in the colon cancer line HT29. 
1.13.1 Specific Objectives 
o Culturing MCF7 and HT29 cells and comparing the protein expression levels between the 
two cell lines. 
o Identification of associations between HSP90 and the members of the Wnt pathway, such 
as GSK-3β, axin1, β-catenin and p- β-catenin, by co-immunoprecipitation, will be 
performed. 
o Identification of the effects of HSP90 inhibition by geldanamycin, 17-AAG and 
novobiocin on protein expression levels of the members of the Wnt pathway. 
o Identification of localization and co-localization of HSP90 and the members of the Wnt 
pathway, and the effect of HSP90 inhibitors on the localization of these proteins.  
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Chapter 2: Materials and Methods 
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2.1 Materials 
All chemicals, culture media, molecular biology reagents, suppliers, catalogue numbers and 
equipment are listed in Appendix A5-8. The antibodies used in this study are listed below 
(Table 2.1-2.3). Unless stated otherwise, all reagents were of the highest grade and purity. 
Table 2.1. List of primary antibodies used for Western analysis and confocal microscopy 
Antibody Company catalogue dilution for 
Western 
detection 
dilution for 
confocal 
microscopy 
mouse anti-human HSP90α/β 
IgG2a monoclonal antibody 
Santa Cruz 
Biotechnologies 
sc 13119 1:1000 1:100 
rabbit polyclonal anti-human 
GSK-3β 
Santa Cruz 
Biotechnologies 
sc 9166 1:1000 1:100 
rabbit polyclonal anti-human 
β-catenin 
Santa Cruz 
Biotechnologies 
sc 7199 1:1000 1:100 
rabbit polyclonal anti-human 
axin1 
Santa Cruz 
Biotechnologies 
sc 14029 1:1000 1:100 
rabbit polyclonal anti-actin Sigma-Aldrich A 2103 1:2000  
mouse monoclonal anti-
phospho-β-catenin 
(pSer33/pSer37) 
Sigma-Aldrich C 4231 1:800 1:100 
mouse monoclonal anti-human 
p-STAT3 IgG2b 
Santa Cruz 
Biotechnologies 
sc 8059 1:1000  
rabbit polyclonal anti-human 
STAT3 IgG 
Santa Cruz 
Biotechnologies 
sc 482 1:1000  
rabbit polyclonal anti-human 
Akt1/2/3 
Santa Cruz 
Biotechnologies 
sc 8312 1:1000  
 
Table 2.2. Secondary antibodies for Western detection 
Antibody Company Catalogue Dilution 
Goat anti-mouse IgG F(ab‟)2 Polyclonal Antibody, 
HRP 
KPL 474 1806 1:5000 
Donkey anti-rabbit IgG polyclonal antibody, HRP GE 
Healthcare 
NA 934V 1:5000 
Table 2.3. Secondary antibodies for confocal microscopy  
Antibody Company Catalogue Dilution Colour 
Alexa Fluor® 488 chicken anti-
rabbit IgG (H+L) 
Invitrogen A21441 1:1000 green 
Alexa Fluor® 546 donkey anti-
mouse IgG (H+L)  
Invitrogen A10036 1:1000 red 
Alexa Fluor® 633 donkey  anti-
goat IgG (H+L) 
Invitrogen A21082 1:1000 purple 
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2.2 Methods 
2.2.1 Mammalian tissue culture 
2.2.1.1 Routine maintenance of MCF7 breast cancer epithelial cells 
The MCF7 human breast epithelial cancer cells (a gift from Dr Sharon Prince, Department of 
Human Biology, University of Cape Town, Cape Town, South Africa) were initially seeded 
onto 25 cm
3
 tissue culture flasks (T25, Corning) to increase cell confluency as determined by 
light microscopy. The cells were then passaged by trypsinization onto 75 cm
3
 tissue culture 
flasks (T75, Corning) and maintained in complete media comprising Dulbecco‟s modified 
Eagle‟s medium (DMEM), 5 % (v/v) heat inactivated fetal calf serum (HIFCS), 50/50 
penicillin/streptomycin (100 U/ml). The cells were incubated in a humidified incubator at    
37 °C, in a 9 % CO2 atmosphere. 
Cell cultures were split 1:2 once 80 % confluency was attained, as judged by light 
microscopy. Cells were split by washing with phosphate buffered saline (PBS) pH 7.4, 
following which trypsin/ethylenediaminetetraacetic acid (EDTA) was added for a few 
minutes at 37 °C to generate a single cell suspension. Complete media was added to the 
trypsin suspension to inhibit further trypsinization, and the cell suspension was transferred to 
a sterile 15 ml tube. A small aliquot was removed from the cell suspension which was used 
for cell counting using a volume hemocytometer. Trypan Blue was used to stain the cells, 
with blue cells being identified as dead. Centrifugation of the cell suspension was carried out 
at 720 g, at 4 °C for 2 minutes. The supernatant was poured off the pelleted cells, and the 
cells were resuspended in the residual volume to create a single cell suspension, before more 
complete media (20 ml) was added. The cells were then seeded onto 2 x 75 cm
3
 tissue culture 
flasks. All cell cultures were routinely checked for Mycoplasma (see Appendix A1 for 
protocol). 
2.2.1.2 Routine maintenance of human colorectal cancer line HT29 
Human colorectal cancer line, HT29 (a gift from Dr C. Penny, Wits University, 
Johannesburg, South Africa) were maintained in the same way as the MCF7 cells (see section 
2.2.1.1). The cells were split 1:4 and more frequently than MCF7 cells. HT29 cells were 
found to be contaminated with Mycoplasma prior to immunoprecipitation studies therefore 
were only used as a comparative cell line for determining the expression level of Wnt 
pathway proteins. 
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2.2.1.3 Cryopreservation of mammalian cells 
Following trypsinization (see section 2.2.1.1), cells from one confluent T75 flask were 
resuspended in complete media, followed by centrifugation at 720 g. The pelleted cells were 
resuspended in 1 ml cryopreservation media (10 % (v/v) dimethyl sulphoxide [DMSO] in 
HIFCS). The solution was transferred to 1 cryo vial, kept on ice for about half an hour before 
being stored at -80 °C.  
2.2.2 Association of members of the Wnt pathway and HSP90 in MCF7 and 
HT29 cells 
2.2.2.1 Harvesting cells for immunoprecipitation 
Four flasks (T75) of MCF7 cells (approximately 2-3 x 10
7
 cells) were harvested at 
approximately 100 % confluency. The cells were washed with PBS (pH 7.4) before 
trypsinization. Further trypsinization was inhibited by adding complete media. A small 
aliquot of cell suspension was then removed to be used for cell counting. Cells were pooled 
and pelleted by centrifugation at 720 g, 4 °C, for 2 minutes. The pooled, pellet of cells was 
resuspended in 1 ml PBS pH 7.4 and transferred to a sterile 1.5 ml microcentrifuge tube.  
2.2.2.2 Cell lysate preparation 
Trypsinized cells were immediately pelleted at 720 g, for 2 minutes. After centrifugation, the 
supernatant was removed and the pelleted cells were resuspended in the residual volume 
before 200 μl of ice cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1mM Na3VO4, 1 % (v/v) Nonidet P40 (NP40), 1 mM 
sodium deoxycholate, 1 mM PMSF, 2 μg/ml protease inhibitor cocktail) was added.  Lysis 
was allowed to occur on ice, on a rocking platform for 30 to 60 minutes. Cell debris was 
discarded by centrifugation at 12 000 g, 4 °C for 30 minutes, and the supernatant used for 
immunoprecipitation. 
2.2.2.3 Immunoprecipitation 
Lysate aliquots (100 μl) were transferred to 2 separate 1.5 ml microcentrifuge tubes. The 
remaining residual volume was aliquoted (10 μl) and stored at -20 °C to be used as the 
positive control. A preclearing step was performed during which protein A/G PLUS-agarose 
immunoprecipitation reagent (Santa Cruz Biotechnologies, USA) (20 μl) was added to the 
lysates and the resulting slurries were incubated for 1 hr on a rotating shaker at 180-200 rpm 
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at 4°C. Centrifugation at 1000 g for 5 mins was performed, and the supernatants were 
transferred to a new 1.5 ml microcentrifuge tube. Primary antibodies (4 μg), such as anti-
human GSK-3β, anti-human HSP90α/β and anti-human β-catenin antibodies (see Table 2.1 
for details of the antibodies), were added to the test sample and incubated for 2 hrs at 4 °C on 
a rotating shake at 180-200 rpm. After incubation, protein A/G PLUS agarose 
immunoprecipitation reagent (40 μl) was added to the sample and incubation was continued 
overnight on ice on a rocking platform at 180-200 rpm. The control samples included lysate 
being subjected to immunoprecipitation without antibody; and protein A/G PLUS-agarose 
and antibody, without lysate. In each case, the volumes were kept constant by the addition of 
RIPA lysis buffer. 
Following overnight incubation, the complexes were centrifuged at 1000 g for 5 mins at 4 °C, 
and the pellet washed 4 times with PBS pH 7.4, repeating the centrifugation steps. The final 
pellet was resuspended in 5 X sodium dodecyl sulphate (SDS) sample loading buffer      
(0.063 M Tris, 10 % glycerol, 2 % SDS, 2.5 % bromophenol blue, 6 % β-mercaptoethanol) 
(50 μl)  and the sample boiled for 10 min. After boiling, the sample (10 μl) was resolved by 
SDS-polyacrylamide gel electrophoresis (PAGE) (12 % acrylamide) according to Laemmli 
(1970) (see section 2.2.3) for Western blot analysis (see section 2.2.4). 
2.2.2.4 Immunoprecipitation using Invitrogen (Dynal bead separations) 
Dynabeads co-immunoprecipitation kit 
Rabbit polyclonal anti-human GSK-3β (5 μg) antibody (Table 2.1) was coupled to 
Dynabeads® M-270 Epoxy (5 mg) overnight according to manufacturer‟s instructions 
(Invitrogen). Bovine serum albumin (5μg) was coupled to Dynabeads® M-270 Epoxy (5 mg) 
overnight as the control. Four T75 flasks (approximately 2-3 x 10
7
 cells) of MCF7 cells were 
harvested (see Section 2.2.2.1) and the resulting pellet was weighed before lysing the cells in 
the calculated volume of extraction buffer for 15 minutes on ice. Co-immunoprecipitation 
was carried out on the supernatant according to manufacturer‟s instructions. 
Immunoprecipitation using bovine serum albumin coupled to Dynabeads® M-270 Epoxy 
instead of antibody coupled to the beads was performed in exactly the same manner as a 
control. In the final step, the protein complex was eluted in 60 μl elution buffer, after which 
20 μl of 5 X SDS sample loading buffer was added to the sample. Samples were boiled for 10 
minutes at 100 °C before the 10 μl aliquots were resolved by SDS-PAGE (12 % acrylamide; 
see section 2.2.3) and Western blot analysis (see section 2.2.4). 
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2.2.3 SDS-PAGE 
Discontinuous SDS-PAGE (12 % acrylamide: bis-acrylamide 30:1) analysis was carried out 
according to Laemmli (1970). Proteins were resolved on an SDS gel (4 % acrylamide 
stacking gel,  pH 6.8, 12 % acrylamide resolving gel, pH 8.8) (see Appendix A6 for recipe) at 
200 V, 64 mA for approximately 1 hour 10 minutes in 1 X SDS-PAGE running buffer (0.3 M 
(w/v) Tris, 1.44 % (w/v) glycine, 0.1 % (w/v) SDS). The gel was stained overnight using 
Coomassie Brilliant Blue staining (0.2 % Coomassie R-250, 40 % (v/v) methanol, 10 % (v/v) 
glacial acetic acid), and destained in destain solution (40 % (v/v) methanol, 10 % (v/v) glacial 
acetic acid). Samples were treated with 5 X SDS-PAGE sample loading buffer (0.063 M Tris, 
10 % glycerol, 2 % SDS, 2.5 % bromophenol blue, 6 % β-mercaptoethanol) and heated for 5 
– 10 minutes at 100 °C on a heating block, before loading onto the gel (12 % acrylamide: bis-
acrylamide 30:1). 
2.2.4 Western blot analysis 
Western blot analysis was performed according to Towbin et al. (1979). Samples were 
resolved on 12 % acrylamide gel by SDS-PAGE. Prior to electroblotting, the gel was washed 
in ice cold transfer buffer (25 mM Tris, 192 mM glycine and 20 % (v/v) methanol) to remove 
excess SDS. Transfer of the resolved proteins was performed onto Trans-Blot® transfer 
nitrocellulose membrane (BioRad, South Africa) in transfer buffer for 1 hr 30 min at 100 V 
(500 mA) with stirring and cooling. Ponceau (0.1 % (w/v) Ponceau S, 1 % (v/v) glacial acetic 
acid) staining was used to confirm protein transfer and the stained membrane was 
photographed. Non-specific binding sites were blocked for 1 hr in 5 % blocking solution (5 % 
(w/v) fat free milk powder in tris-buffered saline (TBS) (0.8 % (w/v) NaCl, 0.24 % (w/v) 
Tris, pH 7.6) in plastic zip-lock bags on a shaker at 180-200 rpm at 4 °C. Primary antibody 
(see Table 2.1) was added to the 2 % blocking solution and the membrane was further 
incubated overnight on the shaker at high speed at 4 °C. The membrane was then washed for 
1 hour in TBS with 0.1 % tween (TBS-T), at 15 min intervals followed by incubation with 
secondary antibody (see Table 2.2) for 45 minutes at 4 °C on the shaker. Three 15 minute 
rinses were performed before detection using the ECL Advanced Western Blotting Kit 
(Amersham Biosciences, GE Healthcare, UK) in Chemidoc
TM 
EQ (BioRad, UK). 
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2.2.4.1 Stripping and reprobing Western blots 
Stripping and reprobing was executed according to the ECL Kit
TM
 (Amersham Biosciences, 
GE Healthcare, UK) protocol. Briefly, the stripping buffer (100 mM 2-mercaptoethanol, 2 % 
(w/v) SDS, 62.5 mM Tris-HCl pH 6.8) was preheated to 50 °C before covering the 
membrane for 10 minutes in an incubator at 50 °C. For a more stringent strip, the membrane 
was incubated with the stripping buffer for 30 minutes. Two 10 minute washes using TBS-T 
were performed at room temperature before the membrane was blocked for 1 hr in blocking 
solution (5 % (w/v) fat free milk powder in TBS). The procedure was performed as 
previously described (Section 2.2.4). 
2.2.5 Inhibition studies 
2.2.5.1 Treatment with 17-Allylamino-17-demethoxygeldanamycin (17-AAG)  
MCF7 and HT29 cells were seeded onto 6 well culture plates (Corning, USA) at a density of 
5 x 10
5 
cells per well, fed with 2 ml complete media and allowed to adhere to the plate 
overnight at 37 °C, 9 % CO2. The following day, the cells were serum-starved for 1 hour 
prior to 17-AAG treatment. 17-AAG stocks (Sigma-Aldrich, USA) were prepared in DMSO 
(1M). Different concentrations of 17-AAG (1 μM, 5 μM, 10 μM) were made up from the 
stock (1M) in complete media and added to the different wells. Media containing only 
DMSO, no 17-AAG, was used as the control. The cells were treated for 72 hours at 37 °C, 9 
% CO2. Following treatment, the media was removed from the cells and non-adherent 
floating cells were pelleted at 720 g for 2 minutes. The adherent and pelleted cells were 
washed with PBS pH 7.4 to removed excess FCS in the media. Lysis was allowed to occur by 
adding 250 μl 5 x SDS-PAGE sample loading buffer to the adherent cells for 15 minutes at 4 
°C, followed by scraping of the lysate into the microcentrifuge tubes containing the pelleted 
cells. The microcentrifuge tubes were boiled for 10 minutes at 100 °C. The samples were 
stored at -20 °C prior to being resolved by SDS-PAGE and Western transfer and analysis.  
2.2.5.2 Treatment with geldanamycin 
MCF7 and HT29 cells were seeded as previously described (see Section 2.2.5.1). The 
following day, the cells were serum starved for 1 hour prior to geldanamycin treatment. 
Geldanamycin stock solutions (BioMol International, USA) (5 mM) were made up in DMSO 
and stored at -20 °C. Working solutions of geldanamycin at 0.1 μM, 0.5 μM, 1 μM, 10 μM 
were made up in complete media and added to the different wells. Media containing only 
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DMSO, no geldanamycin, was used as the control. The cells were treated for 24 hours at 37 
°C, 9 % CO2. Following treatment, the media was removed from the cells and the floating 
cells were pelleted at 720 g for 2 minutes. The same lysis procedure, using 500 μl 5 x SDS-
PAGE sample loading buffer, was performed as previously described (see Section 2.2.5.1). 
2.2.5.3 Treatment with novobiocin  
Fresh stock solutions of novobiocin (10 mM) were made up in distilled water and filter 
sterilized (0.22 μM). The same procedure was carried out as in section 2.2.5.2 with 
concentrations of 100 μM, 260 μM, 500 μM novobiocin being used to treat the cells for 24 
hours. Media without novobiocin was used as the control. 
2.2.6 Comparison of the levels of Wnt pathway proteins between MCF7 and 
HT29 cells 
Each cell line was trypsinized and the single cell suspension was transferred to a 1.5 ml 
microcentrifuge tube in 1 ml PBS. Whole cell lysates were made by lysing the cells in 5 X 
SDS sample loading buffer at a final concentration of 1 x 10
5 
cells/μl and boiling for 10 min 
at 100 °C. The protein samples (5 μl) were resolved by SDS-PAGE and Western blot analysis 
was performed. The Ponceau stained membranes and actin levels were used as the loading 
control. 
2.2.7 Localization of Wnt protein members and co-localization studies 
between Wnt members and HSP90 
2.2.7.1 Treatment of cells for confocal microscopy 
Each cell line was seeded (1 X 10
5
 cells/ well) on borosilicate glass cover slips in 4 well 
culture plates (Nunclon
TM
, Nunc), and allowed to adhere overnight at 37 °C, 9 % CO2. The 
following day, the cells were treated for 5 hours with complete medium containing either 
novobiocin (500 μM final concentration), or 17-AAG (10 μM final concentration). Untreated 
complete medium was used as the control for novobiocin experiments. Completed medium 
containing only DMSO, no 17-AAG was used as the control for 17-AAG experiments. 
Following treatment, complete medium was aspirated, and the cells were washed with PBS 
pH 7.4, before fixing with ice cold methanol (100 % (v/v)). The cells were allowed to dry 
before blocking with filter-sterilized (0.22 μM) blocking solution (1 % bovine serum albumin 
(BSA/ PBS) for 30 mins at room temperature. The cells were then incubated with primary 
antibody (1:100 (v/v) in 0.1 % BSA/PBS solution) (see Table 2.1) overnight at 4 °C. 
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Following overnight incubation, the secondary antibody (1:1000 (v/v) in 0.1 % BSA/PBS 
solution) (see Table 2.3) was incubated at room temperature for 1 hour in the dark, before 2 
washes of 5 minutes were performed with 0.1 % (w/v) BSA/PBS solution. Nuclear material 
was stained with Hoechst 33342 solution (1:1000 in water (v/v)) and the cover slips were 
dried before mounting with Dako fluorescent mounting medium (Dako, USA). The same 
procedure was performed, without primary antibody, as a control. 
Samples were analysed using the Zeiss LSM 510 confocal microscope with 40 X or 60 X oil 
objective with the relevant wavelengths (see Table 2.4). Images were recorded digitally using 
the LSM software (Zeiss, Germany). With each image capture, care was taken that the same 
parameters were used. The inhibitor study images were enhanced by changing the brightness 
and contrast in ImageJ v1.421 (MacroBiophotonics, USA) so that if any change in 
localization occurred, the change could be seen (see Appendix A2, Figures A2.1-A2.3 for 
original images). Cross sections of the cells were analyzed using LSM Image Browser 
v4.2.121 (Zeiss, Germany) to identify the location of the proteins by analyzing the intensity 
of the staining relative to nuclear staining. Non-specific staining was not observed upon 
staining with secondary antibodies only.  
Table 2.4 Excitation and emission wavelengths of the antibodies used in Confocal Microscopy 
Secondary antibody Colour Excitation wavelength (nm) Emission Wavelength (nm) 
Alexa
Fluor
 488 green 499 519 
Alexa
Fluor
 546 red 561 572 
Alexa
Fluor
 633 purple 632 648 
 
2.2.7.1.1    Quantification of co-localization studies  
Quantitative analysis of the co-localization studies on 3 separate, unedited images was 
performed by calculating the average of the Pearson‟s correlation coefficient (Rr), Mander‟s 
overlap coefficient (R) and the coefficients M1 and M2 in the program ImageJ v1.421 
(MacroBiophotonics, USA).  
In addition to this, the colocalization coefficients, M1 (for red signal) and M2 (for green 
signal) were used to identify how well each channel overlapped with the other. These 
coefficients could be used to determine if a red signal overlapped considerably with a green 
signal (Bolte and Cordelières, 2006). 
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3.1 Introduction 
It is well known that molecular chaperones are involved in the modulation of folding and 
assembly of target proteins (Pearl and Prodromou, 2001). Previous studies have shown that 
HSP90 is important for signaling pathways (Schulte, et al., 1995) and it has been suggested 
that HSP90 is involved in the Wnt pathway by association with GSK-3β in Hep3B cells 
(Banz et al., 2009). However, Lochhead et al. (2006) noted that this association in rabbit 
reticulocyte lysates only takes place for the maturation of GSK-3β, and the mature form of   
GSK-3β does not require HSP90.  
3.1.1 Cytoplasmic localization of proteins  
In this study, cytoplasmic localization incorporates both the cytosol and cytoplasm. 
HSP90α/β is mainly localized in the cytoplasm (Taherian et al., 2007), whilst the isoforms 
HSP90N has been found to be associated with the membrane (Grammatikakis et al., 2002), 
Grp94 in the endoplasmic-reticulum (Ni and Lee, 2007) and Trap1 in the mitochondria (Felts 
et al., 2000).  
The members of the Wnt pathway including: β-catenin (López-Knowles et al., 2010), p-β-
catenin (Nakopoulou et al., 2006), GSK-3β and axin1 have also been found to be localized 
mainly to the cytoplasm (Wiechens et al., 2004; Caspi et al., 2008). Two isoforms of axin 
have been identified, which include axin1 and axin2. Axin1 is constitutively expressed and 
regulates the basal level of Wnt signaling, whilst axin2 is upregulated when there is an 
increase in the β-catenin level thus it plays a role in the duration and intensity of a Wnt signal 
(Yan et al., 2001; Lustig et al., 2002). It is thought that axin1 is associated with microtubules 
and is involved in the regulation of the microtubules stability through Dsh (Ciani et al., 
2004). Endogenous axin has been found to be located in small, punctate structures in the 
cytoplasm that shift closer to the plasma membrane when cells are treated with LiCl which 
inhibits GSK-3β (Levina et al., 2004; Wiechens et al., 2004). Since axin recruited other 
members of the destruction complex into these structures, it is thought that these structures 
may be important for β-catenin degradation (Faux et al., 2008). Upon Wnt stimulation, axin 
relocates from the cytoplasm to the plasma membrane in a Dsh dependent manner (Neo et al., 
2000).   
β-catenin forms cell-cell contacts in a complex with E-cadherin and α-catenin at the plasma 
membrane (Kam and Quaranta, 2009). In breast carcinoma cells, β-catenin has been found to 
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be localized in the cytoplasm and plasma membrane (López-Knowles et al., 2010). High 
cytoplasmic β-catenin expression has been associated with poor clinical outcome, high-grade 
tumours with increased rate of proliferation, ER-negative and HER-2 positive breast cancers 
(López-Knowles et al., 2010). β-catenin can become stabilized in the cytoplasm in breast 
cancer due to low APC expression (Ozaki et al., 2005), methylation of the APC promoter 
(Prasad et al., 2008) or APC truncation (Schlosshauer et al., 2000). Studies have suggested 
that cytoplasmic accumulation of β-catenin is linked to endocrine therapy resistance (Hiscox 
et al., 2006; López-Knowles et al., 2010). On the other hand, cytoplasmic localization of p-β-
catenin is linked to good prognosis in breast cancer patients (Nakopoulou et al., 2006). 
3.1.2 Nuclear localization of proteins 
Heat stress and hypoxic shock cause the shift in localization of HSP90α/β to the nucleus 
(Katschinski et al., 2002; Langer et al., 2003). A shift in some of the proteins of the Wnt 
pathway is also seen after Wnt stimulation (Polakis, 2000). This includes the nuclear 
localization of dephosphorylated, stabilized β-catenin (Chan et al., 2002; Staal et al., 2002). 
An increase in nuclear β-catenin can also be seen when stable β-catenin is overexpressed in 
transgenic mice (Harada et al., 1999) or in cell lines (Morin et al., 1999), as well as by using 
inhibitors to prevent β-catenin degradation (Simcha et al., 1998; Henderson et al., 2002).    
GSK-3β and axin1, although mainly localized in the cytoplasm have also been found to occur 
in the nucleus (Salahshor and Woodgett, 2005; Caspi et al., 2008). Nuclear GSK-3β is 
thought to play a role in decreasing the expression level of β-catenin in the Wnt pathway that 
is independent of its phosphorylation of β-catenin (Caspi et al., 2008). It does this by 
decreasing the level of β-catenin/TCF dependent transcription (Caspi et al., 2008). 
Adenocarcinomas and tumours have also been found to have nuclear axin1 and axin2 
(Salahshor and Woodgett, 2005). Since axin1 can move between the cytoplasm and nucleus, 
it is suggested that it acts as a chaperone for β-catenin such that it is required for the shuttling 
of β-catenin from the nucleus into the cytoplasm (Cong et al., 2004A; Wiechens et al., 2004).  
P-β-catenin has also been located in the nucleus of cancers including: melanoma (Kielhorn et 
al., 2003), colorectal (Chung et al., 2001) and breast cancer (Nakopoulou et al., 2006) which 
could be a result of overexpression of the protein and oversaturation of the degradation 
complex such that nuclear localization results (Nakopoulou et al., 2006). Furthermore, 
nuclear p-β-catenin has been linked to poor clinical outcome due to its association with 
aggressive and invasive tumour phenotypes (Nakopoulou et al., 2006). 
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Immunofluorescence and confocal microscopy are used to identify the spatial distribution of 
molecules within a cell. Based on antigen specificity and the development of multiple 
fluorophores, protein presence and location can detected by immunofluorescence (Paddock, 
2005). Co-localization occurs when a signal is emitted at the same pixel position in different 
fluorescence microscopy images (Zinchuk et al., 2007). It gives insight into the structural and 
functional characteristics of proteins analyzed, although not necessarily providing direct 
evidence of their functional relationship (Zinchuk et al., 2007). The Pearson‟s correlation 
coefficient (Rr) describes the similarity between the patterns of the intensity distribution, but 
does not factor the intensities of the signals. The values range from -1 to 1, where 0 
represents no significant correlation and a value from 0.5 to 1 represents co-localization. A 
disadvantage of the Pearson‟s correlation coefficient is that it is restricted to samples with 
approximately equal number of densities in each channel (Manders et al., 1992). To 
overcome this, the Mander‟s overlap coefficient was also used which describes the degree of 
localization by assessing the overlap of the signals. The values range from 0 to 1, with 0.5 
representing 50 % overlap between the pixels in each image (Zinchuk et al., 2007). Values 
from 0.6 to 1 for Mander‟s overlap coefficient indicate co-localization. 
In this study, immunostaining of MCF7 cells was performed to identify whether there is an 
overlap of signals between HSP90 and the components of the Wnt pathway, including GSK-
3β, axin1, β-catenin and p-β-catenin, to see if a possible association of HSP90 exists with 
these proteins. Treatment of MCF7 cells with the HSP90 inhibitors, geldanamycin, 17-AAG 
and novobiocin, was performed to identify whether a change in the localization of the Wnt 
pathway members would occur. 
3.2 Results 
3.2.1 Localization of HSP90 and the Wnt members, GSK-3β, axin1, β-catenin 
and phospho-β-catenin in MCF7 cells 
3.2.1.1 GSK-3β and HSP90α/β 
Using indirect immunofluorescence and confocal microscopy, GSK-3β was found to be 
localized mainly in the cytoplasm in all of the cells, although apparent weak nuclear 
localization was identified in some cells assayed (Figure 3.1A). HSP90α/β was found to be 
localized in the cytoplasm in all of the cells, with some nuclear localization (Figure 3.1A). 
The staining profiles for HSP90α/β and GSK-3β were similar (Figure 3.1B), with both 
proteins having peak intensities outside the nucleus, in the cytoplasmic region. 
43 
 
Immunofluorescence and confocal microscopy also suggested that HSP90α/β was situated in 
a similar location within the cell as GSK-3β (Figure 3.1A, merged).  
Quantitative analysis of the immunofluorescence signals gave a Pearson‟s correlation 
coefficient (Rr) of 0.78 (±0.008) and Mander‟s overlap coefficient (R) of 0.91 (±0.004), 
suggesting co-localization of HSP90α/β and GSK-3β. Furthermore, the M1 (0.996 ±0.002) 
and M2 (0.994 ± (0.002) values indicated that there was a strong overlap between the red and 
green channels, representative of HSP90α/β and GSK-3β staining, respectively.  
 
 
Figure 3.1. HSP90α/β and GSK-3β co-localize. A. Confocal microscopy images of stained MCF7 cells 
captured using a Zeiss LSM 510 confocal microscope. Hoechst: blue nuclear staining.  HSP90α/β (red) using 
anti-human HSP90α/β antibody. GSK-3β (green) using anti-human GSK-3β. Merged: the overlap of Hoechst, 
GSK-3β and HSP90α/β signals with the yellow area highlighting co-localization of GSK-3β and HSP90α/β. B. 
Cross section of a MCF7 cell representing the similar staining profiles for GSK-3β and HSP90α/β.  Profiles 
were obtained using the program Zeiss LSM Image Browser. The blue line represents Hoechst staining of the 
nucleus, the green line represents the signaling for GSK-3β staining and the red line represents the signal for 
HSP90α/β staining. Scale bars represent 20 μm. Dotted line represents cross section of cell used for intensity 
profile. 
 
3.2.1.2 Axin1 and HSP90α/β 
Immunofluorescence and confocal microscopy illustrated how axin1 was localized 
throughout the MCF7 cell in most of the cells (Figure 3.2A), however, the axin1 signal was 
weak. In accordance with section 3.2.1.1, HSP90α/β was found to be localized mainly in the 
cytoplasm in all of the cells assayed, with some nuclear HSP90α/β localization in some of the 
cells (Figure 3.2A). The signals for HSP90α/β staining showed that HSP90α/β appeared to be 
localized mainly in the cytoplasm, with some nuclear localization (Figure 3.2B). The signal 
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for axin1 staining was low and did not change in the different locations throughout the cell. 
(Figure 3.2B). It was difficult to analyze the co-localization between axin1 and HSP90α/β 
since the axin1 staining was weak and there was a difference in the signal intensities of the 
staining of the 2 proteins (Figure 3.2B).   
Quantitative analysis of the immunofluorescence signals gave a low Pearson‟s correlation 
coefficient of 0.237 (±0.1). In contrast, the Mander‟s overlap coefficient of 0.636 (±0.07) 
showed that there was about 64 % co-localization between HSP90α/β and axin1. The 
coefficients, M1 (0.95 ±0.06) and M2 (0.8 ±0.1) values illustrated that there was a higher 
overlap between the red signal of HSP90α/β with the green signal of axin1 than there was 
vice versa.  
 
 
 
Figure 3.2. Co-localization of HSP90α/β and axin1. A. Confocal microscopy images of stained MCF7 cells 
captured using a Zeiss LSM 510 confocal microscope.  Hoechst: blue nuclear staining.  HSP90α/β (red) using 
anti-human HSP90α/β antibody. Axin1 (green) using anti-human axin1. Merged: the overlap of Hoechst, axin1 
and HSP90α/β signals. B. Cross section of MCF7 cell representing the similar staining profiles for axin1 and 
HSP90α/β.  Profiles were obtained using the program Zeiss LSM Image Browser. The blue line represents 
Hoechst staining of the nucleus, the green line represents the signaling for axin1 staining and the red line 
represents the signal for HSP90α/β staining. Scale bars represent 20 μm. Dotted line represents cross section of 
cell used for intensity profile. 
 
3.2.1.3 β-catenin and HSP90α/β 
Immunofluorescence confocal microscopy revealed that β-catenin was localized to distinct 
punctate structures just outside the nucleus in all of the MCF7 cells (Figure 3.3A, arrow), 
whilst there was some localization within the cytoplasm and membranes. The signal 
intensities representative of β-catenin staining were highest just outside the nucleus and at the 
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membrane (Figure 3.3B). On the other hand, HSP90α/β had diffuse cytoplasmic staining with 
some perinuclear staining in most of the cells (Figure 3.3A, top right panel), with high signal 
intensities, representative of HSP90α/β staining, outside the nucleus (Figure 3.3B). 
Quantitative analysis of the immunofluorescence signals gave high values for both the 
Mander‟s overlap coefficient (R=0.819 ±0.03) and the Pearson‟s correlation coefficient 
(Rr=0.654 ±0.1). The M1 (0.98 ±0.02) and M2 (0.98 ±0.02) coefficients suggested that there 
was about a 98 % overlap in signals between the red and green signals representing 
HSP90α/β and β-catenin staining, respectively.  
 
 
Figure 3.3. Co-localization analysis of total β-catenin and HSP90α/β. A. Confocal microscopy images of 
stained MCF7 cells captured using a Zeiss LSM 510 confocal microscope.  Hoechst: blue nuclear staining.  
HSP90α/β (red) using anti-human HSP90α/β antibody. β-catenin (green) using anti-human β-catenin. Merged: 
the overlap of Hoechst, β-catenin and HSP90α/β signals. B. Cross section of MCF7 cell representing the 
staining profiles for β-catenin and HSP90α/β.  Profiles were obtained using the program Zeiss LSM Image 
Browser. The blue line represents Hoechst staining of the nucleus, the green line represents the signaling for 
total β-catenin staining and the red line represents the signal for HSP90α/β staining. Scale bars represent 20 μm. 
Dotted line represents cross section of cell used for intensity profile. Arrows point toward punctate structures. m 
represents β-catenin that is predicted to be at the plasma membrane. pn represents β-catenin that is predicted to 
be in the perinuclear region. 
 
3.2.1.4 Phospho-β-catenin and HSP90α/β 
Using immunofluorescence microscopy staining, both p-β-catenin and HSP90α/β were 
localized mainly in the cytoplasm in all of the cells (Figure 3.4). Both proteins had similar 
localizations (Figure 3.4, merge) and the intensity signals representative of p-β-catenin and 
HSP90α/β staining were highest in the cytoplasm (Figure 3.4B). 
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Quantitative analysis of the immunofluorescence signals gave a Pearson‟s correlation 
coefficient of 0.427 (±0.05) and a Mander‟s overlap coefficient of 0.78 (±0.02) suggesting 
that there was 78 % co-localization between p-β-catenin and HSP90α/β. Both the coefficients 
M1 (0.97 ±0.01) and M2 (0.94 ±0.02) showed a high correlation between the red and green 
signals representative of the staining of HSP90α/β and p-β-catenin respectively. 
These results suggested that there was a high possibility of co-localization between 
HSP90α/β and p-β-catenin. Co-immunoprecipitation of HSP90α/β and p-β-catenin would be 
needed to confirm this finding. 
 
 
Figure 3.4. Co-localization analysis of HSP90α/β and p-β-catenin. A. Confocal microscopy images of stained 
MCF7 cells captured using a Zeiss LSM 510 confocal microscope.  Hoechst: blue nuclear staining.  HSP90α/β 
(red) using anti-human HSP90α/β antibody. P-β-catenin (green) using anti-human p-β-catenin. Merged: the 
overlap of Hoechst, p-β-catenin and HSP90α/β signals. B. Cross section of MCF7 cell representing the staining 
profiles for p-β-catenin and HSP90α/β.  Profiles were obtained using the program Zeiss LSM Image Browser. 
The blue line represents Hoechst staining of the nucleus, the green line represents the signaling for p-β-catenin 
staining and the red line represents the signal for HSP90α/β staining. Scale bars represent 20 μm. Dotted line 
represents cross section of cell used for intensity profile.  
 
3.2.2 Effects of HSP90 inhibitors, 17-AAG and novobiocin on the localization 
of HSP90α/β, GSK-3β, axin1, β-catenin and p-β-catenin 
MCF7 cells were treated with the compounds, 17-AAG and novobiocin, to identify if HSP90 
inhibition had an effect on the localization of the Wnt pathway members, GSK-3β, axin1, β-
catenin and p-β-catenin.  
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3.2.2.1 GSK-3β and HSP90α/β 
Using immunofluorescence and confocal microscopy, it was found that in untreated MCF 7 
cells, HSP90α/β and GSK-3β were localized in the cytoplasm of most of the cells (Figure 
3.5A). Treatment of MCF7 cells with the HSP90 inhibitor, novobiocin (500 μM) (Figure 
3.5B) resulted in very little change in the localization of HSP90α/β and GSK-3β in 
comparison to untreated cells (Figure 3.5A), although it did appear that there was a slight 
shift of HSP90α/β to the perinuclear region in some of the cells after novobiocin treatment 
(Figure 3.5C). Exposure to 17-AAG (10 μM), resulted in a morphological change in most of 
the MCF7 cells whereby the cells had a smaller, rounded phenotype in comparison to 
untreated cells (Figure 3.5C). As a result of this, it appeared that there was a slight shift of 
localization to the perinuclear region for HSP90α/β and GSK-3β in most of the cells (Figure 
3.5C).  
The signal intensity profiles of the pattern distribution of HSP90α/β and GSK-3β (Figure 
3.5D-F) were obtained by taking cross sections of the merged images of HSP90α/β and GSK-
3β (Figure 3.5G-I). In each of the studies: untreated (Figure 3.5D), novobiocin treated (Figure 
3.5E) and 17-AAG (Figure 3.5F) treated MCF7 cells, there was an overlap in the pattern of 
distribution of HSP90α/β and GSK-3β staining. The signal intensity profile of untreated cells 
showed that there was a similar pattern of distribution between HSP90α/β and GSK-3β 
(Figure 3.5D). The highest signal for HSP90α/β and GSK-3β staining, in untreated cells, was 
located outside the nucleus, in what appeared to be the cytoplasmic region, although signals 
were detected within the nucleus (Figure 3.5D). The signal intensity profile of novobiocin 
treated cells showed that there was a slight shift of signals representing HSP90α/β and GSK-
3β staining, to what appeared to be the perinuclear region (Figure 3.5E). This could be due to 
the morphological change of the cells, whereby the cells appeared to be large and flattened 
(Figure 3.5H). There was a slight shift of the pattern of HSP90α/β and GSK-3β staining to 
what appeared to be the perinuclear region in 17-AAG treated cells, with some cytoplasmic 
staining (Figure 3.5I).   
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Figure 3.5. Effects of HSP90 inhibitors on the localization of HSP90α/β and GSK-3β. MCF7 cells were serum-starved for 1 hour prior to 5 hour treatment with inhibitors. 
Confocal microscopy images of stained MCF7 cells captured using a Zeiss LSM 510 confocal microscope. A. Untreated MCF7 cells. B. Novobiocin (500 μM) treated MCF7 
cells. C. 17-AAG (10 μM) treated MCF7 cells. Hoechst: blue nuclear staining.  HSP90α/β (purple) using anti-human HSP90α/β antibody. GSK-3β (green) using anti-human 
GSK-3β antibody. D, E, F: Intensity profile studies of GSK-3β (green), HSP90α/β (red), Hoechst (blue) for: untreated MCF7 cells (D), Novobiocin (500 μM) treated MCF7 
cells (E); and 17-AAG (10 μM) treated MCF7 cells (F). The blue line represents Hoechst staining of the nucleus, the red line represents the signal for HSP90α/β staining and 
the green line represents the signal for GSK-3β staining. G, H, I: Immunofluorescence confocal microscopy images representing the merged images of HSP90α/β, GSK-3β 
and Hoechst. Scale bars represent 20 μm. Dotted line represents cross sections of cells used for intensity profiles. Arrows point towards morphological change to “rounded” 
phenotype after 17-AAG treatment. Images were enhanced by adjusting contrast and brightness using MacBiophotonics ImageJ for better identification of localization 
patterns.  
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3.2.2.2 Axin1 and HSP90α/β  
Immunofluorescence and confocal microscopy revealed that axin1 appeared to be localized 
throughout most of the untreated cells (Figure 3.6A), although the intensity of the staining 
was very weak. After novobiocin treatment, there appeared to be an increase in the 
localization of axin1 at what appeared to be the plasma membrane in most of the cells (Figure 
3.6B, arrows). However, this would need to be confirmed with antibodies that stain 
membrane structures. Although it appeared that axin1 appeared to localize more to what 
appeared to be the perinuclear region, after 17-AAG treatment, this could also be attributed to 
the rounder phenotype of the MCF7 cells (Figure 3.6C). HSP90α/β had similar localization 
patterns as was previously described (Section 3.2.2.1), with what appeared to be cytoplasmic 
localization in most of the untreated cells (Figure 3.6A) and a slight shift to what appeared to 
be the perinuclear region in novobiocin (Figure 3.6B) and 17-AAG (Figure 3.6C) treated 
MCF7 cells. 
Signal intensity profiles were obtained from the cross sections of the merged images of 
HSP90α/β and axin1 (Figure 3.6G-I). In untreated cells, the signal intensity of axin1 staining 
was much lower than that of HSP90α/β staining (Figure 3.6D). Furthermore, the signal 
intensity of axin1 staining was the same throughout the cell in untreated MCF7 cells (Figure 
3.6D). In novobiocin treated cells, the signal intensity of axin1 staining was also lower than 
that of HSP90α/β staining, and remained constant throughout the cell (Figure 3.6E). The 
increase in signal intensity corresponding to axin1 staining at what appeared to be the plasma 
membrane (Figure 3.6H), was difficult to see since the intensity of staining was so low 
(Figure 3.6E). There appeared to be a similar staining profile for axin1 and HSP90α/β after 
17-AAG treatment (Figure 3.6F), with most of the signal for axin1 staining being located 
outside the nucleus in what appeared to be the cytoplasmic region (Figure 3.6F). The signal 
intensity profiles for HSP90α/β were similar to those previously described (Section 3.2.2.1). 
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Figure 3.6. Effects of HSP90 inhibitors on the localization of HSP90α/β and axin1. MCF7 cells were serum-starved for 1 hour prior to 5 hour treatment with inhibitors. 
Confocal microscopy images of stained MCF7 cells captured using a Zeiss LSM 510 confocal microscope. A. Untreated MCF7 cells. B. Novobiocin (500 μM) treated MCF7 
cells. C. 17-AAG (10 μM) treated MCF7 cells. Hoechst: blue nuclear staining.  HSP90α/β (purple) using anti-human HSP90α/β antibody. Axin1 (green) using anti-human 
axin1 antibody. D, E, F: Intensity profile studies of axin1 (green), HSP90α/β (red), Hoechst (blue) for: untreated MCF7 cells (D) (same image as Figure 3.2B), Novobiocin 
(500 μM) treated MCF7 cells (E); and 17-AAG (10 μM) treated MCF7 cells (F). The blue line represents Hoechst staining of the nucleus, the red line represents the signal for 
HSP90α/β staining and the green line represents the signal for axin1 staining. G, H, I: Immunofluorescence confocal microscopy images representing the merged images of 
HSP90α/β, axin1 and Hoechst. Scale bars represent 20 μm. Dotted line represents cross sections of cells used for intensity profiles. Arrows point toward what appears to be 
the plasma membrane. Images were enhanced by adjusting contrast and brightness using MacBiophotonics ImageJ for better identification of localization patterns. 
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3.2.2.3 p-β-catenin and β-catenin 
Immunofluorescence and confocal microscopy revealed that p-β-catenin had what appeared 
to be diffuse cytoplasmic staining in most of the untreated and HSP90 inhibitor-treated 
MCF7 cells (Figure 3.7A-C). Neither novobiocin (Figure 3.7B) nor 17-AAG (Figure 3.7C) 
treatment caused any notable change in the localization of p-β-catenin in MCF7 cells. β- was 
localized to punctate structures in what appeared to be the perinuclear region in all of the 
untreated cells (Figure 3.7A, arrow). There was also diffuse cytoplasmic staining of β-catenin 
in most of the untreated cells (Figure 3.7A), with some localization at what appeared to be the 
plasma membrane (Figure 3.7A). There was no distinct change in the localization pattern of 
β-catenin after treatment with novobiocin (Figure 3.7B) or 17-AAG (Figure 3.7C); however 
it did appear that there was a slight shift in β-catenin to what appeared to be the perinuclear 
region after novobiocin treatment (Figure 3.7B). 
Cross sections of MCF7 cells (Figure 3.7A-C, dotted lines) were used to create signal 
intensity profiles (Figure 3.7D-F) of p-β-catenin and β-catenin staining. The level of signal 
intensity for p-β-catenin staining was low in all of the MCF7 cells (Figure 3.7D-F), although 
it appeared to be slightly higher in what appeared to be the cytoplasmic region in most of the 
cells (Figure 3.7D-F). Treatment with novobiocin and 17-AAG did not cause any notable 
change in the distribution pattern of the signal intensities for p-β-catenin (Figure 3.7E and F). 
The signal intensities for β-catenin staining were highest at what appeared to be the 
perinuclear region in both untreated (Figure 3.7D) and treated (Figure 3.7E and F) MCF7 
cells. There was no notable change in the distribution pattern of β-catenin staining after 
novobiocin (Figure 3.7E) or 17-AAG treatment (Figure 3.7F). 
3.2.2.4 p-β-catenin and HSP90α/β 
The signal intensity profiles of p-β-catenin and HSP90α/β staining in MCF7 cells (Figure 
3.8A-C) were obtained by taking cross-sections of immunofluorescence merged images of  p-
β-catenin and HSP90α/β staining (Figure 3.8D-F). The signal intensity profile of HSP90α/β 
staining was the same as previously described (Section 3.2.2.1) with the signal for HSP90α/β 
staining being highest in what appeared to be the cytoplasm, with some nuclear staining in 
the untreated (Figure 3.8A) and treated (Figure 3.8B and C) MCF7 cells. The signal intensity 
profile for p-β-catenin staining was also the same as previously described (Section 3.2.2.3). 
The staining patterns of p-β-catenin and HSP90α/β are different to each other for untreated 
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(Figure 3.8A) and novobiocin treated (Figure 3.8B) MCF7 cells; however they appear similar 
after treatment with 17-AAG (Figure 3.8C).  
 
Figure 3.7. Effects of HSP90 inhibition on the localization of p-β-catenin and β-catenin. MCF7 cells were 
serum-starved for 1 hour prior to 5 hour treatment with inhibitors. Immunofluorescence confocal microscopy 
images of stained MCF7 cells captured using a Zeiss LSM 510 confocal microscope. A. Untreated MCF7 cells. 
B. Novobiocin (500 μM) treated MCF7 cells. C. 17-AAG (10 μM) treated MCF7 cells. Hoechst: blue nuclear 
staining.  β-catenin (green) using anti-human β-catenin antibody. p-β-catenin (red) using anti-human p-β-catenin 
antibody. Cross sections of MCF7 cell representing the staining profiles for: β-catenin for untreated cells (D); 
novobiocin (500 μM) treated MCF7 cells (E); 17-AAG (10 μM) treated MCF7 cells (F).  Profiles were obtained 
using the program Zeiss LSM Image Browser. The blue line represents Hoechst staining of the nucleus; the 
green line represents the signaling for β-catenin staining. The red line represents the signaling for p-β-catenin 
staining. Scale bars represent 20 μm. Dotted line represents cross section of cell used for intensity profile.  
 
Figure 3.8. Intensity profile studies of the subcellular localization change of p-β-catenin and HSP90α/β in 
response to HSP90 inhibition. MCF7 cells were serum-starved for 1 hour prior to 5 hour treatment with 
inhibitors. Immunofluorescence and confocal microscopy images of stained MCF7 cells were captured using a 
Zeiss LSM 510 confocal microscope. Cross sections of MCF7 cell representing the staining profiles for 
HSP90α/β for: untreated cells (A); novobiocin (500 μM) treated MCF7 cells (B); and 17-AAG (10 μM) treated 
MCF7 cells (C). The blue line represents Hoechst staining of the nucleus, the red line represents the signal for 
HSP90α/β staining and the green line represents the signal for p-β-catenin staining. Confocal microscopy 
images representing the merged images of HSP90α/β, p-β-catenin and Hoechst of untreated MCF7 cells (D), 
novobiocin treated MCF7 cells (E) and 17-AAG treated cells (F). Scale bars represent 20 μm. Dotted line 
represents cross section of cell used for intensity profile.  
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3.3 Discussion 
HSP90α/β was found to be localized mainly in the cytoplasm in untreated MCF7 cells which 
concurs with literature where HSP90α/β is mainly located in the cytoplasm (Borkovich et al., 
1989; Taherian et al., 2007). As expected, GSK-3β was also localized mainly in the 
cytoplasm where it could interact with the destruction complex of the Wnt pathway. 
However, nuclear localization was observed in some of the cells which could be as a result of 
GSK-3β being involved in the regulation of β-catenin independently of the Wnt destruction 
complex (Caspi et al., 2008). Axin1 was localized throughout the cell at a low concentration 
which could be due to axin being the limiting factor in the Wnt pathway and thus found at 
low concentrations (Lee et al., 2003). It must be noted, however, that this could also be a 
result of the primary antibody not being as sensitive as the other antibodies for confocal 
microscopy.  
P-β-catenin was found to be localized in the cytoplasm where it gets targeted for degradation 
by the destruction complex. Furthermore, high levels of cytoplasmic p-β-catenin have been 
linked to good clinical outcome in breast cancer patients (Nakopoulou et al., 2006).  On the 
other hand, total β-catenin was localized to distinct punctate structures in the cytoplasm 
(Figure 3.3), close to the nucleus. Studies have shown that β-catenin exists in different 
subcellular locations within the cell, which include the plasma membrane (Ozawa, 1989), 
cytoplasm (López-Knowles et al., 2010), cytosol or nucleus (Kikuchi, 2000; Morin et al., 
1999). In normal ducts of myoepithelial cells, β-catenin is localized to the plasma membrane, 
whilst breast carcinoma cells have both cytoplasmic and plasma membrane localized 
expression of β-catenin (López-Knowles et al., 2010). Kikuchi (2000) identified cytosolic β-
catenin to be complexed with the destruction complex, whilst Faux et al. (2008) found that 
punctate structures were the sites of these destruction complexes. Schwarz-Romond et al. 
(2005) recognized these structures as protein assemblies instead of vesicles within the 
cytoplasm. Again, they found Dsh to be associated with these complexes providing further 
evidence that these structures are the site of destruction complexes. It can therefore be 
proposed that in this MCF7 cell line, β-catenin was associated with destruction complexes 
close to the nucleus.  
This study showed that there was possible co-localization between HSP90α/β and GSK-3β 
(Figure 3.1) which concurs with literature since HSP90α/β is required for the 
autophosphorylation of GSK-3β (Lochhead et al., 2006; Schlange et al., 2007). Furthermore, 
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since the signals of axin1 and HSP90α/β staining did overlap, as did p-β-catenin and 
HSP90α/β, it is possible that there was some association between HSP90α/β and these 
proteins. Although β-catenin was localized in distinct punctate structures, quantitative 
analysis revealed that there was partial co-localization with HSP90α/β indicating a possible 
association between the two proteins. 
When MCF7 cells were treated with HSP90 inhibitors, 17-AAG and novobiocin, very little 
change occurred in the subcellular localization of  GSK-3β (Figure 3.5), β-catenin (Figure 
3.7) or p-β-catenin (Figure 3.7), although the morphology of the cells did change with both 
17-AAG and novobiocin treatment in most of the cells. Interestingly, a shift of axin1 to what 
appeared to be the plasma membrane was seen after the MCF7 cells were treated with 
novobiocin (Figure 3.6B). A possible explanation for this localization change could be that 
the interaction between HSP90α/β and axin1 was disrupted by novobiocin such that the 
destruction complex was no longer stabilized by HSP90α/β, and axin1 located to the 
membrane.  
In conclusion, analysis by confocal microscopy revealed that there was a possible association 
of HSP90α/β with GSK-3β and possibly with axin1 and p-β-catenin since they appeared to 
share similar subcellular localizations to HSP90α/β. It must be noted, however, that the signal 
intensities of both axin1 and p-β-catenin were very low therefore no definite conclusion could 
be drawn from the study. HSP90 inhibition caused a shift in the localization of axin1 which 
gives further evidence of a possible association between axin1 and HSP90α/β. Although β-
catenin had a different localization pattern in comparison to HSP90α/β, there was an overlap 
of signals. It would therefore be necessary to validate these claims biochemically by 
performing co-immunoprecipitation studies, which will be described in the next chapter. 
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4.1 Introduction 
It is well-known that the Wnt pathway is in a “switched on” state in colon cancer lines due to 
mutations in the destruction complex (Morin et al. 1996; Moon et al., 2004). Although 
mutations within the Wnt pathway in breast cancer have not been identified, other factors, 
such as sFRP1 downregulation and Dsh upregulation may play a role in aberrantly activating 
the pathway (Schlange et al., 2007). Interestingly, in MCF7 cells, treatment with sFRP1 did 
not affect the cell proliferation or result in a reduction in active β-catenin levels, nor did 
knockdown of Dsh have any effect (Schlange et al., 2007). These results indicate that in 
MCF7 cells, some other factor influences the activation of Wnt pathway. It is an interesting 
study to determine the levels of the proteins involved in the Wnt pathway in both breast 
cancer and colon cancer to determine if there is a difference. HT29 is a colorectal cancer cell 
line that is extensively used for research because it has maintained its biologic and 
physiologic features of normal colorectal epithelial cells (von Kleist et al., 1975). In this 
study, the expression levels of the proteins involved in the Wnt pathway in MCF7 and HT29 
cells were determined by Western Blot analysis to ensure that the proteins were detectable 
prior to performing immunoprecipitation studies.  
The association of HSP90 with members of the full Wnt pathway needs to be established. 
The previous study (section 3) gave preliminary evidence that a possible association between 
HSP90 and GSK-3β, axin1 and p-β-catenin since they were localized to similar positions 
within the cell. To further verify these associations in MCF7 cells, co-immunoprecipitation 
experiments were performed to isolate complexes containing Hsp90α/β, β-catenin, GSK-3β 
and axin1. The proteins were resolved by SDS-PAGE and Western Blot analysis was 
performed to identify the complexed proteins. To ensure that each immunoprecipitation had 
worked, the immunoprecipitation samples were subjected to Western analysis for detection of 
the expected protein, before analysis of co-precipitated proteins.   
4.2 Results 
4.2.1 Protein expression levels of MCF7 in comparison to HT29 cells 
Equal numbers of MCF7 and HT29 cells were loaded on the SDS gel by loading the same 
quantity of lysate (see Section 2.2.1). Western blot analysis of the proteins expressed 
indicated that Akt (Figure 4.1A) was expressed at a slightly higher level in MCF7 cells in 
comparison to HT29 cells, whilst HSP90α/β expression levels appeared to be similar between 
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the 2 cell lines (Figure 4.1B). Furthermore, GSK-3β also appeared to be expressed at a 
similar level in both MCF7 and HT29 cells (Figure 4.1C). The higher molecular weight 
protein of axin1 appeared to be expressed at a higher level in HT29 cells in comparison to 
MCF7 cells (Figure 4.1D). A lower molecular weight signal was identified for axin1 which 
could be a degradation product or truncated form of the protein. HT29 cells expressed higher 
levels of both total β-catenin (Figure 4.1E, H) and p-β-catenin (Figure 4.1F) in comparison to 
MCF7 cells (Figure 4.1E and F, M).  
 
Figure 4.1 Wnt pathway is switched on in colorectal cancer line. Western analysis of cell lysates of MCF7 
(M) HT29 cell lysates (H). Equivalent number of cells was loaded per lane. A. Detection of Akt (56 kDa) using 
anti-human Akt antibody. B. Detection of HSP90α/β (90 kDa) using anti-human HSP90α/β antibody. C. 
Detection of GSK-3β (43 kDa) using anti-human GSK-3β antibody. D. Detection of axin1 (95 kDa) using anti-
human axin1 antibody. E. Detection of β-catenin (94 kDa) using anti-human β-catenin antibody. F. Detection of 
p-β-catenin (94 kDa) using anti-human p-β-catenin antibody. Actin was used as the loading control.  
 
4.2.2 Association of members of the Wnt pathway with HSP90 by co-
immunoprecipitation 
 
Immunoprecipitation using anti-HSP90α/β antibodies was successful (Figure 4.2A, lane 4) 
since a signal corresponding to HSP90α/β (Figure 4.2A, lane 1) was identified in the 
immunoprecipitation sample (Figure 4.2A, lane 4). This signal was not detected in either of 
the negative controls (Figure 4.2A, lane 2 and 3) which meant that HSP90α/β did not bind 
non-specifically to the beads. Heavy chain (Figure 4.2, Hc) and light chain (Figure 4.2A, Lc) 
IgG bands were identified in the negative control and immunoprecipitation sample (Figure 
4.2A, lane 3 and 4). 
Immunoprecipitation using β-catenin antibodies was also successful since β-catenin was 
identified in the immunoprecipitation sample (Figure 4.2B, lane 4) and positive control of 
free lysate (Figure 4.2B, lane 1) but not in either of the negative controls (Figure 4.2B, lane 2 
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and 3). Heavy chain (Figure 4.2, Hc) and light chain IgG bands (Figure 4.2A, Lc) were 
identified in the negative control and immunoprecipitation sample (Figure 4.2B, lane 3 and 
4). 
Axin1 was detected as 2 bands in the positive control of free MCF7 lysate (Figure 4.2C, lane 
1), with the lower molecular weight band appearing darker than the higher molecular weight 
band. The higher molecular weight band did not appear in the immunoprecipitation sample 
(Figure 4.2C, lane 4), and the lower molecular weight band may have been masked by the 
heavy chain IgG (Figure 4.2C, lane 4).  
Although GSK-3β was identified in the free MCF7 lysate (Figure 4.2D, lane 1), it was 
difficult to identify whether GSK-3β was successfully isolated by the immunoprecipitation 
experiment since the heavy chain IgG signal potentially masked the GSK-3β signal (Figure 
4.2D, lane 4). The negative control (GSK-3β antibody coupled to protein A/G-PLUS beads 
only) was not performed in this experiment; therefore the size of the heavy chain IgG could 
not be confirmed. 
  
Figure 4.2. Validation of antibodies to Wnt pathway proteins and HSP90 in IP assays. Western Blot 
analyses of immunoprecipitation samples carried out in MCF7 lysates. A. Western detection of HSP90α/β after 
immunoprecipitation using an anti-human HSP90α/β antibody. B. Western detection of β-catenin after 
immunoprecipitation using an anti-human β-catenin antibody. C. Western detection of axin1 after 
immunoprecipitation using an anti-human axin1 antibody. D. Western detection of GSK-3β after 
immunoprecipitation after using an anti-human GSK-3β antibody. Lane 1: free MCF7 lysate. Lane 2: negative 
control: lysate subjected to immunoprecipitation without antibody. Lane 3: immunoprecipitation antibody and 
protein A/G plus agarose beads without lysate. Lane 4: immunoprecipitation sample. 
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To determine whether HSP90 was complexed to β-catenin, the samples of both HSP90α/β 
immunoprecipitation and β-catenin immunoprecipitation were resolved by SDS-PAGE and 
Western detection was performed for β-catenin in the HSP90α/β immunoprecipitation sample 
(Figure 4.3A), and HSP90α/β in the β-catenin immunoprecipitation sample (Figure 4.3B). 
A signal was detected in the immunoprecipitation sample that corresponded to the same 
molecular weight as total β-catenin (Figure 4.3A, lane 4 and lane 1). A faint signal of the 
same molecular weight was also detected in the negative control (Figure 4.3A, lane 2) 
indicating that there was some non-specific binding of  β-catenin to the protein A/G PLUS 
agarose beads. The signal in the immunoprecipitation sample (Figure 4.3A, lane 4) did, 
however, appear to be darker than that in the negative control (Figure 4.3A, lane 2). When the 
anti-human β-catenin antibody was used to immunoprecipitate the complex in MCF7 cells, 
followed by Western detection for HSP90α/β, a clean signal was detected in the 
immunoprecipitation sample (Figure 4.3B, lane 4) which corresponds to the same molecular 
weight as HSP90α/β in the positive control (Figure 4.3B, lane 1). No signal of the same 
molecular weight was detected in either of the negative controls (Figure 4.3B, lanes 2 and 3).  
 
Figure 4.3. HSP90α/β and β-catenin co-immunoprecipitate. A. Western detection for total β-catenin in 
HSP90α/β immunprecipitate. B. Western detection for HSP90α/β in β-catenin immunoprecipitate. Lane 1: free 
MCF7 lysate. Lane 2: negative control: MCF7 lysate subjected to immunoprecipitation without antibody. Lane 
3: immunoprecipitation antibody and protein A/G PLUS agarose beads without lysate. Lane 4: 
immunoprecipitation sample using antibody and MCF7 lysate. 
 
Axin1 appeared to co-immunoprecipitate with HSP90α/β since a signal for axin was detected 
in the HSP90α/β immunoprecipitation sample (Figure 4.4A, lane 4) and HSP90α/β was 
detected in the axin immunoprecipitation sample (Figure 4.4C, lane 4). No signals of the 
same molecular weight as HSP90 (approximately 90 kDa) of axin1 (approximately 95 kDa) 
were detected in either of the negative controls (Figure 4.4A, lane 2 and 3 and Figure 4.4C, 
lane 2 and 3) indicating that both HSP90α/β and axin1 were isolated by the relevant 
immunoprecipitation antibody. P-β-catenin was also detected in the HSP90α/β 
immunoprecipitate (Figure 4.4B, lane 4) and axin immunoprecipitate (Figure 4.4D, lane 4). A 
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signal of the same intensity at the same molecular weight (approximately 94 kDa) was not 
identified in either of the negative controls for both immunoprecipitation experiments (Figure 
4.4B and D, lanes 2 and 3).  
Figure 4.4. HSP90α/β co-immunoprecipitates with axin1 and p-β-catenin. A. Western detection for axin1 
in HSP90α/β immunoprecipitation. B. Western detection for p-β-catenin (pSer33/pSer37) in HSP90α/β  
immunoprecipitate. C. Western detection of  HSP90α/β in axin1 immunoprecipitate. D. Western detection of 
p-β-catenin (pSer33/pSer37) in axin1 immunoprecipitate. Lane 1. Free MCF7 lysate. Lane 2. Negative control 
of MCF7 lysate subjected to immunoprecipitation without the antibody. Lane 3: immunoprecipitation 
antibody and protein A/G PLUS-agarose beads. Lane 4. Immunoprecipitation sample using antibody and 
MCF7 lysate. Arrows point towards the protein of interest. 
 
To further identify whether HSP90α/β was in a common complex with GSK-3β  in MCF7 
cells, immunoprecipitation using anti-human GSK-3β antibodies with protein A/G PLUS 
agarose was carried out and the samples were probed for HSP90α/β (Figure 4.5). The same 
immunoprecipitation experiment was carried out using anti-human HSP90α/β antibodies 
instead of anti-human GSK-3β antibodies to isolate the complex, but no conclusions could be 
made from the Western detections for GSK-3β since the heavy chain IgG masked any 
possible GSK-3β signal in the immunoprecipitation sample.  
A signal corresponding to the same molecular weight as HSP90α/β (about 95 kDa) appeared 
in the immunoprecipitation sample (Figure 4.5, lane 3) and free lysate sample (Figure 4.5, 
lane 1), but did not appear in the negative control (Figure 4.5, lane 2).   
 
Figure 4.5. Potential co-immunoprecipitation of GSK-3β and HSP90α/β. Immunoprecipitation was 
performed using anti-human GSK-3β antibodies with protein A/G PLUS agarose beads. Western detection for 
HSP90α/β using an anti-human HSP90α/β antibody. Lane 1. Free MCF7 lysate. Lane 2. MCF7 lysate subjected 
to immunoprecipitation without antibody. Lane 3. Immunoprecipitate sample using antibody and MCF7 lysate. 
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To test whether the anti-human GSK-3β antibody was indeed working efficiently in isolating 
complexes, and to overcome any possible signals being masked by the heavy chain IgG, the 
immunoprecipitation experiment was performed using the Dynal Bead Separations 
Dynabeads co-immunoprecipitation kit (Dynal Bead Separations). This kit uses antibodies 
coupled to Dynabeads® M-270 Epoxy instead of protein A/G PLUS agarose to isolate any 
possible complexes. The antibody is thus coupled permanently to the Dynabeads® M-270 
Epoxy, and will not dissociate, therefore preventing the detection of the heavy and light chain 
IgG. The anti-human GSK-3β antibody was coupled to the Dynabeads® M-270 Epoxy beads 
according to manufacturer‟s instructions, and the resulting eluted complexes were resolved 
by SDS-PAGE for Western blot analysis (Figure 4.6). 
It appeared that the anti-human GSK-3β antibody coupled to Dynabeads® M-270 Epoxy 
successfully isolated GSK-3β (Figure 4.6A, lane 3). Although p-β-catenin co-
immunoprecipitated with GSK-3β (Figure 4.6B, lane 3), it appeared that the amount of p-β-
catenin detected in the immunoprecipitation sample (Figure 4.6B, lane 3) was much less than 
that in the free lysate (Figure 4.6B, lane 1).  
 
Figure 4.6. Potential co-immunoprecipitation of GSK-3β and p-β-catenin. GSK-3β immunoprecipitation 
was performed with GSK-3β antibody coupled to Dynabeads® M-270 Epoxy. A. Western detection for human 
GSK-3β. B. Western detection for p-β-catenin. Lane 1. Free MCF7 lysate. Lane 2. Negative control of MCF7 
lysate subjected to immunoprecipitation with BSA coupled to Dynabeads® M-270 Epoxy instead of antibody. 
Lane 4. Immunoprecipitation sample. 
 
4.3 Discussion  
The proteins, HSP90α/β, axin1, total β-catenin and p-β-catenin were successfully detected in 
both MCF7 cells and HT29 cells by Western Blot analysis (Figure 4.1), thus allowing for 
further studies on these proteins to be carried out. When a comparison of these protein 
expression levels was made between the 2 cells lines, it was found that HT29 cells had higher 
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levels of both total β-catenin and p-β-catenin compared to MCF7 cells. Since both cell lines 
have an activated Wnt pathway (Morin et al., 1996; Yang et al., 2006; Schlange et al., 2007), 
it was interesting to note that HT29 cells had a higher expression level of both total β-catenin 
and its phosphorylated form. This was unexpected since p-β-catenin gets targeted for 
ubiquitination and degradation and thus the levels should be low. A possible explanation for 
this is that although the Wnt pathway may be aberrantly activated in the HT29 cells, β-
catenin may still be getting phosphorylated, but the phosphorylated form is being prevented 
from being degraded. In contrast to this, another explanation could be that although there 
might be a mutation in the APC gene, which is associated with colorectal cancer (Yang et al., 
2006), the overexpression of axin in the absence of APC in HT29 cells has allowed for the 
destruction complex‟s activity to return to normal (reviewed in Clevers, 2006). Furthermore, 
it can be said that cancer cells are heterogeneous thus pathways are constantly being 
stimulated and inhibited at different time periods, thus a certain time point study of protein 
expression levels might not be indicative of what the protein levels are throughout the cell 
cycle. In addition to this, the qualitative Western analysis did not allow for the proportion of 
β-catenin to p-β-catenin to be determined nor absolute levels to be identified. This was 
because the antibodies might have different sensitivities to the proteins that they detect 
therefore no comparative analysis could be done. Although a qualitative analysis was 
performed on the protein expression levels, a quantitative analysis comparing the protein 
expression levels between HT29 and MCF7 cells could not be performed. This was due to 
different protein amounts (as determined by Ponceau staining) being loaded for the two cell 
lines despite loading the same number of cells. These data confirmed that the Wnt pathway 
proteins were detectable by Western Analysis in MCF7 cells and thus made the cell line 
viable to continue with further studies to identify possible associations of the proteins with 
HSP90. 
Using co-immunoprecipitation analysis of HSP90α/β and β-catenin, it was found that there 
was possible association between the two proteins. By isolating β-catenin using an antibody 
against HSP90α/β and performing the vice versa with a β-catenin antibody and isolating 
HSP90α/β (Figure 4.3), it can be said that HSP90α/β and β-catenin appeared to be associated 
in a common complex. Although there was apparent non-specific binding of β-catenin to the 
protein A/G PLUS agarose beads (Figure 4.3A, lane 2), densitometric analysis revealed that 
the β-catenin isolated by co-immunoprecipitation using anti-HSP90α/β (arbitrary unit: 1) was 
more than the β-catenin bound non-specifically to the beads (arbitrary unit: 0.8) (See 
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Appendix A4). Furthermore, since the reverse IP could be performed, this association 
between HSP90α/β and β-catenin was specific.  
Co-immunoprecipitation, using an anti-HSP90α/β antibody, successfully isolated p-β-catenin 
(Figure 4.4B), thus giving preliminary evidence that p-β-catenin and HSP90α/β are 
associated in a common complex.  This association was not a result of non-specific binding 
of the p-β-catenin to the protein A/G PLUS agarose beads since no signal was detected in 
either of the negative controls (Figure 4.4B, lane 2 and 3).  
A possible association between axin1 and HSP90α/β was identified by co-
immunoprecipitation (Figure 4.4). Axin1 was successfully isolated by immunoprecipitation 
using anti-HSP90α/β antibodies (Figure 4.4A); and the reverse was also seen with HSP90α/β 
being isolated by anti-axin1 antibodies (Figure 4.4C). This therefore revealed that for the first 
time, HSP90α/β has found to occur in a common complex with axin1. Furthermore, anti-
axin1 and anti-HSP90α/β antibodies successfully isolated p-β-catenin, a by-product of the 
Wnt destruction complex (Clevers, 2006). It can thus be proposed that HSP90α/β is 
potentially involved in the destruction complex in the Wnt pathway.  
A possible association was shown between GSK-3β and HSP90α/β by co-
immunoprecipitation since HSP90α/β was isolated using an anti-GSK-3β antibody (Figure 
4.5). The signal detected in the immunoprecipitation sample (Figure 4.5, lane 3) 
corresponded to the same molecular weight as HSP90α/β in the free lysate (Figure 4.5, lane 
1), indicating that HSP90α/β was isolated by GSK-3β antibodies. This signal was not present 
in the negative control (Figure 4.5, lane 2), therefore was not a result of HSP90α/β binding 
non-specifically to the beads. It was difficult to identify whether GSK-3β was isolated from 
the MCF7 lysate by immunoprecipitation using anti-human GSK-3β antibodies, since the 
signal (43 kDa) was potentially masked by the signal for the  heavy chain IgG (55 kDa) 
(Figure 4.2D, lane 4).  
Using anti-human GSK-3β antibodies coupled to Dynabeads® M-270 Epoxy, p-β-catenin 
was successfully isolated (Figure 4.6B). However, the signal for p-β-catenin was faint, 
indicating that the level of p-β-catenin isolated was low. No signal was detected for 
HSP90α/β in the immunoprecipitation sample using anti-human GSK-3β antibodies coupled 
to Dynabeads® M-270 Epoxy (data not shown). A possible explanation for this is that the 
association between HSP90α/β and GSK-3β was only transient, therefore only small amounts 
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of HSP90α/β co-immunoprecipitated with GSK-3β which were too low to be detected by 
Western blot analysis, especially since the large volume of elution buffer required by the 
Dynal Bead Separations Dynabeads co-immunoprecipitation kit to elute the complexed 
proteins would have reduced the concentration of HSP90α/β to untraceable amounts. It would 
therefore be necessary to concentrate the IP fractions so that detection of signals could be 
performed. Another explanation could be that the association between GSK-3β and HSP90 
was unstable, as has been reported of HSP90 with other clients (Arlander et al., 2006). This 
means the association between HSP90 and GSK-3β could not withstand the lysis or washing 
conditions that were performed during immunoprecipitation.  
In conclusion, the protein expression study of the Wnt pathway proteins confirmed that β-
catenin, p-β-catenin, axin1, GSK-3β and HSP90α/β were all detectable by Western analysis 
in MCF7 cells, thus allowing for further biochemical experiments to be performed. The co-
immunoprecipitation data gave the first preliminary evidence that HSP90α/β is associated 
with axin1, p-β-catenin, β-catenin and GSK-3β. In the next chapter, HSP90 inhibition studies, 
will be used to confirm the possible association of HSP90α/β with the Wnt destruction in 
MCF7 cells. 
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Chapter 5: Effects on the Wnt 
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5.1 Introduction 
Numerous HSP90 inhibitors have been investigated for their potential therapeutic uses in 
cancer. The HSP90 client oncoproteins that are being targeted for drug interventions include 
HER-2, Akt, polo-like kinase, EGFR, Src, Abl, c-Met and RAF-1 (Sreedhar et al., 2004). 
HSP90 inhibitors have been found to have a higher affinity for HSP90 in tumour cells, which 
could be due to HSP90 existing mainly in the complexed form in tumour cells (Kamal et al., 
2003), and the HSP90 inhibitors preferentially associating with the HSP90 chaperone 
complex. HSP90 inhibitors not only have clinical uses, but also provide excellent research 
tools to study the HSP90-client and co-chaperone activity..  
5.1.1 Geldanamycin and geldanamycin analogues 
Geldanamycin, a naturally occurring antibiotic, is also an ansamycin with a benzoquinone 
moiety that makes it selective for HSP90 (Figure 5.1) (Zhang and Burrows, 2004). 
Geldanamycin was initially identified as an anti-tumour agent when it could inhibit the 
phosphorylation of v-Src, thus reversing the v-Src transformation in cells (Uehara et al., 
1986). It was later discovered that geldanamycin binds to the ATP-binding pocket of HSP90 
(Prodromou et al., 1997; Roe et al., 1999), preventing the mature HSP90 complex from 
forming and thus linking it to the degradation of the client proteins previously shown by 
Whitesell et al. (1994). Although geldanamycin showed promising anti-tumour activity, it 
was quite hepatotoxic in animals, preventing its further use in humans (Supko et al., 1995). 
This therefore lead to the development of the geldanamycin derivative, 17-AAG, which is a 
geldanamycin analog that has an allyl amino group instead of the methoxy group in the 
position 17 (Figure 5.1) (Goetz et al., 2003). 17-AAG was less hepatotoxic in animals than 
geldanamycin, but had similar antitumour activity (Schulte and Neckers, 1998; Workman et 
al., 2007). It has an IC50 value of about 128 nM for MCF7 cells (Maroney et al., 2006). 17-
AAG is being investigated in clinical trials in the USA and the United Kingdom (Goetz et al., 
2003). Other inhibitors include GA derivative (17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG) and hydroquinone hydrochloride analogue of 17-
AAG, 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504) 
(Workman et al., 2007). 17-DMAG is more water soluble than 17-AAG and has entered 
Phase 1 and 2 clinical testing with lower toxicity in comparison to 17-AAG (Hollingshead et 
al., 2005).  IPI-504 is in Phase 1 and 2 clinical trials for treating chemotherapy-resistant 
cancer (Peng et al., 2007). Radicicol, a macrocyclic natural antibiotic, also competes for the 
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N-terminal HSP90 ATP pocket (Roe et al., 1999). It is however chemically and metabolically 
unstable and therefore had anti-cancer activity in vitro but not in vivo (Pearl et al., 2008). 
Derivatives are currently being investigated (Li et al., 2009).  
 
Figure 5.1. Chemical structure of geldanamycin and its derivatives 17-Allylamino-17-
demethoxygeldanamycin (17-AAG), and 17-dimethylaminoethylamino-17- demethoxygeldanamycin (17-
DMAG) (Li et al., 2009). 
 
5.1.2 Novobiocin 
Novobiocin is a coumarin antibiotic (Figure 5.2) that binds weakly to the ATP binding site of 
HSP90 at its C-terminus, disrupting the HSP90 chaperone complex and resulting in the 
degradation of HSP90 clients (Marcu et al., 2000). Inhibition with novobiocin had similar 
effects as N-terminal inhibitors, such as the degradation of client proteins, HER-2, RAF-1 
and p53 (Marcu et al., 2000; Allan et al., 2006; McConkey and Zhu, 2008). The IC50 of 
novobiocin for MCF7 cells is quite high (260 μM) (Radanyi et al., 2008) therefore for an 
effect to be seen, a high concentration would be required in vivo, which could have 
detrimental effects on other pathways for the normal functioning of the cell. Other related 
coumarin analogs include chlorobiocin and coumermycin A1 which bind to the HSP90 C-
terminus and have better activity in comparison to novobiocin (Marcu et al., 2000; Burlison 
and Blagg, 2006). 
In this study, the HSP90 inhibitors, geldanamycin, 17-AAG and novobiocin were used to 
treat MCF7 to identify whether HSP90 inhibition would have an effect on the expression 
levels of the Wnt proteins, β-catenin, axin1 and GSK-3β. The data presented in this chapter 
will provide further insight into the associations that have already been identified (Chapter 3 
and 4) between HSP90α/β and these Wnt pathway proteins. 
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Figure  5.2. Chemical structure of novobiocin (Li et al., 2009). 
5.2 Results 
5.2.1 Determination of HSP90 protein expression levels by inhibition 
5.2.1.1 Geldanamycin and 17-AAG inhibition 
A range of geldanamycin and 17-AAG concentrations were used to treat MCF7 cells (Figure 
5.3A and B) for 24 hours and 72 hours respectively. No treatment (Figure 5.3A, 0 and Figure 
5.3B, 0) was used as the control in both experiments. In addition to this, cells treated with 
media supplemented with DMSO, were also used as a control in geldanamycin treatment 
(Figure 5.3A, DMSO). 
When MCF7 cells were treated with geldanamycin and 17-AAG (Figure 5.3), little or no 
change occurred in the HSP90α/β expression levels with increasing concentrations of both 
geldanamycin (Figure 5.3A) and 17-AAG (Figure 5.3B).  
 
Figure 5.3. HSP90α/β expression levels in MCF7 cells treated with 17-AAG and geldanamycin.  A. 
Western detection for HSP90α/β in geldanamycin treated MCF cells. B. Western detection for HSP90α/β in 17-
AAG treated MCF7 cells. Actin was used as the loading control. Control cells were treated in normal growth 
media (0) or media containing only DMSO (DMSO), in the absence of 17-AAG or geldanamycin. 
 
5.2.1.2 Novobiocin 
MCF7 cells were treated with increasing concentrations of novobiocin (Figure 5.4, 100 μM, 
260μM, 500μM) for 24 hours. No treatment (Figure 5.4, 0) was used as the control. 
Treatment of MCF7 cells with increasing concentrations of novobiocin resulted in a slight 
increase in HSP90α/β (Figure 5.4) at 100 μM novobiocin concentration, whilst the other 
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concentrations, 260 and 500 μM had expression levels similar to no treatment, 0 μM. It may 
therefore be concluded that no apparent change in HSP90α/β expression occurred after 
novobiocin treatment. 
  
Figure 5.4. HSP90α/β expression levels in MCF7 cells treated with novobiocin. Western detection for 
HSP90α/β in novobiocin treated MCF cells. Actin was used as the loading control. Control cells were treated in 
normal growth media in the absence of novobiocin (0). 
5.2.2 Effect of HSP90 inhibition on client proteins 
The effects of geldanamycin, 17-AAG and novobiocin were tested on known client proteins 
STAT3, p-STAT3, and Akt, so as to establish an experimental framework from which to test 
if β-catenin, p-β-catenin, GSK-3β and axin1 were client proteins. The client proteins have 
previously been found to have decreased expression levels when treated with HSP90 
inhibitors such as geldanamycin (Basso et al., 2002A and B; Sato et al., 2003). HSP90 
stabilizes its client proteins so that they can be activated (Sato et al., 2003). It is involved in 
the activation of client proteins by bringing them in contact with their kinases (Fujita et al., 
2002). Therefore, disruption of this association by geldanamycin, 17-AAG or novobiocin 
would cause a decrease in the phosphorylated, active forms of the client proteins. 
5.2.2.1 STAT3 
5.2.2.1.1 Total STAT3 
A range of geldanamycin and 17-AAG concentrations were used to treat MCF7 cells (Figure 
5.5A and B) for 24 hours and 72 hours respectively. No treatment (Figure 5.5A, 0 and Figure 
5.5B, 0) was used as the control in both experiments. In addition to this, cells treated with 
media supplemented with DMSO were also used as a control in geldanamycin treatment 
(Figure 5.5A, DMSO). 
When MCF7 cells were treated with geldanamycin, a decrease in the level of STAT3 
expression was seen at the higher concentrations of geldanamycin (Figure 5.5A); however 
this decrease was very slight for 1 and 10 μM geldanamycin when normalized to actin 
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(Appendix, Figure A4.1A ). On the other hand, there was very little or no change in the 
STAT3 levels with increasing concentrations of 17-AAG (Figure 5.5B). 
MCF7 cells were treated with increasing concentrations of novobiocin (Figure 5.6, 100 μM, 
260 μM, 500 μM) for 24 hours. No treatment (Figure 5.6, 0) was used as the control. There 
was a decrease in the expression of STAT3 with increasing concentrations of novobiocin 
(Figure 5.6). Although less protein was loaded in lane 4 and 5 (Figure 5.6, 260 and 500 μM 
concentrations), the densitometric analysis confirmed that there was an overall decrease in 
STAT3 with increasing novobiocin concentrations (Appendix, Figure A4.1C).  
 
Figure 5.5. Total STAT3 expression levels in MCF7 cells treated with 17-AAG and geldanamycin. A. 
Western detection for STAT3 in geldanamycin treated MCF cells. B. Western detection for STAT3 in 17-AAG 
treated MCF7 cells. Actin was used as the loading control. Control cells were treated in normal growth media 
(0) or media containing only DMSO (DMSO), in the absence of 17-AAG or geldanamycin. 
 
Figure 5.6. Total STAT3 expression levels in MCF7 cells treated with novobiocin. Western detection for 
STAT3 in novobiocin treated MCF cells. Actin was used as the loading control. Control cells were treated in 
normal growth media in the absence of novobiocin (0). 
5.2.2.1.2 P-STAT3 
MCF7 cells were exposed to increasing concentrations of 17-AAG and novobiocin for 72 and 
24 hours respectively (Figure 5.7 and 5.8). No treatment (Figure 5.7, 0) was used as the 
control. The relative levels of p-STAT3 were analyzed by Western blot analysis of total 
protein lysates after the 17-AAG treatments (Figure 5.7) and novobiocin (Figure 5.8) 
treatments. There was a decrease in the p-STAT3 signal at 10 μM 17-AAG (Figure 5.7A), 
which was also shown when the densitometric analysis was performed (Appendix, Figure 
A4.3).  
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Figure 5.7. p-STAT3 expression levels in MCF7 cells treated with 17-AAG. Western detection for p-STAT3 
in 17-AAG treated MCF7 cells. Actin was used as the loading control. No Control cells were treated in normal 
growth media (0) or media containing only DMSO (DMSO), in the absence of 17-AAG. 
The level of p-STAT3 decreased with increasing concentration of novobiocin (Figure 5.8A), 
with 260 and 500 μM novobiocin causing more of a decrease in the p-STAT3 than 100 μM 
(Figure 5.8B). 
 
Figure 5.8. P-STAT3 expression levels in MCF7 cells treated with novobiocin. Western detection for 
STAT3 in novobiocin treated MCF cells. Actin was used as the loading control. Control cells were treated in 
normal growth media in the absence of novobiocin (0). 
5.2.2.2 Akt 
Akt is another client protein that was used as a control to test the effects of the HSP90 
inhibitors on client proteins (Figure 5.9). HSP90 binds to the active form of Akt, allowing for 
its phosphorylation (Basso et al., 2002A and 2002B). Inhibition of HSP90 by geldanamycin 
and other derivatives results in a decrease in Akt activity and protein expression as shown by 
previous studies (Basso et al., 2002A and B). 
There was not much change in the expression of Akt with 17-AAG treatment (Figure 5.9). 
On the other hand there was a decreasing trend in the Akt expression level with increasing 
concentrations of novobiocin (Figure 5.10).  
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Figure 5.9. Akt expression levels in MCF7 cells treated with 17-AAG. A. Western detection for Akt in 17-
AAG treated MCF7 cells. Actin was used as the loading control. Control cells were treated in normal growth 
media (0) or media containing only DMSO (DMSO), in the absence of 17-AAG. 
 
Figure 5.10. Akt expression levels in MCF7 cells treated with novobiocin. A. Western detection for Akt in 
novobiocin treated MCF cells. Actin was used as the loading control. Control cells were treated in normal 
growth media in the absence of novobiocin (0). 
5.2.2.3 GSK-3β 
 
Different concentrations of geldanamycin and 17-AAG were used to treat MCF7 cells (Figure 
5.11A and B) for 24 hours and 72 hours respectively. No treatment (Figure 5.11A, 0 and 
Figure 5.11B, 0) was used as the control in both experiments. In addition to this, cells treated 
with media supplemented with DMSO were also used as a control in geldanamycin treatment 
(Figure 5.11A, DMSO). 
Treatment with geldanamycin resulted in a decrease in GSK-3β expression at high 
concentrations (Figure 5.11A, 10 μM concentration). HSP90-induced inhibition by 17-AAG 
in MCF7 cells did not result in a notable change in the expression levels of GSK-3β (Figure 
5.11B).  
After treatment of MCF7 cells with varying concentrations of novobiocin, there was a 
decrease in the expression level of GSK-3β at the higher concentrations (Figure 5.12,         
500 μM).  
 
 
Figure 5.11. GSK-3β expression levels in MCF7 cells treated with 17-AAG and geldanamycin.  A. Western 
detection for GSK-3β in geldanamycin treated MCF cells. B. Western detection for GSK-3β in 17-AAG treated 
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MCF7 cells. Actin was used as the loading control. Control cells were treated in normal growth media (0) or 
media containing only DMSO (DMSO), in the absence of 17-AAG or geldanamycin. 
 
Figure 5.12. GSK-3β expression levels in MCF7 cells treated with novobiocin.  Western detection for GSK-
3β in novobiocin treated MCF cells. Actin was used as the loading control. Control cells were treated in normal 
growth media in the absence of novobiocin (0). 
5.2.3 β-catenin 
There is preliminary evidence that HSP90 and total β-catenin associated by co-
immunoprecipitation (Chapter 4, Section 4.2.2); therefore exposure of MCF7 cells to HSP90 
inhibitors could have an effect on the protein expression level of β-catenin. 
MCF7 cells were treated with increasing concentrations of geldanamycin (Figure 5.13A) and 
17-AAG (Figure 5.13B). No treatment (Figure 5.13, lane 0) and media supplemented with 
DMSO (Figure 5.13A, DMSO) were used as the controls. Treatment with geldanamycin 
(Figure 5.13A) and 17-AAG (Figure 5.13B) did not decrease the level of total β-catenin, and 
seemed to cause a very slight increase in protein expression level at the higher concentration 
of 17-AAG (Figure 5.13B, 10 μM). Although it appeared that the level of β-catenin had 
decreased at the high concentration of 17-AAG (Figure 5.13B, 10 μM), densitometric 
analysis of triplicate studies revealed that there was actually a slight increase in the β-catenin 
level (Appendix, Figure A4.6C). 
A decrease in protein expression level of β-catenin was seen at higher concentrations (500 
μM) of novobiocin treatment (Figure 5.14, 500 μM). This decrease was also reflected in the 
densitometric study (Appendix, Figure A4.6B). 
 
Figure 5.13. β-catenin expression levels in MCF7 cells treated with 17-AAG and geldanamycin. A. 
Western detection for β-catenin in geldanamycin treated MCF cells. B. Western detection for β-catenin in 17-
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AAG treated MCF7 cells. Actin was used as the loading control. Control cells were treated in normal growth 
media (0) or media containing only DMSO (DMSO), in the absence of 17-AAG or geldanamycin. 
 
Figure 5.14. β-catenin expression levels in MCF7 cells treated with novobiocin. Western detection for β-
catenin in novobiocin treated MCF cells. Actin was used as the loading control. Control cells were treated in 
normal growth media in the absence of novobiocin (0). 
5.2.3.1 p-β-catenin  
HSP90α/β co-immunoprecipitated with the phosphorylated form of β-catenin (Chapter 4, 
section 4.2.2), therefore giving the first preliminary evidence that there was potential 
association between HSP90α/β and p-β-catenin. Western analysis for p-β-catenin was 
performed on MCF7 cells treated with HSP90 inhibitors at increasing concentrations. MCF7 
cells were treated with geldanamycin (Figure 5.15A, 0.1 μM, 0.5 μM, 1 μM, 10 μM) and 
novobiocin (Figure 5.16, 100 μM, 260 μM, 500 μM) for 24 hours. Treatment with 17-AAG 
(Figure 5.15B, 0.05 μM, 0.1 μM, 0.5 μM, 1 μM) occurred for 72 hours. No treatment (Figure 
5.15 and 5.16, lane 0) and media supplemented with DMSO (Figure 5.15A, DMSO) were 
used as the controls. 
Each HSP90 inhibitor treatment resulted in a decrease in the protein expression level of p-β-
catenin (Figure 5.15A and B; 5.16). At the high concentration of geldanamycin (Figure 
5.15A, 10 μM), the p-β-catenin level had also decreased in comparison to no treatment and 
the DMSO control (Figure 5.15A, DMSO). p-β-catenin protein expression levels also 
decreased with increasing 17-AAG (Figure 5.15B), from a concentration as low as 0.5 μM. 
 
Figure 5.15. p-β-catenin expression levels in MCF7 cells treated with 17-AAG and geldanamycin. A. 
Western detection for p-β-catenin in geldanamycin treated MCF cells. B. Western detection for p-β-catenin in 
17-AAG treated MCF7 cells. Actin was used as the loading control. Control cells were treated in normal growth 
media (0) or media containing only DMSO (DMSO), in the absence of 17-AAG or geldanamycin. 
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Increasing the concentration of novobiocin decreased the concentration of p-β-catenin (Figure 
5.16) such that at 500 μM novobiocin, the p-β-catenin signal was much less than that of no 
treatment (Figure 5.16, 500 μM). 
 
Figure 5.16. P-β-catenin expression levels in MCF7 cells treated with novobiocin. A. Western detection for 
p-β-catenin in novobiocin treated MCF cells. Actin was used as the loading control. Control cells were treated in 
normal growth media in the absence of novobiocin (0). 
 
5.3 Discussion 
The compound, 17-AAG binds to the N-terminus of HSP90, and results in a degradation of 
client proteins. HSP90α/β expression levels were not affected although the 17-AAG was 
preventing ATP from binding to the N-terminus (Roe et al., 1999). The known client 
proteins, STAT3, Akt and p-STAT3 were tested in this study to ensure that the efficacy of the 
compound was not compromised and also to provide a framework to which a comparison of 
the effect of the inhibitors on the Wnt proteins could be made. There was very little change in 
the expression levels of STAT3 (Figure 5.5) and Akt (Figure 5.9) with increasing 
concentrations of 17-AAG, whilst the expression of the phosphorylated form of STAT3 
decreased slightly with increasing concentrations of 17-AAG (Figure 5.7). Interestingly, 
studies have found that client proteins that degrade slowly are more likely to interact with 
HSP90 in a transient manner during conformational maturation and therefore become 
degraded at rates according to their protein half life (Liu et al., 1993; Xu et al., 2001). 
Furthermore, HSP90 inhibition prevented the client protein from becoming activated, such as 
STAT3 from being phosphorylated (Sato et al., 2003). 17-AAG did not have an effect on the 
expression levels of β-catenin (Figure 5.13C) and GSK-3β (Figure 5.11C). In contrast to this, 
the expression level of p-β-catenin decreased with increasing concentrations of 17-AAG thus 
illustrating that p-β-catenin was a potential client of HSP90 and was sensitive to HSP90 
inhibition. It can be suggested that 17-AAG efficiency was only sub-optimal for some of the 
experiments since an effect on the client protein, p-STAT3, was only seen at very high 
concentrations such as 10 μM.  
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To further validate the effects that 17-AAG inhibition had on the Wnt proteins, geldanamycin 
was used. Similar to 17-AAG, increasing concentrations of geldanamycin did not have an 
effect on the expression levels of HSP90, nor did it cause a change in the total β-catenin 
expression. Interestingly, there was only a slight decrease in GSK-3β at high geldanamycin 
concentrations (Figure 5.11A and B); whilst in literature GSK-3β has been found to be 
sensitive to geldanamycin concentrations in Hep3B cells (Banz et al., 2009). P-β-catenin also 
decreased with increasing geldanamycin concentrations (Figure 5.15B) which concurs with 
the study done by Banz et al. (2009). Banz et al. (2009) suggested that geldanamycin-induced 
HSP90 inhibition can also affect the kinases upstream of GSK-3β, such as Akt. This would 
result in the inhibition of GSK-3β, preventing GSK-3β from phosphorylating p-β-catenin. 
Treatment of MCF7 cells with the compound novobiocin did not cause a change in the 
expression level of HSP90α/β (Figure 5.4). On the other hand, the client proteins, STAT3 
(Figure 5.6), p-STAT3 (Figure 5.8) and Akt (Figure 5.10) decreased with increasing 
concentrations of novobiocin. Interestingly, the members of the Wnt pathway, GSK-3β 
(Figure 5.12), β-catenin (Figure 5.14) and p-β-catenin (Figure 5.16) also decreased with 
increasing concentrations of novobiocin.  
Overall, the results obtained in this study are consistent with the data obtained from co-
localization (Chapter 3) and immunoprecipitation (Chapter 4) studies, suggesting that 
HSP90α/β associates with GSK-3β, p-β-catenin and β-catenin. Although previous studies 
(Banz et al., 2009; Kurashina et al., 2009) have described a decrease in p-β-catenin after 
HSP90 inhibition as an indirect result of the inhibition of GSK-3β, the data presented here 
have shown that p-β-catenin and HSP90α/β associate in a common complex. 
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6.1 HSP90 association with Wnt members 
Aberrant activation of the Wnt pathway has been found in cancer, whereby stabilized β-
catenin can translocate to the nucleus and activate and maintain oncogenesis (Hoppler and 
Kavanagh, 2007). This can be due to mutations in genes encoding proteins involved in the 
destruction complex, such as APC, axin and even β-catenin (Polakis, 2000; Fodde et al., 
2001) or autocrine signaling. In colon cancer, the Wnt pathway is known to be stimulated due 
to a mutation in the APC gene (Bienz and Clevers, 2000; Yang et al., 2006). However, in 
breast cancer, it is thought that other factors influence the upregulation of stabilized β-catenin 
(Veeck et al., 2006). A study of the expression levels of axin1, β-catenin, p-β-catenin, GSK-
3β between the breast cancer cell line MCF7 and the colorectal cancer line HT29 confirmed 
that the MCF7 cell line had detectable levels of these proteins by Western analysis, making it 
a viable cell line to work with. These results concurred with literature as the Wnt pathway has 
been found to be “switched on” in breast cancer (Schlange et al., 2007). 
Previous studies have linked HSP90α/β to the Wnt pathway via association with GSK-3β 
(Lochhead et al., 2006), however little is known about the association of HSP90α/β with 
other members of the Wnt pathway in MCF7 cells. For the first time, in this study, an 
association of HSP90α/β with other members of the Wnt pathway, axin1, p-β-catenin and β-
catenin was shown in MCF7 cells.  
HSP90 plays a role in the maturation and stabilization of numerous client proteins, many of 
which are involved in oncogenesis (Grbovic et al., 2006). Of particular interest is that HSP90 
plays a role in many signal transduction pathways, but the mechanistic involvement of 
HSP90 in the Wnt signaling pathway has not been clearly defined.  Although an association 
of HSP90 has been found with GSK-3β (Lochhead et al., 2006), it is argued that this 
association is only transient (Banz et al., 2009). Our studies of co-localization by confocal 
microscopy confirmed that there was a possible association between HSP90 and GSK-3β. 
This was later confirmed by HSP90 inhibition whereby treatment of the cells with high 
geldanamycin concentrations resulted in a disruption of this association, leading to a decrease 
in detectable levels of GSK-3β. Furthermore, treatment with novobiocin, an HSP90 inhibitor, 
that binds to the C-terminus and disrupts co-chaperone interaction (Allan et al., 2006), 
resulted in the decrease in detectable levels of GSK-3β. This illustrated that without the 
stabilization of the chaperone complex, GSK-3β became unstable and was potentially 
degraded. Co-immunoprecipitation analyses confirmed the association of GSK-3β and 
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HSP90 by isolating HSP90 by immunoprecipitation with GSK-3β. However the reverse was 
difficult to analyze by Western detection since the signal was masked by the heavy chain 
IgG. At the same time, a definitive association between GSK-3β and HSP90 was difficult to 
confirm by co-immunoprecipitation possibly because there was steric hindrance between the 
antibody used to isolate the complex and the protein being detected (Tsaytler et al., 2009). It 
could be argued that the association between  GSK-3β and HSP90 is only transient therefore 
the weak interaction did not withstand the stringent lysis and washing conditions that occur 
during immunoprecipitation, as has been reported before for other HSP90 clients (Arlander et 
al., 2006). To confirm that the association between GSK-3β and HSP90 was not transient, 
other techniques could be employed. These could include using another technique of co- 
immunoprecipitation to isolate the HSP90 complex, such as the magnetic DynaBeads® 
therefore preventing any signal of GSK-3β being masked by the antibody‟s heavy and light 
chain.  
Immunofluorescence and confocal microscopy revealed that the expression level of axin1 
was very low in MCF-7 cells which concurs with literature since axin1 is the limiting protein 
of the destruction complex therefore expressed at low levels (Lee et al., 2003). Furthermore, 
axin1 was found to be in a similar location to HSP90 suggesting association which was 
confirmed by co-immunoprecipitation. Taking into account that axin1 is the scaffolding 
protein of the Wnt destruction complex, and gets sequestered to the membrane in the 
presence of a Wnt signal, and thereafter degraded (Willert et al., 1999), it was interesting to 
note that HSP90 inhibition by novobiocin resulted in accumulation of axin1 at the membrane 
(confocal analysis) and a reduction in the expression level (Western analysis). A possible 
explanation for this is that due to the destruction complex being disrupted by HSP90 
inhibition, axin1 is sequestered to the membrane and degraded. It would be important to 
make a comparison between the localization pattern and expression levels of axin1 in normal 
epithelial cells as well as cells that have the Wnt pathway “switched on” such as HT29 to see 
if there is a difference. Furthermore, by stimulating the Wnt pathway in MCF7 cells, confocal 
analysis would reveal whether a similar change in localization of axin1 as that of HSP90-
inhibition would occur, to prove the hypothesis. 
HSP90 was found to have a possible association with the destruction complex via the 
proteins, GSK-3β and axin1, total β-catenin and its phosphorylated form. Co-
immunoprecipitation analyses revealed that HSP90 is associated with both total β-catenin and 
p-β-catenin, with a strong association being found with the p-β-catenin. Furthermore, 
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inhibition by 17-AAG and geldanamycin resulted in a rapid degradation of p-β-catenin, thus 
suggesting its reliance on HSP90 for stabilization, either directly or in the complexed form. 
Novobiocin treatment, at high concentrations resulted in both the total β-catenin and p-β-
catenin expression levels decreasing. This suggested that since the co-chaperone activity of 
HSP90 was being inhibited by novobiocin, β-catenin was not able to enter the destruction 
complex to get phosphorylated. These results could indicate that HSP90 inhibition is 
disrupting a pathway upstream of the Wnt pathway, which could result in the Wnt pathway 
being activated so that axin1 is sequestered to the membrane after novobiocin treatment. This 
theory opposes that of Kurashina and colleagues (2009), who suggested that 17-AAG 
treatment inhibits the Wnt pathway by activating GSK-3β via Akt.   
These data collected in this study support a possible schematic model of the association of 
HSP90α/β with the destruction complex (Figure 6.1). The immunoprecipitation data suggest 
that HSP90α/β associates in a common complex with p-β-catenin (Figure 6.1A), which 
becomes disrupted upon treatment with an HSP90 inhibitor, such as novobiocin (Figure 
6.1B). β-catenin was therefore prevented from associating with the destruction complex 
(Figure 6.1B) and thus prevented from being phosphorylated. On the other hand, p-β-catenin 
was released from the destruction complex and degraded (Figure 6.1B), whilst the other 
destruction complex members, GSK-3β and axin1 were no longer stabilized by HSP90 which 
resulted in their degradation. If this model is true then p-β-catenin constitutes a small 
proportion of the total β-catenin detected. This could explain why there was a notable 
decrease in the expression level of p-β-catenin after novobiocin treatment (Figure 5.16), 
whilst only a small decrease in total β-catenin expression levels (Figure 5.14). If this model is 
true, then care must be taken in designing HSP90 inhibitor drugs since there is a possibility of 
activating the Wnt pathway by HSP90 inhibition, and thus potentially increasing the 
aggressiveness of the cancer. Furthermore, by activating the Wnt pathway, there is potential 
that dormant cancer stem cell-like cells will be activated, since the Wnt pathway is linked to 
stem cell proliferation (Lindvall et al., 2007) 
Taken together, these results suggest that HSP90 is directly involved in the destruction 
complex of HSP90 in the Wnt pathway, in contrast to previous studies which suggest its 
involvement in upstream pathways influencing the Wnt pathway (Banz et al., 2009). It can 
therefore be said, that there is a possible involvement of HSP90 in the modulation or 
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stabilization of p-β-catenin in the Wnt pathway by association with the proteins axin1, GSK-
3β and p-β-catenin. 
 
 
Figure 6.1. Schematic model of the association of HSP90α/β with p-β-catenin in the destruction complex 
in Wnt pathway in MCF7 cells. In the absence of HSP90 inhibition (A), there is a dynamic interaction 
between β-catenin and its phosphosphorylated form p-β-catenin. Immunoprecipitation (IP) studies have shown 
that HSP90α/β associates with p-β-catenin in a common complex (dotted line around complex). In the presence 
of HSP90 inhibitors (B), such as novobiocin, the HSP90 association with the destruction complex is disrupted 
and the proteins get degraded. β-catenin is prevented from being phosphorylated shown by blunted line. Primary 
antibody shown schematically detecting IP complex. Arrows point towards direction of pathway. Dotted lines in 
(B) represent protein degradation. „a‟ and „b‟ represent proteins within destruction complex. 
 
6.2 Future work 
An interesting study that could be performed in the future would be to compare the 
expression levels of the Wnt pathway proteins between a normal breast epithelial cell line and 
MCF7 cells to see if there is a difference, and then to stimulate the Wnt pathway in the 
normal breast epithelial cell line to see if the expression levels of proteins such as β-catenin 
are upregulated to a comparable level.  
Another interesting study would be to identify which other proteins in the Wnt pathway could 
be associated with HSP90. Many questions need to be answered in order to fully understand 
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the role of HSP90 in the Wnt pathway. For example, since HSP90 has been found to be 
associated with the destruction complex via axin1 and GSK-3β, is it also involved with the 
other members, such as APC? Where is HSP90 involved with the destruction complex? How 
strong are the associations of HSP90 with these proposed client proteins? If HSP90 is 
associated with axin1, which is proposed to be also involved in the transport of β-catenin in 
and out of the nucleus, is HSP90 also involved in the nuclear transport of β-catenin?  
These questions could be answered by co-immunoprecipitation studies, as well as cross-
linking HSP90 with other proteins involved in the destruction complex such as APC prior to 
immunoprecipitation. Treatment of the cells with HSP90 inhibitors prior to co-
immunoprecipitation would further reveal dependency of the complexes on HSP90 for 
stabilization and at which terminus the client proteins interact with HSP90. Furthermore, by 
treating MCF7 cells with a compound that is known to stimulate the Wnt pathway, confocal 
analysis could be performed to test if there is an association of HSP90 with the nuclear 
fraction of β-catenin, and whether other associations would change. Co-immunoprecipitations 
on subcellular fractionations would reveal where in the cell the associations with HSP90 
occur. Furthermore, pTopflash reporter assays, which measure the TCF/LEF transcription, 
could be performed to identify whether the Wnt pathway is activated or inhibited after HSP90 
treatment.  
An alternative method for identifying the protein-protein interactions, such as those between 
HSP90 and the APC destruction complex, would be to synthesize a histidine tagged version 
of HSP90 and using it affinity purification of the MCF7 lysate. The resulting isolated 
complex could then be probed for the respective proteins within the APC destruction 
complex. The reverse could be performed by synthesizing histidine tagged versions of the 
APC complex proteins and probing for HSP90.   
Lastly, this is the first study that provides a possible association of HSP90 with the Wnt 
pathway in MCF7 cells. This mechanistic understanding of the involvement of HSP90 in the 
Wnt pathway is important since it gives a framework for studying the association of HSP90 
in the Wnt pathway in cancer stem cells, thus allowing for the development of therapeutic 
drugs targeted at inhibiting the Wnt pathway.  
 
 
83 
 
REFERENCES 
Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J, Garcia JM, Muñoz A, Esteller M and González-
Sancho JM (2006). Epigenetic inactivation of the Wnt antagonist Dickkopf-1 (Dkk-1) gene in human colorectal 
cancer: Dkk-1 methylation in human colorectal cancer. Oncogene 25: 4116–4121. 
Alberts B,  Johnson  A, Lewis J, Raff  M, Roberts K and Walter P (2002). Cancer. In: Molecular Biology of the Cell, 4th 
Edition, Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (eds), 1313−1362. New York:  Garland 
Science Textbooks. 
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF (2003). Prospective identification of 
tumourigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100: 3983–8. 
Ali MMU, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, Prodromou C and Pearl LH (2006). Crystal 
structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440: 1013–1017.  
Allan RK, Mok D, Ward BK and Ratajczak T (2006). Modulation of chaperone function and cochaperone interaction by 
novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. 
J. Biol. Chem. 281: 7161–7171. 
Alves-Guerra MC, Ronchini C and Capobianco AJ (2007). Mastermind-like 1 is a specific coactivator of β-catenin 
transcription activation and is essential for colon carcinoma cell survival. Cancer Res. 67: 8690–8698. 
Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y and Alkalay I (2002). Axin-
mediated CK1 phosphorylation of β-catenin at Ser 45: a molecular switch for the pathway. Genes Dev. 16: 1066 
– 1076. 
Angers S and Moon RT (2009). Proximal events in Wnt signal transduction. Nature 10: 468-477.  
Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO and Karnitz LM (2006). Chaperoning checkpoint kinase 1 
(Chk1), an Hsp90 client, with purified chaperones. J. Biol. Chem. 281: 2989–2998.   
Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP and 
Brisken C (2006). Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a 
Notch-dependent mechanism. Proc. Natl. Acad. Sci. USA 103: 3799-3804. 
Banz VM, Medová M, Keogh A, Furer C, Zimmer Y, Candinas D and Stroka D (2009). Hsp90 transcriptionally and 
post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase 
GSK3beta. Biochim. Biophys. Acta 1793: 1597-1603. 
Barth AI, Pollack AL, Altschuler Y, Mostov KE and Nelson WJ (1997). NH2-terminal deletion of β-catenin results in 
stable colocalization of mutant β-catenin with adenomatous polyposis coli protein and altered MDCK cell 
adhesion. J. Cell. Biol. 136: 693-706. 
Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P and Rosen N (2002B). Akt forms an intracellular complex with heat 
shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277: 
39858–39866. 
Basso AD, Solit DB, Munster PN and Rosen N (2002A). Ansamycin antibiotics inhibit Akt activation and cyclin D 
expression in breast cancer cells that overexpress HER2. Oncogene 21: 1159– 1166. 
Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, Wirtz R, Kühl M, Wedlich D and Birchmeier W (1998). 
Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK-3beta. Science 280: 
596–599. 
Bennet LB, Taurog JD and Bowcock AM (1999). Hereditary breast cancer genes. In: Breast Cancer: Molecular Genetics, 
Pathogenesis, and Therapeutics, Bowcock AM (ed), pp 199–224. Totowa, NJ: Humana Press Inc.  
84 
 
Bienz M and Clevers H (2000). Linking colorectal cancer to Wnt signaling. Cell: 103: 311–320.  
Bilić J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M and Niehrs C (2007). Wnt induces LRP6 
signalosomes and promotes Dishevelled-dependent LRP6 phosphorylation. Science 316: 1619-1622. 
Blagg BS and Kerr TD (2006). Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery 
into a catalyst for protein degradation. Med. Res. Rev. 26: 310–338. 
Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J and Lindquist S (1989). Hsp82 is an essential protein that is 
required in higher concentrations for growth of cells at higher temperatures. Mol. Cell. Biol. 9: 3919–3930. 
Bovolenta P, Esteve P, Ruiz JM, Cisneros E and Lopez-Rios J (2008). Beyond Wnt inhibition: new functions of secreted 
Frizzled-related proteins in development and disease. J. Cell Sci. 121: 737–746. 
Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T (2001). Variable β-
catenin  expression in colorectal cancers indicates tumour progression driven by the tumour environment. Proc. 
Natl. Acad. Sci. USA 98: 10356-10361. 
 
Brown (2001). Wnt signaling in breast cancer: have we come a full circle? Breast Cancer Res. 3: 351 – 5. 
Brown MA, Zhu L, Schmidt C and Tucker PW (2007). HSP90 – from signal transduction to cell transformation. 
Biochem. Biophys. Res. Commun. 363: 241-246. 
Brugge JS (1983). Interaction of the Rous sarcoma virus protein pp60src with cellular proteins pp50 and pp90. Curr. 
Top. Microbiol. Immunol. 123: 1-22. 
Bui TD, Rankin J, Smith K, Huguet EL, Ruben S, Strachan T, Harris AL and Lindsay S (1997). A novel human Wnt 
gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene 14: 1249-1253. 
Burlison JA and Blagg BS (2006). Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein 
folding machinery. Org. Lett. 8: 4855– 4858. 
Cairns J (2002). Somatic stem cells and the kinetics of mutagenesis and carcinogenesis. Proc. Natl. Acad. Sci. USA 99: 
10567 – 70. 
Calvocoressi L, Sun A, Kasl SV, Claus EB and Jones BA (2008). Mammography screening of women in their 40s: 
impact of changes in screening guidelines. Cancer 112: 473 – 480. 
Campbell Marotta LL and Polyak K (2009). Cancer stem cells: a model in the making. Curr. Opin. Genet. Dev. 19: 44-
50. 
Cariati M and Purushotham AD (2008). Stem cells and breast cancer. Histopathology 52: 99 – 107. 
Caspi M, Zilberberg A, Eldar-Finkelman H and Rosin-Arbesfeld R (2008). Nuclear GSK-3β inhibits the canonical Wnt 
signaling pathway in a β-catenin phosphorylation-independent manner. Oncogene 27: 3546-3555. 
Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, 
Gooden JK, Ramanathan R, Cemy RL and Rogan EG (1997). Molecular origin of cancer: catechol estrogen-3,4-
quinones as endogenous tumour initiators. Proc. Natl. Acad. Sci. USA 94:10937–10942. 
Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR and Varmus HE (2005). FGF-20 and DKK1 are 
transcriptional targets of β-catenin  and FGF-20 is implicated in cancer and development. EMBO J. 24: 73–84. 
Chan TA, Wang Z, Dang LH, Vogelstein B and Kinzler KW (2002). Targeted inactivation of CTNNB1 reveals 
unexpected effects of β-catenin mutation. Proc. Natl. Acad. Sci. USA 99: 8265–8270. 
Chen G, Cao P and Goeddel DV (2002). TNF-induced recruitment and activation of the IKK complex require Cdc37 and 
Hsp90. Mol. Cell  9: 401–410. 
85 
 
Chen MS, Woodward WA, Behbod F, Peddibhotla S, Alfaro MP, Buchholz TA and Rosen JM (2007). Wnt/β-catenin  
mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J. Cell Sci. 120: 
468–477. 
Chen WY, Chang FR, Huang ZY, Chen JH, Wu YC and Wu CC (2008). Tubocapsenolide A, a novel withanolide, 
inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins. J. 
Biol. Chem. 283: 17184–17193. 
Chiosis G and Neckers L (2006). Tumour selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. 
Biol. 1:279–284. 
Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL and Rimm DL. (2001). Tissue microarray analysis of β-
catenin in colorectal cancer shows nuclear p-β-catenin is associated with a better prognosis. Clin. Cancer Res. 7: 
4013–4020. 
Ciani L, Krylova O, Smalley MJ, Dale TC and Salinas PC (2004). A divergent canonical WNT-signaling pathway 
regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J. Cell. Biol. 164: 243–
253. 
Clevers H (2006). Wnt/β-catenin  signaling in development and disease. Cell 127: 469–480. 
Cole AR and Sutherland C (2008). Measuring GSK3 expression and activity in cells. Methods Mol. Biol. 468: 45-65. 
Coles C, Condie A, Chetty U, Steel CM, Evans HJ and Prosser J (1992). p53 mutations in breast cancer. Cancer Res. 52: 
5291–5298. 
Collu GM, Meurette M and Brennan K (2009). Is there more to Wnt signaling in breast cancer than stabilisation of β-
catenin? Breast Cancer Res. 11: 105. 
Cong F and Varmus H (2004A). Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of β-catenin . 
Proc. Natl. Acad. Sci. USA 101: 2882–7. 
Cong F, Schweizer L and Varmus H (2004B). Wnt signals across the plasma membrane to activate the β-catenin pathway 
by forming oligomers containing its receptors, Frizzled and LRP. Development 131: 5103-5115. 
Covey TM, Edes K, Coombs GS, Virshup DM and Fitzpatrick FA (2010). Alkylation of the tumour suppressor PTEN 
activates Akt and β-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PLoS 
ONE 5: e13545.  
Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM (1999). The 
metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumours. Oncogene 18: 2883–
2891. 
Cress RD, Morris C, Ellison GL, Goodman MT (2006). Secular changes in colorectal cancer incidence by subsite, stage 
at diagnosis and race/ ethnicity, 1992 – 2001. Cancer 107: 1142 – 52.  
Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by 
insulin mediated by protein kinase B. Nature 378:785–9. 
Cselenyi CS, Jernigan KK, Tahinci E, Thorne CA, Lee LA and Lee E (2008). LRP6 transduces a canonical Wnt signal 
independently of Axin degradation by inhibiting GSK3's phosphorylation of β-catenin. Proc. Nat. Acad. Sci. 
105: 8032-8037. 
Daidone MG, Luisi A, Veneroni S, Benini E and Silvestrini R (1999). Clinical studies of Bcl-2 and treatment benefit in 
breast cancer patients. Endocr. Relat. Cancer 6:61–68. 
Daniels DL and Weis WI (2005). β-catenin  directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated 
transcription activation. Nat. Struct. Mol. Biol. 12: 364–371. 
Darnell JE, Kerr IM and Stark GR (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and 
other extracellular signaling proteins. Science 264: 1415 – 1421. 
86 
 
Davidson G, Wu W, Shen J, Bilić  J, Fenger U, Stannek P, Glinka A and Niehrs C (2005). Casein kinase 1γ couples Wnt 
receptor activation to cytoplasmic signal transduction. Nature 438: 867–872. 
Debruin LS and Josephy PD (2002). Perspectives on the chemical etiology of breast cancer. Environ. Health Perspect. 
110 (suppl. 1): 119-128. 
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL and Rimm DL (2006). Quantitative in situ analysis of β-
catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 
66: 5487–5494. 
Dollins DE, Warren JJ, Immormino RM, Gewirth DT (2007). Structures of GRP94-nucleotide complexes reveal 
mechanistic differences between the hsp90 chaperones. Mol. Cell 28: 41–56. 
Dontu G, El-Ashry D and Wicha MS (2004). Breast cancer, stem/progenitor cells and the estrogen receptor. Trends 
Endocrinol. Metab. 15: 193 – 197. 
Dutta R and Inouye M (2000) GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25: 24–28. 
Eaton L (2003). World cancer rates set to double by 2020. BMJ 326: 728 
Eleftheriou A, Yoshida M and Henderson BR (2001). Nuclear export of human β-catenin can occur independent of 
CRM1 and the adenomatous polyposis coli tumour suppressor. J. Biol. Chem. 276: 25883 – 25888.  
Espinosa L, Inglés-Esteve J, Aguilera C and Bigas A (2003). Phosphorylation by glycogen synthase kinase-3β down-
regulates Notch activity, a link for Notch and Wnt pathways. J. Biol. Chem. 278: 32227–32235. 
Eyler CE and Rich JN (2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. 
Oncol. 26: 2839 – 2845. 
Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM and Eberhart CG (2006). Notch pathway inhibition depletes stem-
like cells and blocks engraftment in embryonal brain tumours. Cancer Res. 66: 7445 – 7452. 
Faux MC, Coates JL, Catimel B, Cody S, Clayton AHA, Layton MJ and AW Burgess (2008). Recruitment of 
adenomatous polyposis coli and β-catenin  to axin-puncta. Oncogene 27: 5808–5820. 
Feinberg AP, Ohlsson R and  Henikoff  S (2006). The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7: 
21-33. 
Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB and Toft DO (2000). The hsp90-related protein TRAP1 is a 
mitochondrial protein with distinct functional properties. J. Biol. Chem. 275: 3305–3312. 
Ferrarini M, Heltai S, Zocchi MR and Rugarli C (1992). Unusual expression and localization of heat-shock proteins in 
human tumour cells. Int. J. Cancer 51: 613 – 619. 
Fodde R, Smits R and Clevers H (2001). APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. 
Cancer 1: 55 – 67. 
Frisén J and Lendahl U (2001). Oh no, Notch again! Bioessays 23: 3–7. 
Fujita N, Sato S, Ishida A and Tsuruo T (2002). Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-
dependent kinase-1. J. Biol. Chem. 277: 10346-10353. 
Gehrke I, Gandhirajan RK and Kreuzer KA (2009). Targeting the WNT/β-catenin/TCF/LEF1 axis in solid and 
haematological cancers: multiplicity of therapeutic options. Eur. J. Cancer 45: 2759 –2767. 
Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM and Hanby AM (2001). Retention of 
the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the 
breast. J.  Pathol. 93: 433–441. 
Goetz MP, Toft DO, Ames MM and Erlichman C (2003) The Hsp90 chaperone complex as a novel target for cancer 
therapy. Annal. Oncol. 14: 1169-1176. 
87 
 
Grammatikakis N, Vultur A, Ramana CV, Siganou A, Schweinfest CW, Watson DK and Raptis L. (2002). The role of 
Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J. Biol. 
Chem. 277: 8312–8320. 
Graziano A, d‟Aquino R, Tirino V, Desiderio V, Rossi A and Pirozzi G (2008). The stem cell hypothesis in head and 
neck cancer. J. Cell. Biochem. 103: 408 – 412. 
Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N (2006). V600E B-Raf requires the Hsp90 
chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA 103: 57–62. 
Hambardzumyan D, Becher OJ and Holland EC (2008). Cancer stem cells and survival pathways. Cell Cycle 7: 1371 – 
1378. 
Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M. and Taketo MM (1999). Intestinal polyposis in mice 
with a dominant stable mutation of the β-catenin gene. EMBO J. 18: 5931–5942. 
Haraguchi N, Ohkima M, Sakashita H, Matsuzaki S, Tanaka F, Mimori, K, Kamohara Y, Inoue H and Mori M (2008). 
CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann. Surg. Oncol. 15: 2927 – 2933. 
Hawle P, Siepmann M, Harst A, Siderius M, Reusch HP and Obermann WM (2006). The middle domain of Hsp90 acts 
as a discriminator between different types of client proteins. Mol. Cell. Biol. 26:8385–8395. 
Hayward P, Balayo T and Martinez Arias A (2006). Notch synergizes with axin to regulate the activity of armadillo in 
Drosophila. Dev. Dyn. 235: 2656–2666. 
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW (1998). 
Identification of c-MYC as a Target of the APC Pathway. Science 281: 1509–1512. 
Helmbrecht K, Zeise E and Rensing L (2000). Chaperones in cell cycle regulation and mitogenic signal transductions: a 
review. Cell Prolif. 33: 341 – 365 
Henderson BE and Feigelson HS (2000). Hormonal carcinogenesis. Carcinogenesis 21:427–43. 
Henderson BR (2000). Nuclear-cytoplasmic shuttling of APC regulates β-catenin subcellular localization and turnover. 
Nat. Cell. Biol. 2: 653 – 660. 
Henderson BR and Fagotto F (2000). The ins and outs of APC and β-catenin nuclear transport. EMBO re. 3: 834-839. 
Henderson BR, Galea M, Schuechner S and Leung L (2002). Lymphoid Enhancer Factor-1 blocks APC-mediated nuclear 
export and degradation of β-catenin: regulation by Histone Deacetylase 1. J. Biol. Chem. 277: 24258–24264. 
Hinz M, Broemer M, Arslan SC, Otto A, Mueller EC, Dettmer R and Scheidereit C (2007). Signal responsiveness of IκB 
kinases is determined by Cdc37-assisted transient interaction with Hsp90. J. Biol. Chem. 282: 32311-32319. 
Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK (2004). A 
distinct “side population” of cells with high drug efflux capacity in human tumour cells. Proc. Natl. Acad. Sci. 
USA 101:14228–14233. 
Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D and Nicholson RI (2006). Tamoxifen 
resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. 
Int. J. Cancer 118: 290–301. 
Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA and Howe PH (2003). Regulation of the Wnt signaling 
pathway by disabled-2 (Dab2). EMBO J. 22: 3084 – 3094. 
Hoffmans R and Basler K (2007). BCL9-2 binds Arm/β-catenin in a Tyr142-independent manner and requires Pygopus 
for its function in Wg/Wnt signaling. Mech. Dev. 124: 59-67. 
Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH and Sausville EA (2005). In vivo antitumour 
efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-
soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 56: 115-125. 
88 
 
Hoppler S and Kavanagh CL (2007). Wnt signaling: variety at the core. J. Cell Sci. 120: 385-393. 
Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe R F and Waterman ML 
(2001). β-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. 
Nat. Genet. 28: 53-57. 
Howard BA (2000). Human breast development. J. Mammary Gland Biol. Neoplasia 5: 119 – 137. 
Howard EM, Lau SK, Lyles RH, Birdsong GG, Tadros TS, Umbreit JN and Kochhar R (2004). Correlation and 
expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-
cancer population. Int. J. Clin. Oncol. 9: 154-60. 
Huang H and He X (2008). Wnt/β-catenin signaling: new (and old) players and new insights. Curr. Opin. Cell Biol. 20: 
119–125. 
Huber AH andWeis WI (2001). The structure of the β-catenin/E-cadherin complex and the molecular basis of diverse 
recognition by β-catenin. Cell 105: 391 – 402.  
Hung MC and Lau YK (1999). Basic science of HER-2/neu: a review. Semin. Oncol. 26: 51–59. 
Ingham PW and McMahon AP (2001). Hedgehog signaling in animal development: paradigms and principles. Genes 
Dev. 15: 3059 – 87. 
Inoki K, Ouyang H, Zhu T, Lindvall C,Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, 
MacDougald OA, You M, Williams BO and Guan KL (2006). TSC2 integrates Wnt and energy signals via a 
coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955–968. 
Iozzo RV, Eichstetter I and Danielson KG (1995). Aberrant expression of the growth factor Wnt-5A in human 
malignancy. Cancer Res. 55: 3495 – 3499. 
Jemal A, Siegal R, Ward E, Hao Y, Xu J, Murray T and Thun MJ (2008). Cancer statistics, 2010. CA Cancer  J. Clin. 58: 
71-96. 
Jin LH, Shao QJ, Luo W, Ye ZY, Li Q, Lin SC (2003). Detection of point mutations of the Axin1 gene in colorectal 
cancers. Int. J. Cancer 107: 696–699. 
Jones PA and Baylin (2002). The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415 – 428. 
Kakarala M and Wicha MS (2008). Implications of the cancer stem-cell hypothesis for breast cancer prevention and 
therapy. J. Clin. Oncol. 26: 2813 – 2820. 
Kam Y and Quaranta Y (2009). Cadherin-Bound β-catenin feeds into the Wnt Pathway upon Adherens junctions 
dissociation: evidence for an intersection between β-catenin pools. PLoS ONE 4: e4580. 
Kamal A, Boehm MF and Burrows FJ (2004). Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. 
Med. 10: 283–290. 
Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and Burrows FJ (2003). A high-affinity conformation of 
Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407–410. 
Kanwar SS, Yu Y, Nautiyal J, Patel BB and Majumdar APN (2010). The Wnt/β-catenin  pathway regulates growth and 
maintenance of colonospheres. Mol. Cancer 9:212 
Katoh M and Katoh M (2007). STAT3 induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, 
chronic persistent inflammation, rheumatoid arthritis and cancer (review). Int. J. Mol. Med. 19: 273 – 278. 
Katschinski DM, Le L, Heinrich D, Wagner KF, Hofer T, Schindler SG and Wenger RH (2002). Heat induction of the 
unphosphorylated form of hypoxia-inducible factor-1α is dependent on heat shock protein-90 activity. J. Biol. 
Chem. 277: 9262-9267. 
89 
 
Kelleher FC, Fennelly D, Rafferty M (2006). Common critical pathways in embryogenesis and cancer. Acta Oncologica 
45: 375-388.  
Khan Z, Vijayakumar S, de la Torre TV, Rotolo S and Bafico A (2007). Analysis of endogenous LRP6 function reveals a 
novel feedback mechanism by which Wnt negatively regulates its receptor. Mol. Cell. Biol. 27: 7291–7301. 
Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL and Rimm DL. (2003). Tissue microarray-based 
analysis shows p-β-catenin expression in malignant melanoma is associated with poor outcome. Int. J. Cancer 
103: 652–656. 
Kikuchi A (2000). Regulation of β-catenin signaling in the Wnt pathway. Biochem. Biophys. Res. Commun. 268: 243–
248. 
Kim HL, Cassone M, Otvos L Jr and Vogiatzi P (2008). HIF-1α and STAT3 client proteins interacting with the cancer 
chaperone HSP90. Cancer Biol. and Therapy 7: 10 -14. 
Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L and Trepel JB (2009). Update on HSP90 inhibitors in 
clinical trial. Curr. Top. Med. Chem. 9: 1479 – 1492. 
Kimelman D and Xu W (2006). β-Catenin destruction complex: insights and questions from a structural perspective. 
Oncogene 25: 7482–7491. 
Kirchner T and Brabletz T (2000). Patterning and nuclear β-catenin  expression in the colonic adenoma-carcinoma 
sequence. Analogies with embryonic gastrulation. Am. J. Pathol. 157: 1113-1121. 
Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M Ishida N, Nakamichi I, Kikuchi A, Nakayama K and Nakayama 
K (1999). An Fbox protein FWD1 mediates ubiquitin dependent proteolysis of β-catenin. EMBO J. 18: 2401 – 
2410. 
Kohler EM, Chandra SHV, Behrens J and Schneikert (2009). β-Catenin degradation mediated by the CID domain of 
APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumours. Human 
Mol. Genet. 18: 213-226. 
Kondo T, Setoguchi T and Taga T (2004). Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma 
cell line. Proc. Natl. Acad. Sci. USA 101:781–786. 
Kopper L and Hadju M (2004). Tumour stem cells. Pathol. Oncol. Res. 10: 69 -  73. 
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and  Clevers H (1997). 
Constitutive transcriptional activation by a β-catenin -Tcf complex in APC-/- colon carcinoma. Science 
275:1784–1787. 
Korkaya H and Wicha MS (2007). Selective targeting of cancer stem cells: a new concept in cancer therapeutics. 
Biodrugs 21: 299 – 310. 
Kotiligam D, Lazar AJ, Pollock RE and Lev D (2008). Desmoid tumour: a disease opportune for molecular insights. 
Histol. Histopathol. 23:117-26. 
Kroboth K, Newton IP, Kita K, Dikovskaya D, Zumbrunn J, Waterman-Storer CM and Näthke IS (2007). Lack of 
adenomatous polyposis coli protein correlates with a decrease in cell migration and overall changes in 
microtubule stability. Mol. Biol. Cell. 18: 910-8. 
 
Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, Kuroki S and Katano M (2004). Hedgehog 
signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 64: 6071 – 6074. 
Kumar S and  Weaver VM (2009). Mechanics, malignancy, and metastasis: the force journey of a tumour cell. Cancer 
Metastasis Rev. 28: 113–127. 
Kurashina R,  Ohyashiki JH, Kobayashi a C, Hamamuraa R,  Zhang  Y, Hirano T and Ohyashiki K (2009). Anti-
proliferative activity of heat shock protein (Hsp) 90 inhibitors via β-catenin/TCF7L2 pathway in adult T cell 
leukemia cells. Cancer Letters 284: 62–70. 
90 
 
Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 
680-685. 
Lagerstedt Robinson K, Liu T, Vandrovcova J, Halvarsson B, Clendenning M, Frebourg T, Papadopoulos N, Kinzler 
KW, Vogelstein B, Peltomäki P, Kolodner RD, Nilbert M and Lindblom A (2007). Lynch Syndrome 
(Hereditary Nonpolyposis Colorectal Cancer) Diagnostics. J. Natl. Cancer Inst. 99: 291-299. 
 
Lamberti C, Lin KM, Yamamoto Y, Verma IM, Byers S and Gaynor RB (2001). Regulation of beta-catenin function by 
the IkappaB kinases. J. Biol. Chem. 276: 42276 – 42286. 
Lammi L, Arte S, Somer M, Järvinen H, Lahermo P, Thesleff I, Pirinen S and Nieminen P (2004). Mutations in AXIN2 
cause familial tooth agenesis and predispose to colorectal cancer. Am. J. Hum. Genet. 74: 1043–1050. 
Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahkle MH, Piso P, Schlitt HJ, Geissler EK and 
Stoeltzing  O (2007). Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-1 
receptor signaling, disrupting an interleukin 6/ signal transducer and activator of transcription 3/ hypoxia 
inducible factor 1 (alpha) autocrine loop and reduces orthotopic tumour growth. Clin. Cancer Res. 13: 6459 – 
68. 
Langer T, Rosmus S and Fasold H (2003). Intracellular localization of the 90 kDA heat shock protein (HSP90α) 
determined by expression of a EGFP-HSP90α-fusion protein in unstressed and heat stressed 3T3 cells. Cell Biol. 
Int. 27: 47-52. 
Lawson JC, Blatch GL and Edkins AL (2009). Cancer stem cells in breast cancer and metastasis. Breast Cancer Res. 
Treat. 118: 241-54.  
Lee E, Salic A, Krüger R, Heinrich R and Kirschner MW (2003). The roles of APC and Axin derived from experimental 
and theoretical analysis of the Wnt pathway. PLoS Biol. 1: e10. 
Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER (2002). Activation of AXIN2 expression 
by β-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J. Biol. Chem. 277: 21657 – 
21665. 
Levina E, Oren M and Ben-Ze‟ev A (2004). Downregulation of β-catenin  by p53 involves changes in the rate of β-
catenin  phosphorylation and Axin dynamics. Oncogene 23: 4444–4453. 
Li L, Yuan H, Weaver CD, Mao J, Farr GH 3rd, Sussman DJ, Jonkers J, Kimelman D and Wu D (1999). Axin and Frat1 
interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 18: 4233–
4240 
Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE and Wu D (2005). Sclerostin binds to LRP5/6 and antagonizes 
canonical Wnt signaling. J. Biol. Chem. 280: 19883–19887. 
Li Y, Zhang T, Schwartz SJ and Sun D (2009). New developments in Hsp90 inhibitors as anti-cancer therapeutics: 
Mechanisms, clinical perspective and more potential. Drug Res. Updat. 12: 17–27. 
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki K 
(2000). Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from 
Sweden, Denmark, and Finland. N. Engl. J. Med. 343:78–85. 
Lin J, Tang H, Jin X, Jia G and Hsieh JT (2002). p53 regulates Stat3 phosphorylation and DNA binding activity in 
human prostate cancer cells expressing constitutively active Stat3. Oncogene. 21:3082-3088. 
Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell  RG and Hung MC (2000). β-catenin, a novel 
prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. 
Sci. USA.  97: 4262-4266. 
Lindvall C, Bu W, Williams BO and Li Y (2007). Wnt signaling, stem cells, and the cellular origin of breast cancer.  
Stem Cell Rev. 3:157–168. 
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS (2006). Analysis of gene 
expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5: 67. 
91 
 
Liu S and Carpenter G (1993). Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor 
tyrosine kinase activities. J. Cell. Physiol. 157: 237–242. 
Liu S, Dontu G and Wicha MS (2005). Mammary stem cells, self-renewal pathways and carcinogenesis. Breast Cancer 
Res. 7: 86 – 95 
Liu S, Dontu G, Mantle ID, Patel S, Ahn N, Jackson KW, Suri P and Wicha MS (2006). Hedgehog signaling and Bmi-1 
Regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66: 6063-71. 
Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian 
C, Christensen E, Schmidt SS, Roche PC, Smith DI and Thibodeau SN (2000). Mutations in AXIN2 cause 
colorectal cancer with defective mismatch repair by activating β-catenin /TCF signaling. Nat. Genet. 26: 146–
147. 
Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N and Cleghon V (2006). A chaperone-dependent GSK3β 
transitional intermediate mediates activation-loop autophosphorylation. Mol. Cell 24: 627-633. 
Logan CY and Nusse R (2004). The Wnt signaling in development and disease.  Annu. Rev. Cell. Dev. Biol. 20: 781-810. 
López-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL and O'Toole SA (2010). 
Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer 
Epidemiol. Biomarkers Prev. 19:301-9. 
Luo W, Peterson A, Garcia BA, Coombs G, Kofahl B, Heinrich R, Shabanowitz J, Hunt DF, Yost HJ and Virshup DM 
(2007). Protein phosphatase 1 regulates assembly and function of the β-catenin  degradation complex. EMBO J. 
26: 1511-1521. 
Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier 
W and Behrens J (2002). Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in 
colorectal and liver tumours. Mol. Cell. Biol. 22: 1184–93. 
Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, Park JK, Wang H, Peng Y, Jiang W and He TC (2004). 
Wnt/β-catenin  signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets 4: 653–71. 
Ma H, Nguyen C, Lee LS and Kahn M (2005). Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-
mediated survivin gene expression. Oncogene 24: 3619–3631. 
Mai M, Qian C, Yokomizo A, Smith DI and Liu W (1999). Cloning the human homolog of conductin (AXIN2), a gene 
mapping to chromosome 17 q23-24. Genomics 55: 341 – 344. 
Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, MacCoss MJ, 
Angers S and Moon RT (2007). Wilms tumour suppressor WTX negatively regulates WNT/β-catenin  signaling. 
Science 316:1043-1046. 
Manders EM, Stap MJ, Brakenhoff GJ, Van Driel R and Aten JA (1992). Dynamics of three-dimensional replication 
patterns during the S-phase, analyzed by double labeling of DNA and confocal microscopy. J. Cell Sci. 103: 
857–862. 
Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ and 
Hanski C (1999). Target genes of beta-catenin T-cell-factor/lymphoid-enhancer-factor signaling in human 
colorectal carcinomas.  Proc. Natl. Acad. Sci. USA  96: 1603–1608. 
Manoukian AS and Woodgett JR (2002). Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other 
signaling pathways. Adv. Cancer Res. 84: 203-229. 
Mao J, Wang J, Liu B, Pan W, Farr GH 3rd, Flynn C, Yuan H, Takada S, Kimelman D, Li L and Wu D (2001). Low-
density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. 
Mol. Cell 7: 801-809. 
92 
 
Marcu MG, Schulte TW and Neckers L (2000). Novobiocin and related coumarins and depletion of heat shock protein 
90- dependent signaling proteins. J. Natl. Cancer Inst. 92: 242–248. 
Maroney AC, Marugan JJ, Mezzasalma TM, Barnakov AN, Garrabrant TA, Weaner LE, Jones WJ, Barnakova LA, 
Koblish HK, Todd MJ, Masucci JA, Deckman IC, Galemmo RA Jr and Johnson DL (2006). Dihydroquinone 
ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of 
geldanamycin derivatives. Biochemistry 45: 5678-5685. 
Martinez-Climent JA, Andreu EJ and Prosper F (2006). Somatic stem cells and the origin of cancer. Clin. Transl. Oncol. 
8: 647 – 663. 
Mastroianni M, Kim S, Kim YC, Esch A, Wagner C and Alexander CM (2010). Wnt signaling can substitute for estrogen 
to induce division of ERα-positive cells in a mouse mammary tumour model. Cancer Letters 289: 23-31. 
Matsuda Y, Schlange T, Oakeley EJ, Boulay A and Hynes NE (2009). WNT signaling enhances breast cancer cell 
motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast 
Cancer Res. 11:R32. 
McConkey DJ and Zhu K (2008). Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. 
Updates 11: 164–179. 
Messaoudi S, Peyrat JF, Brion JD, Alami M (2008). Recent advances in Hsp90 inhibitors as antitumour agents. 
Anticancer Agents Med. Chem.8:761–782. 
Meyer P, Prodromou C, Liao C, Hu B, Roe SM, Vaughan CK, Vlasic I, Panaretou B, Piper PW and Pearl LH. (2004). 
Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J.  
23:1402-1410.  
Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C and Holcombe RF (2004). Expression of Wnt genes and 
frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int. J. Oncol. 25: 1337–
1342. 
Miniño AM, Heron MP, Murphy SL and Kochanek KD (2007). Deaths: final data for 2004. Natl. Vital Stat. Rep. 55: 1– 
120. 
Miyagi K, Yamazaki T, Tsujino I, Takahashi N, Koya Y, Masutani M, Sawada U and Horie T (2001). Application of 
hypothermia to autologous stem cell purging. Cryobiology 42: 190 – 195. 
Miyata Y (2009). Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. 
Cell. Mol. Life Sci. 66: 1840-1849. 
Miyata Y and Yahara I (1992). The 90-kDa heat shock protein, HSP90, binds and protects casein kinase 2 from self-
aggregation and enhances its kinase activity. J. Biol. Chem. 267: 7042 – 7047. 
Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Kakatsuru S, Aoki T, Miki Y, Mori R and Nakamura Y (1992). Somatic 
mutations of the APC gene in colorectal tumours: mutation cluster region in the APC gene. Hum. Mol. Genet. 1: 
229-233. 
Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, 
Johnson RG, Hannah AL and Hudis CA (2007). Combination of trastuzumab and tanespimycin (17-AAG, 
KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-
escalation study. J. Clin. Oncol. 25:5410–5417. 
Moon RT, Kohn AD, De Ferrari GV and Kaykas A (2004). Wnt and β-catenin  signaling: diseases and therapies. Nat. 
Rev. Genet. 5: 691-701. 
Morin PJ (1999). β-catenin signaling and cancer. Bioessays 21: 1021–1030. 
93 
 
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW (1997). Activation of β-catenin-
Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275: 1787-1790.  
Morin PJ, Vogelstein B and Kinzler KW (1996). Apoptosis and APC in colorectal tumourigenesis. Proc. Natl. Acad. Sci. 
USA 93: 7950-7954. 
Morrow D, Cullen JP, Liu W, Guha S, Sweeney C, Birney YA, Collins N, Walls D, Redmond EM and Cahill PA (2009). 
Sonic Hedgehog induces Notch target gene expression in vascular smooth muscle cells via VEGF-A. 
Arterioscler. Thromb. Vasc. Biol. 29: 1112–1118.   
Moser AR, Hegge LF and Cardiff RD (2001). Genetic background affects susceptibility to mammary hyperplasias and 
carcinomas in Apc(min)/+ mice. Cancer Res. 61: 3480-3485. 
Moserle L, Ghisi M, Amadori A and Indraccolo S (2010). Side population and cancer stem cells: therapeutic 
implications. Cancer Letters 288: 1–9. 
Nagahata T, Shimada T, Harada A, Nagai H, Onda M, Yokoyama S, Shiba T, Jin E, Kawanami O and Emi M (2003). 
Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila 
disheveled gene, in primary breast cancers. Cancer Sci. 94: 515–518. 
Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S, Keramopoulos A (2006). Study of 
phospho-β-catenin  subcellular distribution in invasive breast carcinomas in relation to their phenotype and the 
clinical outcome. Mod. Pathol. 19: 556–563. 
Neckers L (2003). Development of small molecule Hsp90 Inhibitors: utilizing both forward and reverse chemical 
genomics for drug identification. Curr. Med. Chem.10: 733–739. 
 
Neckers L (2006). Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb. Exp. Pharmacol. 172:  259–277. 
Neckers L, Minnaugh E and Schulte TW (1999). HSP90 as an anti-cancer target. Drug Res. Updates 2: 165 – 172. 
 
Neo SY, Zhang Y, Yaw LP, Li P and Lin SC. (2000). Axin-induced apoptosis depends on the extent of its JNK 
activation and its ability to down-regulate β-catenin  levels. Biochem. Biophys. Res. Commun. 272:144–50. 
Neufeld KL, Zhang F, Cullen BR and White RL (2000). APC mediated downregulation of β-catenin activity involves 
nuclear sequestration and nuclear export. EMBO re. 1: 519 – 523. 
Ni M and Lee AS (2007). ER chaperones in mammalian development and human diseases. FEBS Lett. 581: 3641–3651.  
Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H 
(2005). Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 25:7432-40. 
Nusse R and Varmus HE (1992). Wnt genes. Cell 69: 1073-1087. 
Oates NA, van Vliet J, Duffy DL, Kroes HY, Martin NG, Boomsma DI, Campbell M, Coulthard MG, Whitelaw E and 
Chong S (2006). Increased DNA methylation at the AXIN1 gene in a monozygotic twin from a pair discordant 
for a caudal duplication anomaly. Am. J. Hum. Genet. 79: 155–162. 
Ossewaarde, JM, de Vries A, Bestebroer T and Angulo AF (1996). Application of Mycoplasma group-specific PCR for 
monitoring decontamination of Mycoplasma-infected Chlamydia sp. Strains. Appl. Environ. Microbiol.  62: 
328–331. 
Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, Arihiro K, Kataoka T, Okajima M and Asahara T 
(2005). Alterations and correlations of the components in the Wnt signaling pathway and its target genes in 
breast cancer. Oncol. Rep. 14: 1437–43. 
Pacey S, Banerji U, Judson I and Workman P (2006). Hsp90 inhibitors in the clinic. Handb. Exp. Pharmacol. 172: 331–
358. 
94 
 
Paddock SW (2005). Microscopy. In: Principles and techniques of biochemistry and molecular biology. Sixth edition 
Wilson K and Walker J (ed), pp 133-151. Cambridge: Cambridge University Press. 
Park JW, Yeh MW, Wong MG, Lobo M, Hyun WC, Duh QY and Clark OH (2003). The heat shock protein 90 binding 
geldanamycin inhibits cancer cell proliferation, down regulates oncoproteins and inhibits epidermal growth 
facton induced invasion in thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 88: 3346 – 3353. 
Parker DS, Ni YY, Chang JL, Li J and Cadigan KM (2008). Wingless signaling induces widespread chromatin 
remodeling of target loci. Mol. Cell. Biol. 28: 1815–1828.  
Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG (2005). Side population is enriched 
in tumourigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2– cancer cells are similarly 
tumourigenic. Cancer Res. 65:6207–6219. 
Pearl LH and Prodromou C (2001) Structure, function and mechanism of the Hsp90 molecular chaperone. Adv. Protein 
Chem. 59: 157-186. 
Pearl LH and Prodromou C (2006). Structure and mechanism of the Hsp90 molecular chaperone machinery (2006). 
Annu. Rev. Biochem. 75: 271–294.  
Pearl LH, Prodromou C and Workman P (2008). The Hsp90 molecular chaperone: an open and shut case for treatment. 
Biochem. J. 410: 439–453. 
Peifer M and Polakis P (2000). Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 
287: 1606– 1609. 
Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D, Pak R, Read M and Li S. (2007). Inhibition of heat shock 
protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem 
cells. Blood 110: 678–685. 
Periyasamy S, Warrier M, Tillekeratne MP, Shou W and Sanchez ER (2007). The immunophilin ligands cyclosporin A 
and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. 
Endocrinology 148:4716-26. 
Picard  D (2002). Heat-shock protein 90, a chaperone for folding and regulation. Cell. Mol. Life Sci. 59: 1640–1648. 
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL and Kluger HM (2007). High HSP90 expression is 
associated wwith decreased survival in breast cancer. Cancer Res. 67: 2932 – 2937. 
Polakis P (2000). Wnt signaling and cancer. Genes Dev. 14: 1837-1851.  
Polakis P (2007). The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17: 45–51. 
Prasad CP, Mirza S, Sharma G, Prashad R, DattaGupta S, Rath G and Ralhan R (2008). Epigenetic alterations of CDH1 
and APC genes: relationship with activation of Wnt/β-catenin pathway in invasive ductal carcinoma of breast. 
Life Sci. 83: 318–325. 
Price MA (2006). CK1, there‟s more than one: casein kinase 1 family members in Wnt and Hedgehog signaling. Genes 
Dev. 20: 399–410. 
Prinsloo E, Cooper LC, Moyo B, de la Mare J, Lawson JC, Edkins A and Blatch GL (2010). Heat shock proteins in 
normal and cancer stem cell biology: implications for regenerative and chemotherapeutic medicine. In: Stem 
Cell, Regenerative Medicine and Cancer, Singh SR (ed), pp 693-713. New York: Nova Science Publishers Inc. 
Prodromou C, Roe SM, O‟Brien R, Ladbury JE, Piper PW and Pearl LH (1997). Identification and structural 
characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90: 65–75. 
Radanyi C, Le Bras G, Messaoudi S, Bouclier C, Peyrat JF, Brion JD, Marsaud V, Renoir JM and Alami M (2008). 
Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of 
heat-shock protein 90 (hsp90). Bioorg. Med. Chem. Lett. 18: 2495-2498. 
95 
 
Restall IJ and Lorimer IAJ (2010). Induction of premature senescence by Hsp90 inhibition in small cell lung cancer. 
PLoS ONE 5: e11076. 
Reya T and Clevers H (2005). Wnt signaling in stem cells and cancer. Nature 434: 843 – 850. 
Reya T, Morrison SJ, Clarke MF and Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414: 105 – 
111. 
Richter K and Buchner J (2001). Hsp90: chaperoning signal transduction. J. Cell. Physiol. 188: 281-90. 
Richter K, Soroka J, Skalniak L, Leskovar A, Hessling M, Reinstein J and Buchner J (2008). Conserved conformational 
changes in the ATPase cycle of human Hsp90. J. Biol. Chem. 283: 17757– 17765. 
Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernández-Majada V, Grilli A, López-Bigas N, Bellora 
N, Albà MM, Torres F, Duñach M, Sanjuan X, Gonzalez S, Gridley T, Capella G, Bigas A and Espinosa L 
(2009). Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc. Natl. 
Acad. Sci. USA 106: 6315–20. 
Roe SM, Prodromou C, O‟Brien R, Ladbury JE, Piper PW and Pearl LH (1999). Structural basis for inhibition of the 
Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J. Med. Chem. 42: 260–
266. 
Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, Bacik J and Motzer RJ (2006). A phase II 
trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell 
carcinoma. Invest. New Drugs 24:543–546.  
Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P (1997). Stabilization of β-catenin by genetic 
defects in melanoma cell lines. Science 275: 1790–1792. 
Russo J and Russo IH (2001). The pathway of neoplastic transformation of human breast epithelial cells. Radiat. Res. 
155: 151–154. 
Sadot E, Conacci-Sorrell M, Zhurinsky J, Shnizer D, Lando Z, Zharhary D, Kam Z, Ben-Ze‟ev A and Geiger B (2002). 
Regulation of S33/S37 phosphorylated β-catenin in normal and transformed cells. J. Cell Sci. 115: 2771-2780. 
Salahshor S and Woodgett JR (2005). The links between axin and carcinogenesis. J. Clin. Pathol. 58 : 225-236. 
Sato N, Yamamoto T, Sekine Y, Yumioka T, Junicho A, Fuse H, Matsuda T (2003). Involvement of heat-shock protein 
90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem. Biophys. Res. Commun. 300: 
847–852. 
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasak Y, 
Imaoka S, Murata M,  Shimano T, Yamaoka Y and Nakamura Y (2000). AXIN1 mutations in hepatocellular 
carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24: 245–
250. 
Schatzkin A, Freedman LS, Dawsey SM and Lanza E (1994). Interpreting precursor studies: what polyp trials tell us 
about large-bowel cancer. J. Natl. Cancer Inst. 86: 1053–7. 
Schlange T, Matsuda Y, Lienhard S, Huber A and Hynes NE (2007). Autocrine WNT signaling contributes to breast 
cancer cell proliferation via the canonical WNT pathway and EGFR trans-activation. Breast Cancer Res. 9: R63. 
Schlosshauer PW, Brown SA, Eisinger K, Yan Q, Guglielminetti ER, Parsons R, Hedrick Ellenson L and Kitajewski J 
(2000). APC truncation and increased β-catenin levels in a human breast cancer cell line. Carcinogenesis 21: 
1453–1456. 
Schorr K, Li M, Krajewski S, Reed JC and Furth PA (1999). Bcl-2 gene family and related proteins in mammary gland 
involution and breast cancer. J. Mammary Gland Biol. Neoplasia 4:153–164. 
96 
 
Schulte TW and Neckers LM (1998). The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to 
HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42: 273–
279. 
Schulte TW, Blagoklonny MV, Ingui C and Neckers L (1995). Disruption of Raf-1-Hsp90 molecular complex results in 
destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem. 270: 24585-24588. 
Schwarz-Romond  T, Merrifield C, Nichols BJ and Bienz M (2005). The Wnt signaling effector Dishevelled forms 
dynamic protein assemblies rather than stable associations with cytoplasmic vesicles. J. Cell Sci. 118: 5269-
5277. 
Schwarz-Romond T, Fiedler M, Shibata N, Butler PJ, Kikuchi A, Higuchi Y and Bienz M (2007A). The DIX domain of 
Dishevelled confers Wnt signaling by dynamic polymerization. Nat. Struct. Mol. Biol. 14: 484–492. 
Schwarz-Romond T, Metcalfe C and Bienz M (2007B). Dynamic recruitment of axin by Dishevelled protein assemblies. 
J. Cell Sci. 120: 2402–2412. 
Sell S (2004). Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51: 1-28. 
Semënov MV, Tamai K, Brott BK, Kuhl M, Sokol S and He X (2001). Head inducer Dickkopf-1 is a ligand for Wnt 
coreceptor LRP6. Curr. Biol. 11: 951–961. 
Sharma S,  Kelly TK and Jones PA (2010). Epigenetics in cancer. Carcinogenesis 31: 27 – 36. 
Shiras A, Chettiar ST, Shepal V, Rajendran G, Prasad GR and Shastry P (2007). Spontaneous transformation of human 
adult nontumourigenic stem cells to cancer stem cells is driven by genomic instability in a human model of 
glioblastoma. Stem Cells 25: 1478–1489. 
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D‟Amico M, Pestell R and Ben-Ze‟ev A (1999). The cyclin D1 gene is 
a target of the β-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96: 5522-5527. 
Simcha I, Shtutman M, Salomon D, Zhurinsky J, Sadot E, Geiger B and Ben-Ze‟ev A (1998). Differential nuclear 
translocation and transactivation potential of β-catenin and plakoglobin. J. Cell. Biol. 141: 1433-1448. 
Solit DB and Chiosis G (2008). Development and application of Hsp90 inhibitors. Drug Discov. Today 13: 38– 43. 
Spira AI and Carducci MA (2003). Differentiation therapy. Curr. Opin. Pharmacol. 3: 338 – 43. 
Sreedhar AS, Soti C and Csermely P (2004). Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim. 
Biophys.  Acta 1697: 233-42. 
Staal FJT, Noort MV, Strous, GJ and Clevers HC (2002). Wnt signals are transmitted through N-terminally 
dephosphorylated β-catenin. EMBO  rep. 3: 63-68. 
Städeli R and Basler K (2005). Dissecting nuclear Wingless signaling: recruitment of the transcriptional co-activator 
Pygopus by a chain of adaptor proteins. Mech. Dev. 122: 1171– 1182. 
Stepanova L, Leng X, Parker SB and Harper JW (1996). Mammalian p50Cdc37 is a protein kinase-targeting subunit of 
HSP90 that binds and stabilizes Cdk4. Genes Dev. 10: 1491 – 1502. 
Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC and Harper JW (2000). Induction of human 
Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic 
hyperplasia. Oncogene 19:2186–2193. 
Stewart SL, Wike JM, Kato I, Lewis DR and Michaud F (2006). A population-based study of colorectal cancer histology 
in the United States, 1998-2001. Cancer 107: 1128 – 41.  
Strange R, Metcalfe T, Thackray L, and Dang M (2001). Apoptosis in normal and neoplastic mammary gland 
development. Micros. Res. Tech. 52: 171 – 181. 
Stylianou S, Clarke RB and Brennan K (2006). Aberrant activation of notch signaling in human breast cancer. Cancer 
Res. 66: 1517– 25. 
97 
 
Supko JG, Hickman RL, Grever MR and Malspeis L (1995). Preclinical pharmacological evaluation of geldanamycin as 
an antitumor agent. Cancer Chemother. Pharmacol. 36: 305–315. 
Suzuki H, Toyota M, Caraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T,  
Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB and Tokino T  (2008). Frequent epigenetic inactivation of 
Wnt antagonist genes in breast cancer. Brit. J.  Cancer 98: 1147 – 1156 
Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van 
Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG and Baylin SB (2004). Epigenetic 
inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36: 417-422. 
Taherian A, Krone PH and Ovsenek N (2007). A comparison of Hsp90α and Hsp90β interactions with cochaperones and 
substrates. Biochem. Cell Biol. 86: 37-45. 
Takayama S, Reed JC and Homma S (2003). Heat-shock proteins as regulators of apoptosis. Oncogene 22: 9041 – 9047. 
Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z and He X (2004). A mechanism for Wnt coreceptor activation. 
Mol. Cell 13: 149–156.  
Terasawa K, Minami M, Minami Y (2005). Constantly updated knowledge of Hsp90.  J. Biochem. 137: 443– 447. 
Thiery JP (2002). Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2: 442-454.  
Towbin H, Staehelin T, and Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to 
nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354 
Tsaytler PA, Krijgsveld J, Goerdayal SS, Rüdiger S and Egmond MR (2009). Novel Hsp90 partners discovered using 
complementary proteomic approaches. Cell Stress Chaperones 14: 629- 638. 
Tutter AV, Fryer CJ and Jones KA (2001). Chromatin-specific regulation of LEF-1-beta-catenin transcription activation 
and inhibition in vitro. Genes Dev. 15: 3342-54.  
 
Uehara Y, Hori M, Takeuchi T, Umezawa H (1986). Phenotypic change from transformed to normal induced by 
benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma 
virus. Mol. Cell. Biol. 6: 2198– 2206. 
 
van Amerongen R, Mikels A and Nusse R (2008). Alternative Wnt signaling is initiated by distinct receptors. Sci.  
Signal. 1:re9. 
Vasen HFA, Mӧslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Freidl W, 
Hes FJ, Hodgson S, Mecklin JP, Møller P, Nagengast F, Parc Y, Renkonen- Sinisalo L, Sampson JR, 
Stormorken A and Wijnen J (2007). Guidelines for the clinical management of Lynch syndrome (hereditary 
non-polyposis cancer). J. Med. Genet. 44: 353-362. 
Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R and Dahl E (2008). Epigenetic inactivation of the 
secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable 
prognosis. Carcinogenesis 29: 991–998. 
Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka 
C, Knüchel R and Dahl E (2006). Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is 
associated with unfavourable prognosis. Oncogene 25: 3479–3488. 
Venezia TA, Merchant AA, Ramos CA, Whitehouse NL, Young AS, Shaw CA and Goodell MA (2004). Molecular 
signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol 2:e301. 
Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Lae M, Louvard D, Ben-Ze‟ev A and Robine S (2007). 
Fascin, a novel target of β-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. 
Cancer Res. 67: 6844–6853. 
98 
 
Vivanco I and Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 
2:489– 501. 
Von Kleist S, Chany E, Burtin P, King M and Fogh J (1975). Immunohistology of the antigenic pattern of a continuous 
cell line from a human colon tumour.  J. Natl. Cancer Inst. 55: 555 – 560. 
Vousden KH and Lu X (2002). Live or let die: the cell‟s response to p53. Nat. Rev. Cancer  2: 594–604. 
Wadhwa R, Takano S, Robert M, Yoshida A, Nomura H, Reddel RR, Mitsui Y and Kaul SC (1998). Inactivation of 
tumour suppressor p53 by mot-2, a hsp70 family member. J. Biol Chem. 273: 29586-29591. 
Wandinger SK, Richter K. and Buchner J (2008). The Hsp90 chaperone machinery. J. Biol. Chem. 283: 18473–18477. 
Wang H, Zeng ZC, Bui TA, DiBiase SJ, Qin W, Xia F, Powell SN and Iliakis G (2001). Nonhomologous end-joining of 
ionizing radiation-induced DNA double-stranded breaks in human tumour cells deficient in BRCA1 or BRCA2. 
Cancer Res. 61: 270–277. 
Westerheide SD and Morimoto RI (2005). Heat shock response modulators as therapeutic tools for diseases of protein 
conformation.  J. Biol. Chem. 280: 33097 – 33100. 
 
Wharton KA Jr (2003). Runnin‟ with Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal 
transduction. Dev. Biol. 253: 1 -17. 
Whitesell L and Lindquist S (2005). Hsp90 and the chaperoning of cancer. Nature Rev. Cancer  5:761–772. 
Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM (1994). Inhibition of heat shock protein HSP90-
pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in 
oncogenic transformation. Proc. Natl. Acad. Sci. USA 91: 8324–8328. 
Wicha MS, Liu S, Dontu G (2006). Cancer stem cells: an old idea – a paradigm shift. Cancer Res. 66: 1883 – 1890. 
Wiechens N, Heinle K, Englmeier L, Schohl A and Fagotto F (2004). Nucleo-cytoplasmic shuttling of Axin, a negative 
regulator of the Wnt–β-catenin  pathway. J. Biol. Chem. 279: 5263–5267. 
Willert K, Shibamoto S and Nusse R (1999). Wnt-induced dephosphorylation of axin releases β-catenin from the axin 
complex. Genes and Dev. 13: 1768–1773. 
Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, 
Hartmann A, Knuechel R, Rosenthal A and Pilarsky C (2003). WIF-1, a component of the Wnt pathway, is 
down-regulated in prostate, breast, lung, and bladder cancer. J.  Pathol. 201: 204-212. 
Wong CM, Fan ST and Ng IO (2001). β-Catenin mutation and overexpression in hepatocellular carcinoma: 
clinicopathologic and prognostic significance. Cancer  92: 136–145. 
Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, Mlodzik M, Shi DL and Zheng J (2003). Direct binding of 
the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol. Cell 
12: 1251–1260. 
Wong SC, Lo SF, Lee KC, Yam JW, Chan JK and Wendy Hsiao WL (2002). Expression of frizzled-related protein and 
Wnt-signaling molecules in invasive human breast tumours. J. Pathol. 196: 145–153. 
Woodgett JR (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9: 2431–2438. 
Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA and Rosen JM (2007). WNT/β-catenin mediates 
radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci USA. 104: 618-623. 
Woodward WA, Chen MS, Behbod F, Rosen JM (2005). On mammary stem cells. J. Cell Sci. 118: 3585 – 3594. 
Workman P, Burrows F, Neckers L and Rosen N (2007). Drugging the cancer chaperone HSP90:combinatorial 
therapeutic exploitation of oncogene addiction and tumour stress. Ann. NY Acad. Sci. 1113: 202–216. 
99 
 
Wullschleger S, Loewith R and Hall MN (2006). TOR signaling in growth and metabolism. Cell 124: 471–484. 
Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y and Neckers L (2001). Sensitivity of mature Erbb2 to 
geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 
276: 3702–3708. 
Yan D, Wiesmann M, Rohan M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, 
Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ and Williams LT (2001). Elevated expression of 
axin2 and hnkd mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumours. 
Proc. Natl. Acad. Sci. USA 98: 14973–8. 
Yang J, Zhang W, Evans PM, Chen X, He X and Liu C (2006). Adenomatous polyposis coli (APC) differentially 
regulates β-catenin phosphorylation and ubiquitination in colon cancer cells. J. Biol. Chem. 281: 17751–17757. 
Yoo CB and Jones PA (2006). Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discovery 5: 37-50. 
Young JC, Moarefi I and Hartl FU (2001). Hsp90: a specialized but essential protein-folding tool. J. Cell Biol. 154: 267–
273. 
Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL 3rd, Lee JJ, Tilghman SM, Gumbiner BM and Costantini F 
(1997). The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates 
embryonic axis formation. Cell  90: 181–192. 
Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J, Wynshaw-Boris 
A, Hsieh JC and He X (2008). Initiation of Wnt signaling: control of Wnt coreceptor LRP6 phosphorylation/ 
activation via frizzled, dishevelled and axin functions. Development 135: 367-375. 
Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J and He X (2005). A dual-kinase 
mechanism for Wnt co-receptor phosphorylation and activation. Nature 438: 873–877. 
Zhang H and Burrows F (2004). Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. 
Med. 82: 488-499.  
Zhang T, Li Y, Yu Y, Zou P, Jiang Y and Sun D (2009B). Characterization of celastrol to inhibit hsp90 and cdc37 
interaction. J. Biol. Chem. 284:35381-35389. 
Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ and Boman BM (2001). Evidence that APC regulates survivin 
expression, a possible mechanism contribution to the stem cell origin of colon cancer. Cancer Res. 61: 8664–
8667. 
Zhang W, Yang J, Liu Y, Chen X, Yu T, Jia J and Liu C (2009A). PR55 alpha, a regulatory subunit of PP2A, specifically 
regulates PP2A-mediated beta-catenin dephosphorylation. J. Biol. Chem. 284: 22649-56. 
 
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Ill EP and Zhang Y (2007). Activation 
of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. 
Proc. Nat. Acad. Sci. USA 104: 16158 – 1613. 
Zinchuk V and Zinchuk O (2008). Quantitative colocalization analysis of confocal fluorescence microscopy images. 
Curr. Protoc. Cell Biol. 4.19.1-4.19.16 
Zinchuk V, Zinchuk O and Okada T (2007). Quantitative colocalization analysis of multicolour confocal 
immunofluorescence microscopy images: pushing pixels to explore biological phenomena. Acta. Histochem. 
Cytochem. 40: 101-111. 
 
 
 
 
100 
 
WEBSITES REFERENCED 
Reference Website name and address Date accessed 
Website 1 CANSA, www.cansa.org.za. December 2010 
Website 2 IARC, www.iarc.fr. December 2010 
Website 3 The WNT signaling pathway and its role in 
human solid tumours. Atlas of genetics and 
cytogenetics in oncology and haematology, 
http://atlasgeneticsoncology.org/Deep/WNTSignP
athID20042.html. 
December 2010 
Website 4 PICARD LIST OF HSP90 INTERACTORS  
http://www.picard.ch/downloads/downloads.htm 
 
December 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
 
APPENDIX 
A1 Mycoplasma detection protocol 
Briefly, Mycoplasma were tested for using immunofluorescent microscopy and amplification 
of a fragment of the 16S rRNA gene. 
Detection by confocal microscopy 
 Seed cells and grow on sterile glass cover slips overnight at 37 °C 
 Remove media, and wash with PBS 
 Fix cells with ice cold methanol (add briefly) 
 Dip cover slip into Hoechst 33342 (1:1000 dilution in water) for 15 seconds 
 Leave cover slip to dry on paper towel 
 Mount cover slip onto glass slide with mounting medium and seal with nail varnish 
Negative detection: 
 Clean blue nuclei without any other speckled staining around 
 
Positive detection: 
 Blue specks (nuclear staining) around and on top of the area on the cytoplasm (Figure 
A1). 
Figure A1.1 Confocal microscopy image of Caco2 cells contaminated with Mycoplasma. Caco2 cell nuclei 
stained with Hoechst. Scale bar represents 20 μM. Arrows point toward Mycoplasma. 
Detection by PCR 
1. Isolation of DNA by boiling cells 
 T25 flask of cells trypsinized (approx 280 000 cells) 
 Inhibited further trypsinization by adding media  
 Transferred cells in TE buffer into eppendorf 
 Centrifuged 2000 rpm, 2 mins 
 Resuspended cells in 50 μl TE buffer 
 Boiled samples in kettle for 15 minutes to lyse cells (viscosity) 
 DNA used for PCR reaction 
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2. PCR Reaction 
NB Dilute forward and reverse primers stock 1:10 in water before PCR 
Mycoplasma primers  
Specific for 16S rRNA gene 
Forward ( XXIDT 60298391) 
Upstream primer GPO-3  5‟-GGG AGC AAA CAG GAT  TAG  ATA CCC T-3‟)  
Position 774-798 on gene (Ossewaarde et al.,  1996).   
 
Reverse ( XXIDT 60298392) 
Downstream primer MGSO  5‟ – TGC ACC ATC TGT CAC TCT GTT AAC CTC -3‟)  
Position 1029-1055 on gene (Ossewaarde et al.,  1996).   
 
Table A1.1 PCR reaction  
Reagent in 50 μl final 
volume 
Final concentration Company of reagent 
Buffer 5 X Green GoTaq 10 μl 1 X Promega, M 791A 
dNTP 2 μl 0.4 mM Roche, 13873400 
forward primer (diluted) 5 μl 1 μM XXIDT, 60298391 
reverse primer (diluted) 5 μl 1 μM XXIDT, 60298392 
GoTaq polymerase (5 U/ μl) 0.25 μl 1.25 U Promega, 9PIM300 
DNA 5 μl   
Water 22.75 μl   
 
 Table A1.2 PCR Conditions (adapted from Ossewaarde et al., 1996) 
Temperature Time 
94 °C (denaturation) 1 min 
72 °C (extension) 1 min 
65 °C (annealing) 1 min 
every 2 cycles annealing temperature decreased 
by 2 °C until 55 °C 
 
55 °C (final annealing) 30 cycles 
4 °C α 
 Set up water control, substituting DNA with water 
 
3. Resolving PCR samples on 2 % agarose gel 
2 % = 1 g agarose in 50 ml TAE buffer 
The size of the PCR product of Mycoplasma contaminated cells is approximately 270 bp 
(Figure A1.2). 
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Figure A1.2. AGE (2 % acrylamide) of PCR product of cells contaminated with Mycoplasma. Positive 
signal is detected at 270 bp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
270 bp 
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A2 ORIGINAL, UNEDITED CONFOCAL IMAGES 
 
Figure A2.1. Unedited confocal images showing the effects of HSP90 inhibitors on the localization of 
HSP90α/β, GSK-3β and p-β-catenin. MCF7 cells were serum-starved for 1 hour prior to 5 hour treatment with 
inhibitors. Confocal microscopy images of stained MCF7 cells were captured using a Zeiss LSM 510 confocal 
microscope. A. Untreated MCF7 cells. B. Novobiocin (500 μM) treated MCF7 cells. C. 17-AAG (10 μM) 
treated MCF7 cells. Hoechst: blue nuclear staining.  HSP90α/β (purple) using anti-human HSP90α/β antibody. 
GSK-3β (green) using anti-human GSK-3β antibody.  P-β-catenin (red) using anti-human p-β-catenin. Scale 
bars represent 20 μM. 
 
Figure A2.2 Unedited confocal images showing the effects of HSP90 inhibitors on the localization of 
HSP90α/β, axin1 and p-β-catenin. MCF7 cells were serum-starved for 1 hour prior to 5 hour treatment with 
inhibitors. Immunofluorescence confocal microscopy images of stained MCF7 cells captured using a Zeiss LSM 
510 confocal microscope. A. Untreated MCF7 cells. B. Novobiocin (500 μM) treated MCF7 cells. C. 17-AAG 
(10 μM) treated MCF7 cells. Hoechst: blue nuclear staining.  HSP90α/β (purple) using anti-human HSP90α/β 
antibody. Axin1 (green) using anti-human axin1 antibody. P-β-catenin (red) using anti-human p-β-catenin. Scale 
bars represent 20 μM. 
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Figure A2.3. Unedited confocal images showing the effect of HSP90 inhibitors on β-catenin and p-β-
catenin localization. MCF7 cells were serum-starved for 1 hour prior to 5 hour treatment with inhibitors. 
Immunofluorescence confocal microscopy images of stained MCF7 cells captured using a Zeiss LSM 510 
confocal microscope. A. Untreated MCF7 cells. B. Novobiocin (500 μM) treated MCF7 cells. C. 17-AAG (10 
μM) treated MCF7 cells. Hoechst: blue nuclear staining.  β-catenin (green) using anti-human β-catenin antibody. 
p-β-catenin (red) using anti-human p-β-catenin antibody. Scale bars represent 20 μm.  
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A3 DENSITOMETRIC ANALYSIS SHOWING TOTAL β-CATENIN 
ISOLATED BY HSP90 IMMUNOPRECIPITATION WAS GREATER 
THAN NON-SPECIFIC PROTEIN 
 
Figure A3.1. Western detection signal representing total β-catenin was higher than the non-specific 
signal.  Densitometric analysis of signals representing β-catenin and non-specific bands detected in HSP90 
immunoprecipitation. Control: protein A/G agarose-PLUS beads in the absence of antibody. IP sample: Signal 
representing β-catenin isolated by HSP90α/β immunoprecipitation.    
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A4 DENSITOMETRIC ANALYSIS OF PROTEINS NORMALIZED AGAINST 
ACTIN IN HSP90 INHIBITION STUDY 
 
Figure A4.1. Densitometric analysis of HSP90α/β normalized against actin in geldanamycin (A), 17-AAG 
(B) and novobiocin (C) treated MCF7 cells. No treatment (0) and DMSO were used as the controls.  
 
Figure A4.2. Densitometric analysis of STAT3 normalized against actin in geldanamycin (A), 17-AAG (B) 
and novobiocin (C) treated MCF7 cells. No treatment (0) and DMSO were used as the controls. 
  
 
Figure A4.3. Densitometric analysis of p-STAT3 normalized against actin in geldanamycin (A) and 17-
AAG (B) treated MCF7 cells. No treatment (0) was used as the control. 
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Figure A4.4. Densitometric analysis of Akt normalized against actin in geldanamycin (A), 17-AAG (B) 
and novobiocin (C) treated MCF7 cells. No treatment (0)  was used as the control. 
 
 
Figure A4.5. Densitometric analysis of GSK-3β normalized against actin in geldanamycin (A), 17-AAG 
(B) and novobiocin (C) treated MCF7 cells. No treatment (0)  and DMSO were used as the controls. 
 
Figure A4.6. Densitometric analysis of β-catenin normalized against actin in geldanamycin (A), 
novobiocin (B) 17-AAG (C) treated MCF7 cells. No treatment (0)  and DMSO were used as the controls. 
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A5 MEDIA AND SOLUTION PREPARATION 
10 X phosphate buffered saline (PBS) pH 7.4 
Dilute stock 10 X to make 1 X 
Reagent Final Concentration (in 1L) Mass (g) 
NaCl 1.37 M 80 
KCl 0.03 M 2 
Na3HPO4 0.16 M 11.5 
KH2PO4 0.02 M 2 
 
RIPA lysis buffer 
Protease inhibitor cocktail added according to the vendor‟s instructions (1 % v/v) 
Reagent Final concentration (in 200 μl) volume (μl) 
Tris-HCl and NaCl solution 50 mM and 150 mM 189.8 
EGTA/EDTA 1 mM 2 
Na3VO4 1 mM 2.2 
NP40 1 % (v/v) 2 
Na deoxycholate 1 mM 2 
PMSF 1 mM 2 
protease inhibitor 2 μg/ml 2 
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A6 SDS-PAGE PAGE BUFFERS AND GEL PREPARATIONS 
Reagent volume 
dH20 3.55 ml 
0.5 M Tris-HCl pH 6.8 1.25 ml 
glycerol 2.5 ml 
10 % (w/v) SDS 2 ml 
0.5 % (w/v) bromophenol blue 0.2 ml 
Add 50 μl β-mercaptoethanol to 950 μl prior to use to make 5 X sample treatment buffer 
SDS-PAGE gel preparation 
12 % acrylamide resolving gel 
Reagent Volume 
dH20 3.35 ml 
1.5 M Tris-HCl (Ph 8.8) 2.5 ml 
10 % SDS 100 μl 
Bis-acrylamide 4 ml 
10 % ammonium persulphate 100 μl 
TEMED 20 μl 
4 % acrylamide stacking gel 
Reagent Volume 
dH20 3.05 ml 
0.5 M Tris-HCl (Ph 6.8) 1.25 ml 
10 % SDS 50 μl 
Bis-acrylamide 665 μl 
10 % ammonium persulphate 100 μl 
TEMED 20 μl 
10 X SDS-PAGE running buffer  
Reagent mass (in 1 L water) 
glycine 144 g 
SDS 10 g 
Tris 30.3 g 
Dilute to 1 X prior to use 
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A7 REAGENTS, CHEMICALS AND SOURCES 
Tissue culture 
Reagent Company Country 
4 well culture plates (Nunclon
TM
) NUNC USA 
6 well culture plates  Corning USA 
Dako fluorescent mounting medium Dako USA 
dimethyl sulphoxide (DMSO) Sigma-Aldrich USA 
Dulbecco‟s Modified Eagle Medium (DMEM) 
with 4.5 g/L D-glucose, L-glutamine, pyruvate 
Gibco, Invitrogen USA 
Fetal calf serum (FCS) PAA Laboratories USA 
Hoechst 33342 Invitrogen USA 
L-glutamine Gibco USA 
Penicillin-Streptomycin solution stabilizer (5 
000U and 5 mg strep) 
Sigma-Aldrich USA 
T25 (25 cm
3
) tissue culture flasks Corning USA 
T75 (75 cm
3
) tissue culture flasks Corning USA 
Trypan Blue solution (0.4 %)  Sigma-Aldrich USA 
Trypsin/ ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich USA 
 
General reagents 
Reagents Vendor Country 
17-AAG Sigma-Aldrich USA 
2-mercaptoethanol MERCK South Africa 
50 bp marker New England BioLabs UK 
Acetic acid SAARCHEM, MERCK South Africa 
Acrylamide BioRad USA 
Agarose Whitehead Scientific South Africa 
Ammonium persulphate SAARCHEM South Africa 
Bromophenol blue Sigma-Aldrich USA 
BSA Roche Diagnostics Germany 
Coomassie Brilliant Blue-R250 Sigma-Aldrich USA 
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Disodium hydrogen orthophosphate Merck South Africa 
Dynabeads® co-immunoprecipitation kit Invitrogen USA 
ECL kit GE Healthcare, Amersham USA 
EDTA Saarchem USA 
Ethidium bromide Sigma-Aldrich USA 
Fermentas Marker Plus Fermentas USA 
geldanamycin BioMol International USA 
Glacial acetic acid SAARCHEM South Africa 
Glycerol SAARCHEM South Africa 
Glycine Sigma-Aldrich South Africa 
HCl Merck South Africa 
KCl SAARCHEM South Africa 
NaCl Sigma-Aldrich South Africa 
NP40 Roche Germany 
PBS tablets Sigma-Aldrich USA 
pEQ Gold Marker IV peQ-Lab Germany 
Ponceau S Sigma-Aldrich USA 
Potassium diydrogen phosphate Merck South Africa 
protease inhibitor cocktail Sigma-Aldrich USA 
protein A/G PLUS-agarose 
immunoprecipitation reagent 
Santa Cruz Biotechnologies USA 
Sodium diodecyl sulphate Sigma-Aldrich USA 
TEMED Sigma-Aldrich USA 
Trans-Blot® nitrocellulose membrane Bio-Rad South Africa 
trisodium citrate Saarchem South Africa 
Triton X-100 Sigma-Aldrich USA 
Trizma base Sigma-Aldrich USA 
Tryptone (pancreatic digestion of casein) Biolab, Merck UK 
Tween-20 SAARCHEM, MERCK South Africa 
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A8 Instruments and sources 
Instrument Source 
Western blotting power pack Bio-Rad, UK 
Centrifuge 8000R Centurion Scientific, UK 
Centrifuge 5804R Eppendorf, Germany 
Centrifuge 5415R Eppendorf, Germany 
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A9 PICARD LIST OF HSP90 INTERACTORS 
 (website 4) 
Chaperones and relatives Transcription factors 
- Aha1 and its homolog Hch1 
- Cdc37 (p50) and its relative Harc 
- p23 (=Sba1) 
- proteins with TPR motifs, including Hop 
(=Sti1), FKBP52 (and high MW plant 
homologs), FKBP51, FKBP8 (=FKBP38), 
FKBP36 (= FKBP6), Plasmodium 
FKBP35, cyclophilin-40 (Cpr6 and Cpr7), 
PP5 (and yeast Ppt1), Tom70, probably 
also related Tom71=Tom72, XAP-2 
(=AIP=ARA9), Cns1 and its Drosophila 
and human relatives Dpit47 and TTC4, 
CHIP, GCUNC-45 (also UNC-45 and 
She4), DnaJC7 (=Tpr2=mDj11=CCRP), 
CRN, WISp39 (=FKBPL), Tah1 
(=Spaghetti), NASP, Toc64, TPR1 (=Ttc1), 
SGT (=αSGT=SGTA), DYX1C1 
- CS-containing p23 relatives SGT1 
(=SUGT1), RAR1, Siah-1-interacting 
protein (SIP), Chp1/Morgana, B-ind1, 
melusin, CHORDC1 
- Hsp60 
- Hsc70/Hsp70/Hsp72 
- Human DnaJ homolog Hsj1b 
- S100A1 
- Sse1, Sse2 
- valosin-containing protein (VCP)/p97 
- NudC and NudCL2 
- Pih1 (=Nop17) (mostly through Tah1) 
- Cullin5 
- Tel2-Tti1-Tti2 complex 
- 12(S)-HETE receptor 
- AF9/MLLT3 
- all vertebrate steroid receptors (GR, MR, 
ERα, ERβ, PR, AR) 
- BCL-6 
- CAR 
- cytoplasmic v-erbA 
- EcR 
- PPARα (PPARβ) 
- PXR 
- Hap1 
- HSF-1 
- IRF3 
- Mal63 
- p53 
- PAS family members: Dioxin receptor 
(=AhR), Sim, HIF–1α, HIF-2α, HIF-3α 
- Sp1 
- Stat3 (also in caveolin-1 complexes in 
rafts) 
- TonEBP/OREBP 
- Ure2 
- VDR 
- water mold Achlya steroid (antheridiol) 
receptor 
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Kinases  
- Akt/PKB 
- ASK1 
- Aurora B 
- Bcr-Abl 
- casein kinase IIα catalytic subunit 
- Cdc2 (=Cdk1) 
- Cdc25c 
- Cdk2, Cdk4, Cdk6, Cdk9, Cdk11 
- Chk1 
- Cot = Tpl-2 
- Death-associated kinases DAPK, 
DAPK2, DAPK3 
- death domain kinase RIP 
- eEF-2 kinase 
- eIF2-α kinases HRI, Gcn2, Perk, PKR 
- EphA2 
- ErbB2 (and mutant EGF receptor) 
- ERK5 
- Flt3 
- Fused 
- GRK2 and GRK6 
- GSK3β 
- HER3 
- IκB kinases α, β, γ, ε 
- Insulin receptor 
- Insulin-like growth factor 1 receptor 
- Integrin-linked kinase 
- IP6K2 
- IRAK-1 
- Ire1 
- JAK1 
- JNK 
- c-Kit 
- KSR 
- Lkb1 
- LRRK2 
- MAPK6 
- MEK 
- MEKK1 and MEKK3 
- Mik1 
- MLK3 
- MOK, MAK, MRK 
- c-Mos 
- NIK 
- Nucleophosmin-Anaplastic Lymphoma 
Kinase 
- p38 
- p90RSK 
- platelet-derived growth factor receptor α 
- PDK1 
- Pim-1 
- Pink1 
- PKCλ, PKCε and other PKCs 
- Plk1 
- pp60v-src, c-src 
- src related tyrosine kinases: fer, fes, fgr, 
fps, lck, yes 
- Raf-1, B-Raf, Ste11 
- RET 
- RET/PTC1 
- Ron 
- Ryk 
- SGK-1 
- Slt2 
- SRPK1 
- SSTK (= Tssk6) 
- TAK1 
- TBK1 
- TGFβ receptors I and II 
- TrkB 
- TrkAI and III 
- Tyk2 
- VEGFR1, VEGFR2 
- Wee1, Swe1 
- ZAP-70 
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Others  
- Annexin II 
- ANP receptor 
- Apaf-1 
- apoB 
- Argonaute-1 
- Argonaute-2 (= GERp95) 
- Bcl-2 
- Bcl-xL 
- Bid 
BLM helicase 
- BRMS1 
- calcineurin (Cna2; catalytic subunit) 
- calmodulin 
- calponin 
- CB2 cannabinoid receptor 
- CD91 
- Cdc13 
- Cdk5 activator p35 
- CFTR (nascent polypeptide) 
- Chronophin 
- ClC-2 chloride channel 
- COG complex 
- CTA1 
- Ctf13/Skp1 component of CBF3 
- Cup 
- cyclin B 
- cyclophilin D (mitochondrial) 
- cytoskelettal proteins: actin, tubulin 
(including ciliary β4-tubulin), myosin 
- DEDD 
- Dengue virus protein E 
- DNA polymerase α 
- DNA polymerase η 
- DNMT1 
- Dsn1 
- eNOS, nNOS (?) 
- ether-a-gogo-related cardiac potassium 
channel 
- FLIPS and FLIPL 
- free βγ subunit of G protein 
- Gα0, Gα12 
- Hepatitis virus C protein NS3 
- glutathione S-transferase subunit 3 (KS 
type) 
- HDAC6 
Hepatitis E virus capsid protein 
- HERG 
- Histones H1, H2A, H2B, H3 and H4 
- c-IAP1 
- Importin β 
- Inositol 1,4,5-trisphosphate receptor 3 
- KSHV K1 
- Kir6.2 
- knob complexes (in the membrane of 
Plasmodium-infected erythrocytes) 
- LAMP-2A 
- LAP 
- LIS1 
- macromolecular aminoacyl-tRNA 
synthetase complex 
- Macrophage scavenger receptor 
- Mdm2 
- MMP2, MMP9 
- MRE11/Rad50/NBS1 (MRN) complex 
- Msps/XMAP215/ch-TOG 
- MTG8 
- MUC1 
- Na+-K+-Cl- cotransporter 1 
- NB-LRR proteins: RPM1 and RPS2, 
Nod1, Nod2, NALP2, NALP3, NALP4, 
NALP12, IPAF 
- Neuropeptide Y 
- N-myc downstream-regulated gene 1 
(NRDG1) 
- Nsl1 
- Nup62 
- N-WASP 
- OsCERK1 
- P1 (picornaviral capsid precursor protein 
P1) 
- p300 
- P450 CYP2E1 
- P2X7 purinergic receptor 
- PB2 subunit of influenza RNA pol. 
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- perilipin 
- Mg2+-dependent phosphatidate 
phosphohydrolase 
- polysomal ribonuclease 1 (PMR1) 
- PRMT5 
- prolactin receptor 
- prostacyclin synthase 
- proteasome 
- R2TP complex through Pih1 
- Rab-αGDI 
- Rab11a 
- Rac/Rop GTPase Rac1 (rice) 
- Rac1 
- Ral-binding protein 1 
- Raptor 
- reovirus protein σ1 
- reverse transcriptase of hepatitis B virus 
- ribosomal proteins S3 and S6 
- ribosomal protein L2 (E. coli) 
- ricin catalytic A chain 
- RIG-I 
- Rpb1 
- R-protein I-2 
- SIR2 (SIR2RP1 in Leishmania) 
- SKP2 complexes 
- SMYD1, SMYD2, SMYD3 
- snoRNP complexes 
- SREC-I 
- DNA helicase Ssl2 
- SUR1 (subunit of β-cell ATP-sensitive 
potassium 
channel) 
- survivin 
- SV40 large T-antigen 
- α-synuclein 
- Tab2/3 
- Tau protein 
- telomerase 
- thiopurine S-methyltransferase 
- thrombin receptor (PAR-1) 
- thromboxane synthase 
- Tissue plasminogen activator (tPA) 
- TLR4/MD-2 complex 
- TOM40 
- Trithorax (and ortholog MLL) 
- Tyrosine hydroxylase 
- UCH-L1 
- Uroporphyrinogen decarboxylase 
(HemE) [in cyanobacteria] 
- Vaccinia core protein 4a 
- misfolded VHL 
- Vimentin 
 
